View source for Psilocybin

{{Short description|Chemical compound found in some species of mushrooms}}
{{Use mdy dates|date=August 2018}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
| Watchedfields = verified
| verifiedrevid = 479504713
| drug_name = 
| INN = Psilocybine
| USAN = Psilocybin
| image = Psilocybin, Kekulé, skeletal formula of canonical psilocybin.svg
| image_class = skin-invert-image
| width = 200px
| caption = Kekulé, skeletal formula of canonical psilocybin
| image2 = Psilocybin zwitterion 3D ball.png
| image_class2 = bg-transparent
| width2 = 200px
| caption2 = Ball-and-stick model of canonical psilocybin

<!-- Clinical data -->
| pronounce = {{IPAc-en|ˌ|s|aɪ|l|ə|ˈ|s|aɪ|b|ɪ|n}} {{respell|sy|lə|SY|bin}}, {{IPAc-en|ˌ|s|ɪ|l|-}}<!-- Pronunciation according to Wiktionary -->
| Drugs.com = 
| MedlinePlus = 
| licence_CA = 
| licence_EU = 
| DailyMedID = 
| licence_US = 
| pregnancy_AU = 
| pregnancy_category = 
| dependency_liability = Low<ref name="JohnsonGriffithsHendricks2018">{{cite journal | vauthors = Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE | title = The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | journal = Neuropharmacology | volume = 142 | issue = | pages = 143–166 | date = November 2018 | pmid = 29753748 | pmc = 6791528 | doi = 10.1016/j.neuropharm.2018.05.012 }}</ref><ref name="Passie2002" /><ref name="Chen2008" /><ref name="Amsterdam2010" /><ref name="Nutt2010" />
| addiction_liability = Low<ref name="JohnsonGriffithsHendricks2018" /><ref name="Nicholas2006" />
| routes_of_administration = {{plainlist|
* [[Oral administration|By mouth]], 
* [[intravenous administration|intravenous]]<ref name="LoweToyangSteele2021" />}}
| class = [[Serotonergic psychedelic]]; [[Hallucinogen]]; [[Serotonin receptor agonist]]; [[Serotonin]] [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] [[agonist]]<ref name="SzafoniGręblowskiGrabowska2024">{{cite journal | vauthors = Szafoni S, Gręblowski P, Grabowska K, Więckiewicz G | title = Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder | journal = Frontiers in Psychiatry | volume = 15 | article-number = 1406888 | date = 11 June 2024 | pmid = 38919636 | pmc = 11196758 | doi = 10.3389/fpsyt.2024.1406888 | doi-access = free }}</ref>
| ATC_prefix = None
| ATC_suffix =

<!-- Legal status -->
| legal_AU = S9/S8 (Controlled Drug)
| legal_BR = F2
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-07-24 |title=RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 |url-status=live |archive-url=https://web.archive.org/web/20230827163149/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 |archive-date=2023-08-27 |access-date=2023-08-27 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-07-25}}</ref>
| legal_CA = Schedule III
| legal_UK = Class A
| legal_US = Schedule I
| legal_status =

<!-- Pharmacokinetic data -->
| bioavailability = [[Oral administration|Oral]]: 52.7 ± 20.4% (as [[psilocin]]) (n=3)<ref name="DoddNormanEyre2023" /><ref name="MacCallumLoPistawka2022">{{cite journal | vauthors = MacCallum CA, Lo LA, Pistawka CA, Deol JK | title = Therapeutic use of psilocybin: Practical considerations for dosing and administration | journal = Frontiers in Psychiatry | volume = 13 | issue =  | article-number = 1040217 | date = 2022 | pmid = 36532184 | pmc = 9751063 | doi = 10.3389/fpsyt.2022.1040217 | doi-access = free }}</ref><ref name="HaslerBourquinBrenneisen1997">{{cite journal | vauthors = Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX | title = Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man | journal = Pharm Acta Helv | volume = 72 | issue = 3 | pages = 175–184 | date = June 1997 | pmid = 9204776 | doi = 10.1016/s0031-6865(97)00014-9 }}</ref>
| protein_bound = 66%<ref name="ČamparaKovačić2024">{{cite book | vauthors = Čampara A, Kovačić D | title=MEDICON'23 and CMBEBIH'23 | chapter=Exploring Psilocybin as a Tool for Studying Parkinsonism-Related Psychosis: A Narrative Review Supplemented with a Computational Approach | series=IFMBE Proceedings | publisher=Springer Nature Switzerland | publication-place=Cham | volume=94 | date=2024 | isbn=978-3-031-49067-5 | doi=10.1007/978-3-031-49068-2_54 | pages=530–547 | quote = With a logS value of −3.009 and a plasma protein binding of 0.66, respectively, psilocybin has poor water solubility and is moderately bound to plasma proteins.}}</ref>
| metabolism = [[Liver]], other [[tissue (biology)|tissue]]s:<ref name="MacCallumLoPistawka2022" /><ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021">{{cite journal | vauthors = Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L | title = The Therapeutic Potential of Psilocybin | journal = Molecules | volume = 26 | issue = 10 | date = May 2021 | page = 2948 | pmid = 34063505 | pmc = 8156539 | doi = 10.3390/molecules26102948 | doi-access = free }}</ref><ref name="CoppolaBevioneMondola2022">{{cite journal | vauthors = Coppola M, Bevione F, Mondola R | title = Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective? | journal = Journal of Xenobiotics | volume = 12 | issue = 1 | pages = 41–52 | date = February 2022 | pmid = 35225956 | pmc = 8883979 | doi = 10.3390/jox12010004 | doi-access = free }}</ref><br />• [[Dephosphorylation]] ({{Abbrlink|ALP|alkaline phosphatase}})<br />• [[Demethylation]] and [[deamination]] ({{Abbrlink|MAO|monoamine oxidase}})<br />• [[Oxidation]] ({{Abbrlink|ALDH|aldehyde dehydrogenase}})<br />• [[Glucuronidation]] ([[UDP-glucuronyltransferase|{{Abbr|UGTs|UDP-glucuronyltransferases}}]])
| metabolites = • [[Psilocin]]<ref name="MacCallumLoPistawka2022" /><ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /><br />• Psilocin-''O''-glucuronide<ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /><br />• 4-Hydroxyindole-3-acetaldehyde<ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /><br />• 4-Hydroxyindole-3-acetic acid (4-HIAA)<ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /><br />• 4-Hydroxytryptophol<ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" />
| onset = [[Oral administration|Oral]]: 0.5–0.8 (range 0.1–1.5) h<ref name="HolzeSinghLiechti2024" /><ref name="MacCallumLoPistawka2022" /><br />{{Abbrlink|IV|Intravenous injection}}: immediate<ref name="Nichols2016" /><ref name="Carhart-HarrisWilliams2011" />
| elimination_half-life = [[Oral administration|Oral]] (as [[psilocin]]): 2.1–4.7{{nbsp}}h (range 1.2–18.6{{nbsp}}h)<ref name="DoddNormanEyre2023" /><ref name="OttovanderHeijdenSchoones2025" /><ref name="Manzano-NunezGomezToledo-Mendoza2025" /><br />{{Abbrlink|IV|Intravenous administration}} (as psilocin): 1.2{{nbsp}}h (range 1.8–4.5{{nbsp}}h)<ref name="DoddNormanEyre2023" /><ref name="Passie2002" />
| duration_of_action = [[Oral administration|Oral]]: 4–6{{nbsp}}h (range 3–12{{nbsp}}h)<ref name="MacCallumLoPistawka2022" /><ref name="YerubandiThomasBhuiya2024">{{cite journal | vauthors = Yerubandi A, Thomas JE, Bhuiya NM, Harrington C, Villa Zapata L, Caballero J | title = Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis | journal = JAMA Network Open | volume = 7 | issue = 4 |article-number=e245960 | date = April 2024 | pmid = 38598236 | pmc = 11007582 | doi = 10.1001/jamanetworkopen.2024.5960 | quote = When selecting adverse event profile rates, the shortest time period available was selected and analyzed (eg, day 1 instead of day 30) since the half-life of psilocin is 3 ± 1.1 hours when taken orally and the duration of action can range between 3 to 12 hours.12,13 }}</ref><ref name="GeigerWurstDaniels2018" /><br />{{Abbrlink|IV|Intravenous injection}}: 15–60{{nbsp}}min (1–2{{nbsp}}mg)<ref name="Passie2002" /><ref name="HaslerBourquinBrenneisen1997" /><ref name="Nichols2016" /><ref name="Carhart-HarrisWilliams2011" />
| excretion = [[Urine]] (mainly as psilocin-''O''-glucuronide, 2–4% as unchanged psilocin)<ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /><ref name="TylšPáleníčekHoráček2014" />

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 520-52-5
| CAS_supplemental = 
| PubChem = 10624
| IUPHAR_ligand = 
| DrugBank = DB11664
| ChemSpiderID = 10178
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2RV7212BP0
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D12881
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 8614
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 194378
| NIAID_ChemDB = 
| PDB_ligand = 
| synonyms = Psilocybine; Psilocibin; Psylocybin; Psilotsibin; Psilocin phosphate; Psilocin phosphate ester; ''O''-Phosphoryl-4-hydroxy-''N'',''N''-dimethyltryptamine; 4-Phosphoryloxy-''N'',''N''-dimethyltryptamine; 4-Phosphoryl-''N'',''N''-dimethyltryptamine; 4-PO-DMT; COMP360; COMP-360; CY-39; CY39; PSOP

<!-- Chemical data -->
| IUPAC_name = [3-[2-(dimethylamino)ethyl]-1''H''-indol-4-yl] dihydrogen phosphate
| C = 12
| H = 17
| N = 2
| O = 4
| P = 1
| SMILES = CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O
| Jmol = 
| StdInChI = 1S/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17)
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QVDSEJDULKLHCG-UHFFFAOYSA-N
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

<!-- Physical data -->
| density = 
| density_notes = 
| melting_point = 220-228
| melting_high = 
| melting_notes = <ref name="Merck">''[[Merck Index]]'', 11th Edition, '''7942'''</ref>
| boiling_point = 
| boiling_notes = 
| solubility = 
| sol_units = 
| specific_rotation = 
}}
<!-- Definition and effects -->
'''Psilocybin''', also known as '''4-phosphoryloxy-''N'',''N''-dimethyltryptamine''' ('''4-PO-DMT'''),{{efn|Synonyms and alternate spellings of psilocybin include 4-PO-DMT (PO: [[phosphate]]; DMT: [[dimethyltryptamine]]), psilocybine, psilocibin, psilocybinum, psilotsibin, and psilocin phosphate ester, among others.<ref name="Pubchem" />}} is a [[natural product|naturally occurring]] [[substituted tryptamine|tryptamine]] [[alkaloid]] and [[Investigational New Drug|investigational drug]] found in more than [[List of psilocybin mushroom species|200 species]] of [[mushroom]]s, with [[hallucinogen]]ic and [[Serotonin|serotonergic]] effects.<ref name="GeigerWurstDaniels2018">{{cite journal | vauthors = Geiger HA, Wurst MG, Daniels RN | title = DARK Classics in Chemical Neuroscience: Psilocybin | journal = ACS Chem Neurosci | volume = 9 | issue = 10 | pages = 2438–2447 | date = October 2018 | pmid = 29956917 | doi = 10.1021/acschemneuro.8b00186 | url = https://shaunlacob.com/wp-content/uploads/2020/12/DC-PSILO.pdf}}</ref><ref>{{Cite web | work = PubChem | publisher = U.S. National Library of Medicine | title=Psilocybin |url=https://pubchem.ncbi.nlm.nih.gov/compound/Psilocybin |access-date=2025-05-22 |language=en}}</ref> Effects include [[euphoria]], changes in [[perception]], a distorted [[sense of time]] (via brain desynchronization),<ref name=":1">{{cite journal | vauthors = Siegel JS, Subramanian S, Perry D, Kay BP, Gordon EM, Laumann TO, Reneau TR, Metcalf NV, Chacko RV, Gratton C, Horan C, Krimmel SR, Shimony JS, Schweiger JA, Wong DF, Bender DA, Scheidter KM, Whiting FI, Padawer-Curry JA, Shinohara RT, Chen Y, Moser J, Yacoub E, Nelson SM, Vizioli L, Fair DA, Lenze EJ, Carhart-Harris R, Raison CL, Raichle ME, Snyder AZ, Nicol GE, Dosenbach NU | title = Psilocybin desynchronizes the human brain | journal = Nature | volume = 632 | issue = 8023 | pages = 131–138 | date = August 2024 | pmid = 39020167 | pmc = 11291293 | doi = 10.1038/s41586-024-07624-5 | doi-access = free | bibcode = 2024Natur.632..131S }}</ref> and perceived [[spiritual experiences]]. It can also cause [[adverse reaction]]s such as [[nausea]] and [[panic attack]]s.

<!-- Pharmacology and chemistry -->
Psilocybin is a [[prodrug]] of [[psilocin]].<ref name="GeigerWurstDaniels2018" /> That is, the compound itself is biologically inactive but quickly converted by the body to psilocin.<ref name="GeigerWurstDaniels2018" /> Psilocybin is transformed into psilocin by [[dephosphorylation]] mediated via [[phosphatase]] [[enzyme]]s.<ref name="Nichols2020" /><ref name="GeigerWurstDaniels2018" /> Psilocin is [[structural analog|chemically related]] to the [[neurotransmitter]] [[serotonin]] and acts as a [[binding selectivity|non-selective]] [[agonist]] of the [[serotonin receptor]]s.<ref name="GeigerWurstDaniels2018" /> Activation of one serotonin receptor, the serotonin [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]], is specifically responsible for the hallucinogenic effects of psilocin and other [[serotonergic psychedelic]]s.<ref name="GeigerWurstDaniels2018" /> Psilocybin is usually taken [[oral administration|orally]].<ref name="GeigerWurstDaniels2018" /> By this [[route of administration|route]], its [[onset of action|onset]] is about 20 to 50{{nbsp}}minutes, [[Tmax (pharmacology)|peak effect]]s occur after about 1 to 2{{nbsp}}hours, and its [[duration of action|duration]] is about 4 to 6{{nbsp}}hours.<ref name="MacCallumLoPistawka2022" /><ref name="YerubandiThomasBhuiya2024" /><ref name="GeigerWurstDaniels2018" /><ref name="HolzeSinghLiechti2024" />

<!-- History, society, and culture -->
Psilocybin mushrooms were used ritualistically in [[pre-Columbian Mexico]], but claims of their widespread ancient use are largely exaggerated and shaped by modern idealization and ideology.<ref name=":2" /> In 1958, the Swiss chemist [[Albert Hofmann]] isolated psilocybin and psilocin from the mushroom ''[[Psilocybe mexicana]]''. His employer, [[Sandoz]], marketed and sold pure psilocybin to physicians and clinicians worldwide for use in [[psychedelic therapy]]. Increasingly restrictive drug laws of the [[Single Convention on Narcotic Drugs|1960s]] and the [[Convention on Psychotropic Substances|1970s]] curbed scientific research into the effects of psilocybin and other hallucinogens, but its popularity as an [[entheogen]] grew in the next decade, owing largely to the increased availability of information on how to cultivate psilocybin mushrooms.

Possession of psilocybin-containing mushrooms [[Legal status of psilocybin mushrooms|has been outlawed]] in most countries, and psilocybin has been classified as a [[Convention on Psychotropic Substances#Schedule I|Schedule I controlled substance]] under the 1971 United Nations [[Convention on Psychotropic Substances]]. Psilocybin is being studied as a possible medicine in the treatment of [[psychiatric disorder]]s such as [[depression (mood)|depression]], [[substance use disorder]]s, [[obsessive–compulsive disorder]], and other conditions such as [[cluster headache]]s.<ref name="MaddenFloodYoungShing2024">{{cite journal | vauthors = Madden K, Flood B, Young Shing D, Ade-Conde M, Kashir I, Mark M, MacKillop J, Bhandari M, Adili A | title = Psilocybin for clinical indications: A scoping review | journal = J Psychopharmacol | volume = 38 | issue = 10 | pages = 839–845 | date = October 2024 | pmid = 39135496 | pmc = 11481402 | doi = 10.1177/02698811241269751 | url = }}</ref>  Psilocybin was approved for [[treatment-resistant depression]] in [[Australia]] in 2023.<ref name="Nutt_20242">{{cite journal |vauthors=Nutt DJ, Hunt P, Schlag AK, Fitzgerald P |date=December 2024 |title=The Australia story: Current status and future challenges for the clinical applications of psychedelics |journal=British Journal of Pharmacology |doi=10.1111/bph.17398 |pmid=39701143 |doi-access=free |article-number=bph.17398}}</ref><ref name="Donley_20232">{{cite journal |vauthors=Donley CN, Dixon Ritchie G, Dixon Ritchie O |date=2023 |title=From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia |journal=Drug Science, Policy and Law |volume=9 |doi=10.1177/20503245231198472 |issn=2050-3245 |doi-access=free |article-number=20503245231198472}}</ref> It is in late-stage [[clinical trial]]s in the United States for treatment-resistant depression.<ref name="MelaniBonasoBiso2025">{{cite journal | vauthors = Melani A, Bonaso M, Biso L, Zucchini B, Conversano C, Scarselli M | title = Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications | journal = Pharmaceuticals (Basel) | volume = 18 | issue = 1 | date = January 2025 | page = 130 | pmid = 39861191 | pmc = 11769142 | doi = 10.3390/ph18010130 | doi-access = free | url = }}</ref><ref name="Najib2024">{{cite journal | vauthors = Najib J | title = The role of psilocybin in depressive disorders | journal = Curr Med Res Opin | volume = 40 | issue = 10 | pages = 1793–1808 | date = October 2024 | pmid = 39177339 | doi = 10.1080/03007995.2024.2396536 | url = }}</ref><ref name="AdisInsight" /> Especially at higher doses and [[Psychedelic therapy|combined with psychological support]], psilocybin can produce rapid and sometimes lasting antidepressant effects that generally outperform placebo but show only modest advantages over conventional [[Selective serotonin reuptake inhibitor|SSRIs]]; evidence quality is generally low and trial bias is common.

{{TOC limit|3}}

==Uses==
{{See also|Psychedelic drug#Uses}}

Psilocybin is used [[recreational drug|recreationally]], [[spirituality|spiritually]] (as an [[entheogen]]), and [[medicine|medically]].<ref name="FradetKellyDonnelly2025" /> It is primarily taken [[oral administration|orally]], but other [[routes of administration]], such as [[intravenous injection]], are sometimes employed by licensed medical researchers using pharmaceutical-grade psilocybin powder designed for injection. Injection should never be attempted by unlicensed people.<ref name="LoweToyangSteele2021" />

===Medical===
In 2023, the [[Therapeutic Goods Administration]] (TGA) approved psilocybin for treatment of treatment-resistant depression in [[Australia]].<ref name="Nutt_2024">{{cite journal | vauthors = Nutt DJ, Hunt P, Schlag AK, Fitzgerald P | title = The Australia story: Current status and future challenges for the clinical applications of psychedelics | journal = British Journal of Pharmacology | date = December 2024 | article-number = bph.17398 | pmid = 39701143 | doi = 10.1111/bph.17398 | doi-access = free }}</ref><ref name="Donley_2023">{{cite journal | vauthors = Donley CN, Dixon Ritchie G, Dixon Ritchie O | title = From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia | journal = Drug Science, Policy and Law | volume = 9 | date = 2023 | article-number = 20503245231198472 | doi = 10.1177/20503245231198472 | issn = 2050-3245 | doi-access = free }}</ref><ref name="Zagorski_2023">{{cite journal | vauthors = Zagorski N | title = Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy | journal = Psychiatric News | volume = 58 | issue = 9 | date = 1 September 2023 | article-number = appi.pn.2023.09.9.20 | doi = 10.1176/appi.pn.2023.09.9.20 | issn = 0033-2704 | url = https://psychiatryonline.org/doi/10.1176/appi.pn.2023.09.9.20 | access-date = 17 May 2025 | url-access = subscription }}</ref> It is also under development for the treatment of [[depression (mood)|depression]] and for various other indications elsewhere, such as the [[United States]] and [[Europe]], but has not yet been approved in other countries (see [[#Research|below]]).<ref name="DoddNormanEyre2023" /><ref name="MaddenFloodYoungShing2024" /><ref name="AdisInsight" />

===Dosing===
{{See also|Psychedelic drug#Dosing|Psilocybin mushroom#Dosing}}

Psilocybin is used as a psychedelic at doses of 5 to 40{{nbsp}}mg [[oral administration|orally]].<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022">{{cite book | vauthors = Liechti ME, Holze F | title = Disruptive Psychopharmacology | chapter = Dosing Psychedelics and MDMA | series = Curr Top Behav Neurosci | volume = 56 | pages = 3–21 | date = 2022 | pmid = 34734392 | doi = 10.1007/7854_2021_270 | isbn = 978-3-031-12183-8 | chapter-url = https://www.researchgate.net/publication/355943062}}</ref> Low doses are 5 to 10{{nbsp}}mg, an intermediate or "good effect" dose is 20{{nbsp}}mg, and high or [[ego dissolution|ego-dissolution]] doses are 30 to 40{{nbsp}}mg.<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022" /> Psilocybin's effects can be subjectively perceived at a dose as low as 3{{nbsp}}mg per 70{{nbsp}}kg body weight.<ref name="LiechtiHolze2022" /><ref name="HaslerGrimbergBenz2004">{{cite journal | vauthors = Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX | title = Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study | journal = Psychopharmacology | volume = 172 | issue = 2 | pages = 145–156 | date = March 2004 | pmid = 14615876 | doi = 10.1007/s00213-003-1640-6 | url = http://www.maps.org/research-archive/w3pb/2004/2004_Hasler_20465_2.pdf | url-status = live | access-date = April 10, 2019 | s2cid = 15263504 | archive-url = https://web.archive.org/web/20200418005513/https://maps.org/research-archive/w3pb/2004/2004_Hasler_20465_2.pdf | archive-date = April 18, 2020 }}</ref> [[Psychedelic microdosing|Microdosing]] involves the use of subthreshold psilocybin doses of less than 2.5{{nbsp}}mg.<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022" />

When psilocybin is used in the form of [[psilocybin-containing mushroom]]s, microdoses are 0.1{{nbsp}}g to 0.3{{nbsp}}g and psychedelic doses are 1.0{{nbsp}}g to 3.5–5.0{{nbsp}}g in the case of dried mushrooms.<ref name="KozlowskaNicholsWiatr2022">{{cite journal | vauthors = Kozlowska U, Nichols C, Wiatr K, Figiel M | title = From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders | journal = J Neurochem | volume = 162 | issue = 1 | pages = 89–108 | date = July 2022 | pmid = 34519052 | doi = 10.1111/jnc.15509 | url = | quote = One dosing method of psychedelics is the use of so called “microdoses”—very low concentrations of various psychedelics that do not reach the threshold of perceivable behavioral effects. This is usually 10% of active recreational doses (e.g., 10–15 µg of LSD, or 0.1–0.3 g of dry “magic mushrooms”) taken up to three times per week.}}</ref><ref name="vanAmsterdamOpperhuizenvandenBrink2011">{{cite journal | vauthors = van Amsterdam J, Opperhuizen A, van den Brink W | title = Harm potential of magic mushroom use: a review | journal = Regul Toxicol Pharmacol | volume = 59 | issue = 3 | pages = 423–429 | date = April 2011 | pmid = 21256914 | doi = 10.1016/j.yrtph.2011.01.006 | url = https://psilosybiini.info/paperit/Harm%20potential%20of%20magic%20mushroom%20use,%20A%20review%20(van%20Amsterdam%20et%20al.,%202011).pdf }}</ref><ref name="LoweToyangSteele2021" /> The preceding 1.0 to 5.0{{nbsp}}g range corresponds to psilocybin doses of about 10 to 50{{nbsp}}mg.<ref name="LoweToyangSteele2021" /> Psilocybin-containing mushrooms vary in their psilocybin and [[psilocin]] content, but are typically around 1% of the dried weight of the mushrooms (in terms of total or combined psilocybin and psilocin content).<ref name="vanAmsterdamOpperhuizenvandenBrink2011" /><ref name="PepeHesamidelaCerda2023">{{cite journal | vauthors = Pepe M, Hesami M, de la Cerda KA, Perreault ML, Hsiang T, Jones AM | title = A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond | journal = Biotechnol Adv | volume = 69 | issue = | article-number = 108247 | date = December 2023 | pmid = 37659744 | doi = 10.1016/j.biotechadv.2023.108247 | url = }}</ref><ref name="TylšPáleníčekHoráček2014" /><ref name="LoweToyangSteele2021" /><ref name="Nichols2020">{{cite journal | vauthors = Nichols DE | title = Psilocybin: from ancient magic to modern medicine | journal = J Antibiot (Tokyo) | volume = 73 | issue = 10 | pages = 679–686 | date = October 2020 | pmid = 32398764 | doi = 10.1038/s41429-020-0311-8 | url = https://www.researchgate.net/publication/341321407 | quote = Total psilocybin and psilocin levels in species known to be used recreationally varied from 0.1% to nearly 2% by dry weight [8]. The medium oral dose of psilocybin is 4–8 mg, which elicits the same symptoms as the consumption of about 2 g of dried Psilocybe Mexicana [9].}}</ref><ref name="KurzbaumPáleníčekShrchaton2025">{{cite journal | vauthors = Kurzbaum E, Páleníček T, Shrchaton A, Azerrad S, Dekel Y | title = Exploring ''Psilocybe cubensis'' Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps | journal = Journal of Fungi | volume = 11 | issue = 2 | page = 99 | date = January 2025 | pmid = 39997393 | pmc = 11856550 | doi = 10.3390/jof11020099 | doi-access = free }}</ref><ref name="GoffSmithIslam2024">{{cite journal | vauthors = Goff R, Smith M, Islam S, Sisley S, Ferguson J, Kuzdzal S, Badal S, Kumar AB, Sreenivasan U, Schug KA | title = Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry | journal = Anal Chim Acta | volume = 1288 | issue = | article-number = 342161 | date = February 2024 | pmid = 38220293 | doi = 10.1016/j.aca.2023.342161 | bibcode = 2024AcAC.128842161G | url = | quote = A method for clinical potency determination of psilocybin and psilocin in hallucinogenic mushroom species Psilocybe cubensis was developed using liquid chromatography with tandem mass spectrometry (LC-MS/MS). Five strains of dried, intact mushrooms were obtained and analyzed: Blue Meanie, Creeper, B-Plus, Texas Yellow, and Thai Cubensis. [...] From most to least potent, the study found that the average total psilocybin and psilocin concentrations for the Creeper, Blue Meanie, B+, Texas Yellow, and Thai Cubensis strains were 1.36, 1.221, 1.134, 1.103, and 0.879 % (w/w), respectively.}}</ref><ref name="GotvaldováBorovičkaHájková2022">{{cite journal | vauthors = Gotvaldová K, Borovička J, Hájková K, Cihlářová P, Rockefeller A, Kuchař M | title = Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids | journal = Int J Mol Sci | volume = 23 | issue = 22 | date = November 2022 |article-number=14068 | pmid = 36430546 | pmc = 9693126 | doi = 10.3390/ijms232214068 | doi-access = free | url = }}</ref> Psilocin is about 1.4 times as potent as psilocybin because of the two compounds' difference in [[Molar mass|molecular weight]].<ref name="TylšPáleníčekHoráček2014" /><ref name="Hofmann1968">{{cite book | author = [[Albert Hofmann]] | chapter = Psychotomimetic Agents | pages = 169–235 | veditors = Burger A | title = Drugs Affecting the Central Nervous System | volume = 2 | date = 1968 | publisher = M. Dekker | location = New York | oclc = 245452885 | ol = OL13539506M | chapter-url = https://archive.org/details/drugsaffectingce0000edit/page/169/mode/1up | url = https://books.google.com/books?id=o_GMwgEACAAJ | quote = Psilocin is approximately 1.4 times as potent as psilocybin. This ratio is the same as that of the molecular weights of the two drugs.}}</ref><ref name="WolbachMinerIsbell1962">{{cite journal | vauthors = Wolbach AB, Miner EJ, Isbell H | title = Comparison of psilocin with psilocybin, mescaline and LSD-25 | journal = Psychopharmacologia | volume = 3 | issue = 3| pages = 219–223 | date = 1962 | pmid = 14007905 | doi = 10.1007/BF00412109 | url = | quote = Psilocin is approximately 1.4 times as potent as psilocybin. This ratio is the same as that of the molecular weights of the two drugs.}}</ref>

===Available forms===
Psilocybin is most commonly consumed in the form of [[psilocybin-containing mushroom]]s, such as ''[[Psilocybe]]'' species like ''[[Psilocybe cubensis]]''. It may also be prepared [[chemical synthesis|synthetically]], but outside of [[clinical research|research settings]] it is not typically used in this form. Regardless of form, psilocybin is usually taken [[oral administration|orally]]. The psilocybin present in certain species of mushrooms can be ingested in several ways: by consuming fresh or dried fruit bodies, by preparing an [[herbal tea]], or by combining with other foods to mask the bitter taste.<ref name=EMCDDA/> In rare cases people have [[intravenous]]ly [[injection (medicine)|injected]] [[mushroom extract]]s, with serious [[medical complication]]s such as [[systemic disease|systemic]] [[fungal infection|mycological infection]] and [[hospitalization]].<ref name=Amsterdam2011/><ref name="GiancolaKorsonCaplan2021">{{cite journal | vauthors = Giancola NB, Korson CJ, Caplan JP, McKnight CA | title = A "Trip" to the Intensive Care Unit: An Intravenous Injection of Psilocybin | journal = J Acad Consult Liaison Psychiatry | volume = 62 | issue = 3 | pages = 370–371 | date = 2021 | pmid = 34102133 | doi = 10.1016/j.jaclp.2020.12.012 | url = }}</ref><ref name="SivyerDorrington1984">{{cite journal | vauthors = Sivyer G, Dorrington L | title = Intravenous injection of mushrooms | journal = Med J Aust | volume = 140 | issue = 3 | pages = 182 | date = February 1984 | pmid = 6694611 | doi = 10.5694/j.1326-5377.1984.tb103978.x | url = }}</ref><ref name="CurryRose1985">{{cite journal | vauthors = Curry SC, Rose MC | title = Intravenous mushroom poisoning | journal = Ann Emerg Med | volume = 14 | issue = 9 | pages = 900–902 | date = September 1985 | pmid = 4025991 | doi = 10.1016/s0196-0644(85)80643-0 | url = }}</ref> Another form of psilocybin (as well as of related psychedelics like [[4-AcO-DMT]]) is [[psychedelic mushroom edible|mushroom edible]]s such as [[chocolate bar]]s and [[gummy|gummies]], which may be purchased at [[psychedelic mushroom store]]s.

==Effects==
[[File:Timothy-Leary-Los-Angeles-1989.jpg|thumb|American psychologist and [[Counterculture of the 1960s|counterculture]] figure [[Timothy Leary]] conducted early experiments into the effects of psychedelic drugs, including psilocybin (1989 photo).]]

Psilocybin produces a variety of [[psychological]], [[perceptual]], [[interpersonal]], and [[physiological|physical]] effects.<ref name="HolzeSinghLiechti2024" />

===Psychological and perceptual effects===
[[File:Prefrontal cortex.png|thumb|class=skin-invert-image|The ability of psilocybin to cause perceptual distortions is linked to its influence on the activity of the [[prefrontal cortex]].]]

After ingesting psilocybin, the user may experience a wide range of emotional effects, which can include disorientation, lethargy, giddiness, [[euphoria]], joy, and [[depression (mood)|depression]]. In one study, 31% of volunteers given a high dose reported feelings of significant fear and 17% experienced transient [[paranoia]].<ref name=Amsterdam2011/> In studies at [[Johns Hopkins University|Johns Hopkins]], among those given a moderate dose (but enough to "give a high probability of a profound and beneficial experience"), negative experiences were rare, whereas one-third of those given a high dose experienced anxiety or paranoia.<ref>{{Cite news |date=December 1, 2016 |title=Hallucinogenic Drug Psilocybin Eases Existential Anxiety in People With Life-Threatening Cancer |url=https://www.hopkinsmedicine.org/news/media/releases/hallucinogenic_drug_psilocybin_eases_existential_anxiety_in_people_with_life_threatening_cancer |url-status=live |archive-url=https://web.archive.org/web/20210407123910/https://www.hopkinsmedicine.org/news/media/releases/hallucinogenic_drug_psilocybin_eases_existential_anxiety_in_people_with_life_threatening_cancer |archive-date=April 7, 2021 |access-date=April 9, 2019 |publisher=Johns Hopkins}}</ref><ref name="Hopkins2011">{{cite journal | vauthors = Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R | title = Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects | journal = Psychopharmacology | volume = 218 | issue = 4 | pages = 649–665 | date = December 2011 | pmid = 21674151 | pmc = 3308357 | doi = 10.1007/s00213-011-2358-5 }}</ref> Low doses can induce hallucinatory effects. [[Closed-eye hallucination]]s may occur, where the affected person sees multicolored geometric shapes and vivid imaginative sequences.<ref name="HaslerGrimbergBenz2004" /> Some people report [[synesthesia]], such as tactile sensations when viewing colors.<ref name="Ballesteros_2006">{{Cite book |title=New Research on Street Drugs |vauthors=Ballesteros S, Ramón MF, Iturralde MJ, Martínez-Arrieta R |publisher=[[Nova Science Publishers]] |year=2006 |isbn=978-1-59454-961-8 |veditors=Cole SM |location=New York, New York |pages=167–186 |chapter=Natural sources of drugs of abuse: magic mushrooms |access-date=February 27, 2016 |chapter-url=https://books.google.com/books?id=ovGcMmz5emUC&pg=PA167 |archive-url=https://web.archive.org/web/20170404021804/https://books.google.com/books?id=ovGcMmz5emUC&pg=PA167 |archive-date=April 4, 2017 |url-status=live}}</ref>{{rp|175}} At higher doses, psilocybin can lead to "intensification of affective responses, enhanced ability for introspection, regression to primitive and childlike thinking, and activation of vivid memory traces with pronounced emotional undertones".<ref name=Studerus2011/> Open-eye visual hallucinations are common and may be very detailed, although [[Pseudohallucination|rarely confused with reality.]]<ref name="HaslerGrimbergBenz2004" />

Psilocybin is known to strongly affect the subjective experience of the [[time perception|passage of time]].<ref name="Heimann1994">{{Cite book |title=50 Years of LSD. Current Status and Perspectives of Hallucinogens |vauthors=Heimann H |publisher=The Parthenon Publishing Group |year=1994 |isbn=978-1-85070-569-7 |veditors=Pletscher A, Ladewig D |location=New York, New York |pages=59–66 |chapter=Experience of time and space in model psychoses}}</ref><ref name=":1" /> Users often feel as if time is slowed down, resulting in the perception that "minutes appear to be hours" or "time is standing still".<ref name=Wittmann2007/> Studies have demonstrated that psilocybin significantly impairs subjects' ability to gauge time intervals longer than 2.5 seconds, impairs their ability to synchronize to inter-beat intervals longer than 2 seconds, and reduces their preferred [[tapping rate]].<ref name=Wittmann2007/><ref name=Wackermann2008/> These results are consistent with the drug's role in affecting [[prefrontal cortex]] activity<ref name=Carter2005/> and the role that the prefrontal cortex plays in time perception,<ref name=Harrington1999/> but the neurochemical basis of psilocybin's effects on perception of time is not known with certainty.<ref name=Coull2011/>

Users having a pleasant experience can feel a sense of connection to others, nature, and the universe; other perceptions and emotions are also often intensified. Users having an unpleasant experience (a "[[bad trip]]") describe a reaction accompanied by fear, other unpleasant feelings, and occasionally by dangerous behavior. The term "bad trip" is generally used to describe a reaction characterized primarily by fear or other unpleasant emotions, not just a transitory experience of such feelings. A variety of factors may contribute to a bad trip, including "tripping" during an emotional or physical low or in a non-supportive environment (see: [[set and setting]]). Ingesting psilocybin in combination with other drugs, including [[alcohol (drug)|alcohol]], can also increase the likelihood of a bad trip.<ref name=Amsterdam2011/><ref name=Attema2007/> Other than the duration of the experience, the effects of psilocybin are similar to comparable doses of [[lysergic acid diethylamide]] (LSD) or [[mescaline]]. But in the ''Psychedelics Encyclopedia'', author [[Peter Stafford]] writes: "The psilocybin experience seems to be warmer, not as forceful and less isolating. It tends to build connections between people, who are generally much more in communication than when they use LSD."<ref name=Stafford1992>{{Cite book |title=Psychedelics Encyclopedia |vauthors=Stafford PJ |publisher=Ronin Publishing |year=1992 |isbn=978-0-914171-51-5 |edition=3rd |location=Berkeley, California |author-link=Peter Stafford}}</ref>{{rp|273}}

====Set and setting and moderating factors====
The effects of psilocybin are highly variable and depend on the mindset and environment in which the user has the experience, factors commonly called [[set and setting]]. In the early 1960s, [[Timothy Leary]] and his Harvard colleagues investigated the role of set and setting in psilocybin's effects. They administered the drug to 175 volunteers (from various backgrounds) in an environment intended to be similar to a comfortable living room. 98 of the subjects were given questionnaires to assess their experiences and the contribution of background and situational factors. Those who had prior experience with psilocybin reported more pleasant experiences than those for whom the drug was novel. Group size, dose, preparation, and expectancy were important determinants of the drug response. In general, those in groups of more than eight felt that the groups were less supportive and their experiences less pleasant. Conversely, smaller groups (fewer than six) were seen as more supportive and reported more positive reactions to the drug in those groups. Leary and colleagues proposed that psilocybin heightens suggestibility, making a user more receptive to interpersonal interactions and environmental stimuli.<ref name=Leary1963/> These findings were affirmed in a later review by Jos ten Berge (1999), who concluded that dose, set, and setting are fundamental factors in determining the outcome of experiments that tested the effects of psychedelic drugs on artists' creativity.<ref name=Berge1999/>

Further studies demonstrate that supportive settings significantly reduce the likelihood of adverse reactions, including panic, paranoia, or psychological distress. Positive therapeutic outcomes are strongly correlated with the participant's trust in the environment and the facilitators.<ref>{{cite journal | vauthors = Hartogsohn I | title = Modalities of the psychedelic experience: Microclimates of set and setting in hallucinogen research and culture | journal = Transcultural Psychiatry | volume = 59 | issue = 5 | pages = 579–591 | date = October 2022 | pmid = 35818775 | doi = 10.1177/13634615221100385 }}</ref><ref>{{cite journal | vauthors = Devenot N, Seale-Feldman A, Smith E, Noorani T, Garcia-Romeu A, Johnson MW | title = Psychedelic Identity Shift: A Critical Approach to Set And Setting | journal = Kennedy Institute of Ethics Journal | volume = 32 | issue = 4 | pages = 359–399 | date = December 2022 | pmid = 38588216 | doi = 10.1353/ken.2022.0022 }}</ref>

====Theory of mind network and default mode network====
Psychedelics, including psilocybin, have been shown to affect different clusters of brain regions known as the "theory of mind network" (ToMN) and the [[default mode network]] (DMN).<ref name=":0">{{cite journal | vauthors = Soares C, Gonzalo G, Castelhano J, Castelo-Branco M | title = The relationship between the default mode network and the theory of mind network as revealed by psychedelics - A meta-analysis | journal = Neuroscience and Biobehavioral Reviews | volume = 152 | article-number = 105325 | date = September 2023 | pmid = 37467907 | doi = 10.1016/j.neubiorev.2023.105325 | doi-access = free }}</ref> The ToMN involves making inferences and understanding social situations based on patterns,<ref>{{cite journal | vauthors = Theriault J, Waytz A, Heiphetz L, Young L | title = Theory of mind network activity is associated with metaethical judgment: An item analysis | journal = Neuropsychologia | volume = 143 | article-number = 107475 | date = June 2020 | pmid = 32360298 | doi = 10.1016/j.neuropsychologia.2020.107475 }}</ref> whereas the DMN relates more to introspection and one's sense of self.<ref name=":0" /> The DMN, in particular, is related to increased rumination and worsening self-image in patients with major depressive disorder (MDD).<ref>{{cite journal | vauthors = Chou T, Deckersbach T, Dougherty DD, Hooley JM | title = The default mode network and rumination in individuals at risk for depression | journal = Social Cognitive and Affective Neuroscience | volume = 18 | issue = 1 | article-number = nsad032 | date = June 2023 | pmid = 37261927 | pmc = 10634292 | doi = 10.1093/scan/nsad032 }}</ref> In studies done with single use psilocybin, areas of the DMN showed decreased functional connectivity (communication between areas of the brain). This provides functional insight into the work of psilocybin in increasing one's sense of connection to one's surroundings, as the areas of the brain involved in introspection decrease in functionality under the effects of the drug.<ref>{{cite journal | vauthors = Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH, Timmermann C, Castle D, Rossell SL, Downey LA, Pagni BA, Galvão-Coelho NL, Nutt D, Sarris J | title = Default Mode Network Modulation by Psychedelics: A Systematic Review | journal = The International Journal of Neuropsychopharmacology | volume = 26 | issue = 3 | pages = 155–188 | date = March 2023 | pmid = 36272145 | pmc = 10032309 | doi = 10.1093/ijnp/pyac074 | author-link9 = Susan Rossell }}</ref> Conversely, areas of the brain involved in the ToMN showed increased activity and functional activation in response to psychedelics. These results were not unique to psilocybin and there was no significant difference in brain activation found in similar trials of mescaline and LSD. Information and studies into the DMN and ToMN are relatively sparse and their connections to other psychiatric illnesses and the use of psychedelics is still largely unknown.<ref name=":0" />

====Group perceptions====
Through further [[anthropological]] studies regarding "personal insights"<ref>{{Cite web |title=Drug Addictions, Hallucinogens and Shamanism: the View from Anthropology - Document - Gale Academic OneFile<!-- Bot generated title --> |url=https://go.gale.com/ps/i.do?id=GALE%7CA76445692&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=15254283&p=AONE&sw=w&userGroupName=anon%7Ef134fbbe |url-status=live |archive-url=https://web.archive.org/web/20210823013553/https://go.gale.com/ps/i.do?id=GALE%7CA76445692&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=15254283&p=AONE&sw=w&userGroupName=anon~f134fbbe |archive-date=August 23, 2021 |access-date=August 23, 2021}}</ref> and the psychosocial effects of psilocybin, it can be seen in many traditional societies that powerful mind-active substances such as psilocybin are regularly "consumed ritually for therapeutic purposes or for transcending normal, everyday reality".<ref name="Batchelder_2001">{{Cite journal |vauthors=Batchelder T |date=2001 |title=Drug Addictions, Hallucinogens and Shamanism: the View from Anthropology |url=https://link.gale.com/apps/doc/A76445692/AONE?u=anon~f134fbbe&sid=googleScholar&xid=67117c36 |url-status=live |journal=Drug Addictions, Hallucinogens and Shamanism |series=Townsend Letter for Doctors and Patients |volume=217 |pages=74–77 |archive-url=https://web.archive.org/web/20211019195214/https://go.gale.com/ps/i.do?p=AONE&u=anon~f134fbbe&id=GALE%7CA76445692&v=2.1&it=r&sid=googleScholar&asid=67117c36 |archive-date=October 19, 2021 |access-date=August 23, 2021 |via=Gale Academic OneFile}}</ref> Positive effects that psilocybin has on individuals can be observed by taking on an anthropological approach and moving away from the Western biomedical view; this is aided by the studies done by Leary.<ref>{{Cite book |title=The psychedelic experience : a manual based on the Tibetan book of the dead |vauthors=Leary T |date=2007 |publisher=Citadel Press |others=Ralph Metzner, Ram Dass, activeth century Karma-gliṅ-pa |isbn=978-0-8065-1652-3 |location=New York |oclc=318713242 }}</ref> Within certain traditional societies, where the use of psilocybin is frequent for shamanic healing rituals, group collectives praise their guide, healer and shaman for helping alleviate their pains, aches and hurt. They do this through a group ritual practice where the group, or just the guide, ingests psilocybin to help extract any "toxic psychic residues or sorcerous implants"<ref name="Batchelder_2001" /> found in one's body.

Group therapies using "classic" psychedelics are becoming more commonly used in the Western world in clinical practice.<ref>{{cite journal | vauthors = Dos Santos RG, Bouso JC, Rocha JM, Rossi GN, Hallak JE | title = The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges | journal = Risk Management and Healthcare Policy | volume = 14 | pages = 901–910 | date = 2024-04-24 | pmid = 33707976 | pmc = 7943545 | doi = 10.2147/RMHP.S300656 | doi-access = free }}</ref> This is speculated to grow, provided the evidence remains indicative of their safety and efficacy.<ref>{{cite journal | vauthors = Hendricks PS | title = Psilocybin-assisted group therapy: A new hope for demoralization | journal = eClinicalMedicine | volume = 27 | article-number = 100557 | date = October 2020 | pmid = 33073220 | pmc = 7549063 | doi = 10.1016/j.eclinm.2020.100557 }}</ref> In social sense, the group is shaped by their experiences surrounding psilocybin and how they view the fungus collectively. As mentioned in the anthropology article,<ref name="Batchelder_2001" /> the group partakes in a "journey" together, thus adding to the spiritual, social body where roles, hierarchies and gender are subjectively understood.<ref name="Batchelder_2001" />

====Cultural significance and "mystical" experiences====
[[File:Johns Hopkins psilocybin session room-SessionRm 2176x.jpg|thumb|In their studies on the psilocybin experience, Johns Hopkins researchers use peaceful music and a comfortable room to help ensure a comfortable setting, and experienced guides to monitor and reassure the volunteers.]]

Psilocybin mushrooms have been and continue to be used in [[Indigenous peoples of the Americas|Indigenous American]] cultures in religious, [[divinatory]], or [[spirituality|spiritual]] contexts. Reflecting the meaning of the word ''[[entheogen]]'' ("the god within"), the mushrooms are revered as powerful spiritual [[sacrament]]s that provide access to sacred worlds. Typically used in small group community settings, they enhance [[group cohesion]] and reaffirm traditional values.<ref name=Winkelman2007/> [[Terence McKenna]] documented the worldwide practices of psilocybin mushroom usage as part of a cultural [[ethos]] relating to the Earth and mysteries of nature, and suggested that mushrooms enhanced [[self-awareness]] and a sense of contact with a "Transcendent Other"—reflecting a deeper understanding of our connectedness with nature.<ref name=McKenna1992/>

Psychedelic drugs can induce states of [[consciousness]] that have lasting personal meaning and spiritual significance in religious or spiritually inclined people; these states are called [[mystical experience]]s. Some scholars have proposed that many of the qualities of a drug-induced mystical experience are indistinguishable from mystical experiences achieved through [[Religious experience#Causes of religious experiences|non-drug techniques]] such as meditation or [[holotropic breathwork]].<ref name=James1997/><ref name=Metzner1998/> In the 1960s, [[Walter Pahnke]] and colleagues systematically evaluated mystical experiences (which they called "mystical consciousness") by categorizing their common features. According to Pahnke, these categories "describe the core of a universal psychological experience, free from culturally determined philosophical or theological interpretations", and allow researchers to assess mystical experiences on a qualitative, numerical scale.<ref name=Pahnke1969/>

In the 1962 [[Marsh Chapel Experiment]], run by Pahnke at the [[Harvard Divinity School]] under Leary's supervision,<ref name=Pahnke1966/> almost all the graduate degree [[seminary|divinity]] student volunteers who received psilocybin reported profound religious experiences.<ref name=Griffiths2008/> One of the participants was religious scholar [[Huston Smith]], author of several textbooks on [[comparative religion]]; he called his experience "the most powerful cosmic homecoming I have ever experienced."<ref name=Smith2000/> In a 25-year followup to the experiment, all the subjects given psilocybin said their experience had elements of "a genuine mystical nature and characterized it as one of the high points of their spiritual life".<ref name="Doblin_1991">{{Cite journal |author-link=Rick Doblin |vauthors=Doblin R |year=1991 |title=Pahnke's "Good Friday Experiment": a long-term follow-up and methodological critique |journal=Journal of Transpersonal Psychology |volume=23 |issue=1 |pages=1–25}}</ref>{{rp|13}} Psychedelic researcher [[Rick Doblin]] considered the study partially flawed due to incorrect implementation of the [[double-blind]] procedure and several imprecise questions in the mystical experience questionnaire. Nevertheless, he said that the study cast "considerable doubt on the assertion that mystical experiences catalyzed by drugs are in any way inferior to non-drug mystical experiences in both their immediate content and long-term effects".<ref name="Doblin_1991" />{{rp|24}} Psychiatrist William A. Richards echoed this sentiment, writing in a 2007 review, "[psychedelic] mushroom use may constitute one technology for evoking revelatory experiences that are similar, if not identical, to those that occur through so-called spontaneous alterations of brain chemistry."<ref name=Richards2008/>

A group of researchers from [[Johns Hopkins School of Medicine]] led by [[Roland Griffiths]] conducted a study to assess the immediate and long-term psychological effects of the psilocybin experience, using a modified version of the mystical experience questionnaire and a rigorous double-blind procedure.<ref name=Griffiths2006/> When asked in an interview about the similarity of his work to Leary's, Griffiths explained the difference: "We are conducting rigorous, systematic research with psilocybin under carefully monitored conditions, a route which Dr. Leary abandoned in the early 1960s."<ref name="JHMed: Griffiths Interview" /> Experts have praised the [[National Institute of Drug Abuse]]-funded study, published in 2006, for the soundness of its experimental design.{{efn|The academic communities' approval for the methodology employed is exemplified by the quartet of commentaries published in the journal ''[[Psychopharmacology (journal)|Psychopharmacology]]'' titled "[http://www.hopkinsmedicine.org/Press_releases/2006/GriffithsCommentaries.pdf Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual experience by Griffiths ''et al''.]", by HD Kleber (pp.&nbsp;291–292), DE Nichols (pp.&nbsp;284–286), CR Schuster (pp.&nbsp;289–290), and SH Snyder (pp.&nbsp;287–288).}} In the experiment, 36 volunteers with no experience with hallucinogens were given psilocybin and [[methylphenidate]] (Ritalin) in separate sessions; the methylphenidate sessions served as a [[Scientific control|control]] and psychoactive [[placebo]]. The degree of mystical experience was measured using a questionnaire developed by Ralph W. Hood;<ref name=Hood1975/> 61% of subjects reported a "complete mystical experience" after their psilocybin session, while only 13% reported such an outcome after their experience with methylphenidate. Two months after taking psilocybin, 79% of the participants reported moderately to greatly increased [[life satisfaction]] and sense of well-being. About 36% of participants also had a strong to extreme "experience of fear" or [[dysphoria]] (i.e., a "bad trip") at some point during the psilocybin session (which was not reported by any subject during the methylphenidate session); about one-third of these (13% of the total) reported that this dysphoria dominated the entire session. These negative effects were reported to be easily managed by the researchers and did not have a lasting negative effect on the subject's sense of well-being.<ref name="urlMedical News" />

A follow-up study 14{{nbsp}}months later confirmed that participants continued to attribute deep personal meaning to the experience. Almost a third of the subjects reported that the experience was the single most meaningful or spiritually significant event of their lives, and over two-thirds reported it was among their five most spiritually significant events. About two-thirds said the experience increased their sense of well-being or life satisfaction.<ref name=Griffiths2008/> Even after 14 months, those who reported mystical experiences scored on average 4 percentage points higher on the personality trait of [[Openness to experience|Openness/Intellect]]; personality traits are normally stable across the lifespan for adults. Likewise, in a 2010 web-based questionnaire study designed to investigate user perceptions of the benefits and harms of hallucinogenic drug use, 60% of the 503 psilocybin users reported that their use of psilocybin had a long-term positive impact on their sense of well-being.<ref name=Amsterdam2011/><ref name=CarhartHarris2010/>

===Physical effects===
Common responses include [[Mydriasis|pupil dilation]] (93%); changes in [[heart rate]] (100%), including increases (56%), decreases (13%), and variable responses (31%); changes in [[blood pressure]] (84%), including [[hypotension]] (34%), [[hypertension]] (28%), and general instability (22%); changes in [[stretch reflex]] (86%), including increases (80%) and decreases (6%); nausea (44%); [[tremor]] (25%); and [[dysmetria]] (16%) (inability to properly direct or limit motions).<ref name="Passie2002" />{{efn|Percentages are derived from a [[Blind experiment#Double-blind trials|non-blind]] clinical study of 30 individuals who were given a dose of 8 to 12{{nbsp}}mg of psilocybin; from Passie (2002),<ref name=Passie2002/> citing Quentin (1960).<ref name=Quentin1960/>}} Psilocybin's [[sympathomimetic]] or [[cardiovascular]] effects, including increased [[heart rate]] and [[blood pressure]], are usually mild.<ref name="FradetKellyDonnelly2025" /><ref name="Passie2002" /> On average, peak heart rate is increased by 5{{nbsp}}bpm, peak [[systolic blood pressure]] by 10 to 15{{nbsp}}mm{{nbsp}}Hg, and peak [[diastolic blood pressure]] by 5 to 10{{nbsp}}mm{{nbsp}}Hg.<ref name="FradetKellyDonnelly2025" /><ref name="Passie2002" /> But temporary increases in blood pressure can be a risk factor for users with preexisting hypertension.<ref name="HaslerGrimbergBenz2004" /> Psilocybin's somatic effects have been corroborated by several early clinical studies.<ref>See for example:

* {{cite journal | vauthors = Isbell H | title = Comparison of the reactions induced by psilocybin and LSD-25 in man | journal = Psychopharmacologia | volume = 1 | issue = 1 | pages = 29–38 | year = 1959 | pmid = 14405870 | doi = 10.1007/BF00408109 | s2cid = 19508675 }}
* {{cite journal | vauthors = Hollister LE, Prusmack JJ, Paulsen A, Rosenquist N | title = Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects | journal = The Journal of Nervous and Mental Disease | volume = 131 | issue = 5 | pages = 428–434 | date = November 1960 | pmid = 13715375 | doi = 10.1097/00005053-196011000-00007 | s2cid = 8255131 }}
* {{cite journal | vauthors = Malitz S, Esecover H, Wilkens B, Hoch PH | title = Some observations on psilocybin, a new hallucinogen, in volunteer subjects | journal = Comprehensive Psychiatry | volume = 1 | pages = 8–17 | date = February 1960 | pmid = 14420328 | doi = 10.1016/S0010-440X(60)80045-4 }}{{Dead link|date=March 2023 |bot=InternetArchiveBot |fix-attempted=yes }}
* {{cite journal | vauthors = Rinkel M, Atwell CR, Dimascio A, Brown J | title = Experimental psychiatry. V. Psilocybine, a new psychotogenic drug | journal = The New England Journal of Medicine | volume = 262 | issue = 6 | pages = 295–297 | date = February 1960 | pmid = 14437505 | doi = 10.1056/NEJM196002112620606 }}
* {{cite journal | vauthors = Parashos AJ | title = The psilocybin-induced "state of drunkenness" in normal volunteers and schizophrenics | journal = Behavioral Neuropsychiatry | volume = 8 | issue = 1–12 | pages = 83–86 | year = 1976 | pmid = 1052267 }}</ref> A 2005 magazine survey of clubgoers in the UK found that over a quarter of those who had used psilocybin mushrooms in the preceding year experienced nausea or vomiting, although this was caused by the mushroom rather than psilocybin itself.<ref name=Amsterdam2011/> In one study, administration of gradually increasing doses of psilocybin daily for 21 days had no measurable effect on [[electrolyte]] levels, [[blood sugar]] levels, or [[Liver function tests|liver toxicity tests]].<ref name=Passie2002/>

===Onset and duration===
The [[onset of action]] of psilocybin taken [[oral administration|orally]] is 0.5 to 0.8{{nbsp}}hours (30–50{{nbsp}}minutes) on average, with a range of 0.1 to 1.5{{nbsp}}hours (5–90{{nbsp}}minutes).<ref name="HolzeSinghLiechti2024" /><ref name="MacCallumLoPistawka2022" /> Peak [[psychoactive drug|psychoactive]] effects occur at about 1.0 to 2.2{{nbsp}}hours (60–130{{nbsp}}minutes).<ref name="MacCallumLoPistawka2022" /><ref name="HolzeSinghLiechti2024" /> The [[time to offset]] of psilocybin orally is about 6 to 7{{nbsp}}hours on average.<ref name="HolzeBeckerKolaczynska2023" /> The [[duration of action]] of psilocybin is about 4 to 6{{nbsp}}hours (range 3–12{{nbsp}}hours) orally.<ref name="MacCallumLoPistawka2022" /><ref name="HolzeSinghLiechti2024" /><ref name="YerubandiThomasBhuiya2024">{{cite journal | vauthors = Yerubandi A, Thomas JE, Bhuiya NM, Harrington C, Villa Zapata L, Caballero J | title = Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis | journal = JAMA Network Open | volume = 7 | issue = 4 |article-number=e245960 | date = April 2024 | pmid = 38598236 | pmc = 11007582 | doi = 10.1001/jamanetworkopen.2024.5960 | quote = When selecting adverse event profile rates, the shortest time period available was selected and analyzed (eg, day 1 instead of day 30) since the half-life of psilocin is 3 ± 1.1 hours when taken orally and the duration of action can range between 3 to 12 hours.12,13 }}</ref> A small dose of 1{{nbsp}}mg by [[intravenous injection]] had a duration of 15 to 30{{nbsp}}minutes.<ref name="Passie2002" /><ref name="HaslerBourquinBrenneisen1997" /> In another study, 2{{nbsp}}mg psilocybin by intravenous injection given over 60{{nbsp}}seconds had an immediate onset, reached a sustained peak after 4{{nbsp}}minutes, and subsided completely after 45 to 60{{nbsp}}minutes.<ref name="Nichols2016">{{cite journal | vauthors = Nichols DE | title = Psychedelics | journal = Pharmacological Reviews | volume = 68 | issue = 2 | pages = 264–355 | date = April 2016 | pmid = 26841800 | pmc = 4813425 | doi = 10.1124/pr.115.011478 | quote = [...] psilocybin is not typically administered to humans by injection, nor are Psilocybe mushrooms generally taken in routes other than by mouth. In the Hermle et al. (1992), Vollenweider et al. (1997a,b), and GouzoulisMayfrank et al. (1999) studies cited earlier, the drug was administered orally, but psilocybin was administered intravenously in the studies by Carhart-Harris et al. Subjective reports from the two different routes of administration indicate profound differences in the speed of onset, as well as the intensity of the subjective effects. Psilocybin given orally generally takes about 40 minutes to begin to manifest its effect, with a duration of action lasting 4–6 hours. By contrast, subjective effects of 2 mg psilocybin given as an intravenous injection over 60 seconds begin at the injection period, reach a sustained peak after 4 minutes, and subside completely after 45–60 minutes (Carhart-Harris et al., 2011). }}</ref><ref name="Carhart-HarrisWilliams2011">{{cite journal | vauthors = Carhart-Harris RL, Williams TM, Sessa B, Tyacke RJ, Rich AS, Feilding A, Nutt DJ | title = The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability | journal = Journal of Psychopharmacology | volume = 25 | issue = 11 | pages = 1562–1567 | date = November 2011 | pmid = 20395317 | doi = 10.1177/0269881110367445 }}</ref>

==Contraindications==
[[Contraindication]]s of psilocybin are mostly [[psychiatric condition]]s that increase the risk of [[psychological distress]], including the rare [[adverse effect]] of [[psychosis]] during or after the psychedelic experience.<ref name="MacCallumLoPistawka2022" /><ref name="SabéSulstarovaGlangetas2025">{{cite journal | vauthors = Sabé M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, Richard-Lepouriel H, Penzenstadler L, Seragnoli F, Thorens G, Zullino D, Preller K, Böge K, Leucht S, Correll CU, Solmi M, Kaiser S, Kirschner M | title = Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies | journal = Mol Psychiatry | volume = 30 | issue = 3 | pages = 1223–1255 | date = March 2025 | pmid = 39592825 | pmc = 11835720 | doi = 10.1038/s41380-024-02800-5 | url = }}</ref> These conditions may include history of psychosis, [[schizophrenia]], [[bipolar disorder]], or [[borderline personality disorder]].<ref name="MacCallumLoPistawka2022" /><ref name="DowneyBradleyLerche2024">{{cite journal | vauthors = Downey AE, Bradley ER, Lerche AS, O'Donovan A, Krystal AD, Woolley J | title = A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy? | journal = Psychedelic Med (New Rochelle) | volume = 2 | issue = 2 | pages = 61–73 | date = June 2024 | pmid = 40051581 | doi = 10.1089/psymed.2023.0051 | pmc = 11658676 | url = https://odonovanlab.ucsf.edu/sites/g/files/tkssra7476/f/Downey%2C%20A.%20E.%20-%20A%20Plea%20for%20Nuance_%20Should%20People%20with%20a%20Family%20History%20of%20Bipolar%20Disorder%20Be%20Excluded%20from%20Clinical%20Trials%20of%20Psilocybin%20Therapy_.pdf#page=2}}</ref> Further research may provide more [[drug safety|safety]] information about the use of psilocybin in people with such conditions.<ref name="MacCallumLoPistawka2022" /> It is notable in this regard that psilocybin and other psychedelics are being studied for the potential treatment of all the preceding conditions.<ref name="YaoGuoLu2024" /><ref name="WolfSinghBlakolmer2023">{{cite journal | vauthors = Wolf G, Singh S, Blakolmer K, Lerer L, Lifschytz T, Heresco-Levy U, Lotan A, Lerer B | title = Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation | journal = Mol Psychiatry | volume = 28 | issue = 1 | pages = 44–58 | date = January 2023 | pmid = 36280752 | doi = 10.1038/s41380-022-01832-z | url = }}</ref><ref name="SapienzaMartiniComai2025">{{cite journal | vauthors = Sapienza J, Martini F, Comai S, Cavallaro R, Spangaro M, De Gregorio D, Bosia M | title = Psychedelics and schizophrenia: a double-edged sword | journal = Mol Psychiatry | volume = 30 | issue = 2 | pages = 679–692 | date = February 2025 | pmid = 39294303 | doi = 10.1038/s41380-024-02743-x | url = }}</ref><ref name="Maćkowiak2023">{{cite journal | vauthors = Maćkowiak M | title = Psychedelics action and schizophrenia | journal = Pharmacol Rep | volume = 75 | issue = 6 | pages = 1350–1361 | date = December 2023 | pmid = 37899392 | pmc = 10661800 | doi = 10.1007/s43440-023-00546-5 | url = }}</ref><ref name="BoschHalmSeifritz2022">{{cite journal | vauthors = Bosch OG, Halm S, Seifritz E | title = Psychedelics in the treatment of unipolar and bipolar depression | journal = Int J Bipolar Disord | volume = 10 | issue = 1 | article-number = 18 | date = July 2022 | pmid = 35788817 | pmc = 9256889 | doi = 10.1186/s40345-022-00265-5 | doi-access = free | url = }}</ref><ref name="CarrithersRobertsWeiss2025">{{cite journal | vauthors = Carrithers BM, Roberts DE, Weiss BM, King JD, Carhart-Harris RL, Gordon AR, Pagni BA, Moreau M, Ross S, Zeifman RJ | title = Exploring Serotonergic Psychedelics as a Treatment for Personality Disorders | journal = Neuropharmacology | volume = 272| issue = | article-number = 110413 | date = March 2025 | pmid = 40081794 | doi = 10.1016/j.neuropharm.2025.110413 | url = }}</ref>

Psilocybin is also considered to be contraindicated in women who are [[pregnancy|pregnant]] or [[breastfeeding]] due to insufficient research in this population.<ref name="MacCallumLoPistawka2022" /> There are transient increases in [[heart rate]] and [[blood pressure]] with psilocybin, and hence uncontrolled [[cardiovascular condition]]s are a relative contraindication for psilocybin.<ref name="MacCallumLoPistawka2022" /> [[Serotonin]] [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] [[receptor antagonist|antagonist]]s such as [[atypical antipsychotic]]s and certain [[antidepressant]]s may block psilocybin's hallucinogenic effects and hence may be considered contraindicated in this sense.<ref name="HalmanKongSarris2024" /><ref name="YatesMelon2024" /> [[Monoamine oxidase inhibitor]]s (MAOIs) may potentiate psilocybin's effects and augment its risks.<ref name="HalmanKongSarris2024" />

==Adverse effects==
Most of the comparatively few fatal incidents associated with psychedelic mushroom usage involve the simultaneous use of other drugs, especially [[ethanol|alcohol]]. A common [[adverse effect]] resulting from psilocybin mushroom use involves "bad trips" or [[panic attack|panic reactions]], in which people become anxious, confused, agitated, or disoriented.<ref name="nida">{{Cite web |date=2024-01-24 |title=Psilocybin (Magic Mushrooms)|publisher=National Institute on Drug Abuse, US National Institutes of Health |url=https://nida.nih.gov/research-topics/psilocybin-magic-mushrooms |archive-url=https://web.archive.org/web/20240125041854/https://nida.nih.gov/research-topics/psilocybin-magic-mushrooms |url-status=dead |archive-date=January 25, 2024 |access-date=2024-04-24}}</ref> Accidents, [[self-injury]], or [[suicide attempt]]s can result from serious cases of acute [[psychotic episodes]].<ref name="Amsterdam2011" /> No studies have linked psilocybin with [[birth defects]],<ref name="Pagliaro2012" /> but it is recommended that pregnant women avoid its usage.<ref name="Schaefer2001" />

===Psychiatric adverse effects===
Panic reactions can occur after consumption of psilocybin-containing mushrooms, especially if the ingestion is accidental or otherwise unexpected. Reactions characterized by violent behavior, suicidal thoughts,<ref name="Peden1982" /> schizophrenia-like [[psychosis]],<ref name="Vollenweider1998" /><ref name="Hyde1978" /> and [[convulsion]]s<ref name="Mack1983" /> have been reported in the literature. A 2005 survey conducted in the United Kingdom found that almost a quarter of those who had used psilocybin mushrooms in the past year had experienced a panic attack.<ref name="Amsterdam2011" /> {{Failed verification|date=April 2023}} Less frequently reported adverse effects include paranoia, [[confusion]], prolonged [[derealization]] (disconnection from reality), and [[mania]].<ref name="CarhartHarris2010" /> Psilocybin usage can temporarily induce a state of [[Depersonalization-derealization disorder|depersonalization disorder]].<ref name="Simeon2011" /> Usage by those with [[schizophrenia]] can induce acute psychotic states requiring hospitalization.<ref>{{cite journal | vauthors = Nielen RJ, van der Heijden FM, Tuinier S, Verhoeven WM | title = Khat and mushrooms associated with psychosis | journal = The World Journal of Biological Psychiatry | volume = 5 | issue = 1 | pages = 49–53 | date = January 2004 | pmid = 15048636 | doi = 10.1080/15622970410029908 | s2cid = 44321700 }}</ref>

The similarity of psilocybin-induced symptoms to those of schizophrenia has made the drug a useful research tool in behavioral and [[neuroimaging]] studies of schizophrenia.<ref name="Geyer1998" /><ref name="Vollenweider2001" /><ref name="Geyer2008" /> In both cases, psychotic symptoms are thought to arise from a "deficient gating of sensory and cognitive information" in the brain that leads to "cognitive fragmentation and psychosis".<ref name="Vollenweider2001" /> [[Flashback (psychology)|Flashbacks]] (spontaneous recurrences of a previous psilocybin experience) can occur long after psilocybin use. [[Hallucinogen persisting perception disorder]] (HPPD) is characterized by a continual presence of visual disturbances similar to those generated by psychedelic substances. Neither flashbacks nor HPPD are commonly associated with psilocybin usage,<ref name="Amsterdam2011" /> and correlations between HPPD and psychedelics are further obscured by [[polydrug use]] and other variables.<ref name="Myers1998" />

===Tolerance and dependence===
[[File:Drug danger and dependence-no title.svg|class=skin-invert-image|thumb|upright=2.5|600px|Chart of dependence potential and effective dose/lethal dose ratio of several [[psychoactive drug]]s.<ref name="Fish2006" />]]

[[Drug tolerance|Tolerance]] to psilocybin builds and dissipates quickly; ingesting it more than about once a week can lead to diminished effects. Tolerance dissipates after a few days, so doses can be spaced several days apart to avoid the effect.<ref name="Nicholas2006" /> A [[cross-tolerance]] can develop between psilocybin and LSD,<ref name="Passie2008" /> and between psilocybin and [[phenethylamine]]s such as [[mescaline]] and [[2,5-dimethoxy-4-methylamphetamine|DOM]].<ref name="HalberstadtGeyer2011" />

Repeated use of psilocybin does not lead to [[physical dependence]].<ref name="Passie2002" /> A 2008 study concluded that, based on U.S. data from 2000 to 2002, adolescent-onset (defined here as ages 11–17) usage of hallucinogenic drugs (including psilocybin) did not increase the risk of [[drug dependence]] in adulthood; this was in contrast to adolescent usage of [[cannabis (drug)|cannabis]], [[cocaine]], [[inhalant]]s, [[anxiolytic]] medicines, and [[stimulant]]s, all of which were associated with "an excess risk of developing clinical features associated with drug dependence".<ref name="Chen2008" /> Likewise, a 2010 Dutch study ranked the relative harm of psilocybin mushrooms compared to a selection of 19 [[recreational drugs]], including alcohol, cannabis, cocaine, [[MDMA|ecstasy]], [[heroin]], and [[tobacco]]. Psilocybin mushrooms were ranked as the illicit drug with the lowest harm,<ref name="Amsterdam2010" /> corroborating conclusions reached earlier by expert groups in the United Kingdom.<ref name="Nutt2010" />

===Long-term effects===
A potential risk of frequent repeated use of psilocybin and other psychedelics is [[cardiac fibrosis]] and [[valvular heart disease|valvulopathy]] caused by [[serotonin]] [[5-HT2B receptor|5-HT<sub>2B</sub> receptor]] activation.<ref name="TagenMantuanivanHeerden2023"/><ref name="RouaudCalderHasler2024"/> But single high doses or widely spaced doses (e.g., months apart) are thought to be safe, and concerns about cardiac toxicity apply more to chronic [[psychedelic microdosing]] or very frequent intermittent use (e.g., weekly).<ref name="TagenMantuanivanHeerden2023" /><ref name="RouaudCalderHasler2024" />

==Overdose==
Psilocybin has low [[toxicity]], meaning that it has a low risk of inducing life-threatening events like breathing or heart problems.<ref name="Thomas2024" /><ref name=nida/> Research shows that health risks may develop with use of psilocybin. Nonetheless, [[hospitalization]]s from it are rare, and [[overdose]]s are generally mild and self-limiting.<ref name="Thomas2024" /><ref name=nida/> The lethal dose of psilocybin in humans is unknown, but has been estimated to be approximately 200{{nbsp}}times a typical recreational dose.<ref name="Thomas2024" />

A review of the management of psychedelic overdoses suggested that psilocybin-related overdose management should prioritize managing the immediate adverse effects, such as [[anxiety]] and [[paranoia]], rather than specific pharmacological interventions, as psilocybin's physiological toxicity tends to be rather limited.<ref name="Reinert2020" /> One analysis of people hospitalized for psilocybin poisoning found high urine concentrations of [[phenethylamine]] (PEA), suggesting that PEA might contribute to the effects of psilocybin poisoning.<ref name="Reinert2020" />

Despite acting as [[binding selectivity|non-selective]] [[serotonin receptor agonist]]s, psilocybin and other major serotonergic psychedelics like [[lysergic acid diethylamide]] (LSD) do not cause [[serotonin syndrome]] even in the context of extreme overdose.<ref name="MalcolmThomas2022">{{cite journal | vauthors = Malcolm B, Thomas K | title = Serotonin toxicity of serotonergic psychedelics | journal = Psychopharmacology (Berl) | volume = 239 | issue = 6 | pages = 1881–1891 | date = June 2022 | pmid = 34251464 | doi = 10.1007/s00213-021-05876-x | url = }}</ref><ref name="Thomas2024">{{cite book | vauthors = Thomas K | title=Toxicology and Pharmacological Interactions of Classic Psychedelics | series=Current Topics in Behavioral Neurosciences | publisher=Springer Berlin Heidelberg | publication-place=Berlin, Heidelberg | date=2024 | doi=10.1007/7854_2024_508 | url=https://link.springer.com/10.1007/7854_2024_508 | access-date=14 May 2025 | page=| pmid=39042251 }}</ref><ref name="TapThomasPáleníček2025">{{cite journal | vauthors = Tap SC, Thomas K, Páleníček T, Stenbæk DS, Oliveira-Maia AJ, van Dalfsen J, Schoevers R | title = Concomitant use of antidepressants and classic psychedelics: A scoping review | journal = J Psychopharmacol | volume = 39| issue = 10| pages = 2698811251368360 | date = September 2025 | article-number = 02698811251368360 | pmid = 40937732 | doi = 10.1177/02698811251368360 | pmc = 12572353 | url = | quote = Importantly, the idea of increased risk for developing serotonin syndrome and/or serotonin toxicity, when [antidepressants (ADs)] are co-administered with high doses of psychedelics, has recently been challenged, in part because classic psychedelics are partial agonists of the 5-HT2A receptor and would also compete for serotonin binding (Malcolm and Thomas, 2022; Rickli et al., 2016; Sarparast et al., 2022). Based on this clinical rationale, the concomitant use of ADs and classic psychedelics may be preferred, or patients could temporarily reduce the dose of ADs around dosing days with psychedelics to have minimal interactions. Simultaneously, the competition for 5-HT2A receptors could impede the biological action of psychedelics during concomitant use of ADs and potentially limit efficacy (Halman et al., 2024), particularly as the 5-HT2A receptor induces neuroplasticity (Cameron et al., 2023; Ly et al., 2018; Vargas et al., 2023).}}</ref> This is thought to be because they act as [[partial agonist]]s of [[serotonin receptor]]s like the serotonin [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]], in contrast to serotonin itself, which is a [[full agonist]].<ref name="MalcolmThomas2022" /><ref name="TapThomasPáleníček2025" />

In rats, the [[median lethal dose]] (LD<sub>50</sub>) of psilocybin when administered orally is 280{{nbsp}}mg/kg, approximately 1.5{{nbsp}}times that of [[caffeine]]. The lethal dose of psilocybin when administered [[intravenously]] in mice is 285{{nbsp}}mg/kg, in rats is 280{{nbsp}}mg/kg, and in rabbits is 12.5{{nbsp}}mg/kg.<ref name="Merck"/><ref name="Merck13th" /> Psilocybin comprises approximately 1% of the weight of ''Psilocybe cubensis'' mushrooms, and so nearly {{convert|1.7|kg}} of dried mushrooms, or {{convert|17|kg}} of fresh mushrooms, would be required for a {{convert|60|kg|adj=on}} person to reach the 280{{nbsp}}mg/kg LD<sub>50</sub> value of rats.<ref name="Amsterdam2011" /> Based on the results of animal studies and limited human [[case report]]s, the human lethal dose of psilocybin has been extrapolated to be 2,000 to 6,000{{nbsp}}mg, which is around 1,000 times greater than its [[effective dose (pharmacology)|effective dose]] of 6{{nbsp}}mg and 200{{nbsp}}times the typical recreational dose of 10 to 30{{nbsp}}mg.<ref name="Gable2004" /><ref name="Thomas2024">{{cite book | vauthors = Thomas K | title=Toxicology and Pharmacological Interactions of Classic Psychedelics | series=Current Topics in Behavioral Neurosciences | publisher=Springer Berlin Heidelberg | publication-place=Berlin, Heidelberg | date=2024 | doi=10.1007/7854_2024_508 | url=https://link.springer.com/10.1007/7854_2024_508 | access-date=14 May 2025 | page=| pmid=39042251 }}</ref> The [[Registry of Toxic Effects of Chemical Substances]] assigns psilocybin a relatively high [[therapeutic index]] of 641 (higher values correspond to a better safety profile); for comparison, the therapeutic indices of [[aspirin]] and [[nicotine]] are 199 and 21, respectively.<ref name="Strassman2008" /> The lethal dose from psilocybin toxicity alone is unknown, and has rarely been documented—{{As of|2011|lc=y}}, only two cases attributed to overdosing on hallucinogenic mushrooms (without concurrent use of other drugs) have been reported in the scientific literature, and those may involve factors other than psilocybin.<ref name="Amsterdam2011" />{{efn|One of the reported fatalities, that of a 22-year-old French man who died in 1993,<ref name=Gerault1996/> was later challenged in the literature by Jochen Gartz and colleagues, who concluded "the few reported data concerning the victim are insufficient to exclude other possible causes of the fatality".<ref name=Gartz1996/>}}

==Interactions==
{{See also|Psychedelic drug#Interactions|Trip killer#Serotonergic psychedelic antidotes|Head-twitch response#Modulators of the head-twitch response}}

Serotonin [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] [[receptor antagonist|antagonist]]s can block the hallucinogenic effects of serotonergic psychedelics like psilocybin.<ref name="HalmanKongSarris2024" /><ref name="SarparastThomasMalcolm2022">{{cite journal | vauthors = Sarparast A, Thomas K, Malcolm B, Stauffer CS | title = Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review | journal = Psychopharmacology (Berl) | volume = 239 | issue = 6 | pages = 1945–1976 | date = June 2022 | pmid = 35253070 | pmc = 9177763 | doi = 10.1007/s00213-022-06083-y | url = }}</ref> Numerous drugs act as serotonin 5-HT<sub>2A</sub> receptor antagonists, including [[antidepressant]]s like [[trazodone]] and [[mirtazapine]], [[antipsychotic]]s like [[quetiapine]], [[olanzapine]], and [[risperidone]], and other agents like [[ketanserin]], [[pimavanserin]], [[cyproheptadine]], and [[pizotifen]].<ref name="HalmanKongSarris2024" /><ref name="YatesMelon2024">{{Cite journal |vauthors=Yates G, Melon E |date=January 2024 |title=Trip-killers: a concerning practice associated with psychedelic drug use |journal=Emerg Med J |volume=41 |issue=2 |pages=112–113 |doi=10.1136/emermed-2023-213377 |pmid=38123961 |url=https://s3.amazonaws.com/crawl.prod.proquest.com/fpcache/71f445805bfb61341cbc438c8ae23bd3.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBMaCXVzLWVhc3QtMSJIMEYCIQDETX7YpaG5THA%2FNbKR0d92wr6h%2Bgg9preNcKjAsEqo%2BQIhAIlPGGWOeUc23LqhBzRYbxvSXB9aqSe2vVonl4nacAhhKp0CCLz%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMNTE4MzQ2ODQ4MzQxIgy9ji58Qtbi%2BavuKeYq8QEDL1U5KZDQ0bXFyVapeqJgE%2FX6x8DcJfFU8DAXYZPSQEwrIdfPbZWcYsH340deru%2FUHnNaGGpuHFoVzui%2FMbqBz7MANcowj%2FL1%2BQZzQ5hXh5KM3BW8E6NRzrQyuPRmBy7kQUkx8%2BjTN%2BXSMgF%2FCAs6Dn9fScgBGz3ddkwRZXDkjasqMP65RCPKhagK68cyMbf3oX%2BKS8a4Kltc2rk3CnWEhOKrZU4mIxq07DikLAXQbl8YRZJIkeOhN5TgBaLWJqyn1td2VWCMymAaFsqtPWHwXnEfsolRlfDooe6QXfE2YwX5PxBVJU7GPXRgrAqPjwtJMOCHgsEGOpwBYif%2BaDMBdz3IEghuvCvorAS0mkHzdcOz%2Fi7AzuN9nch%2FIm8llhMsN41aAWHuSG25pnhhftauFsg7rbGsrW2nl2kq2upi9zP7y%2Fnqk93jcP0kr0jM8zU12bYoSTsToQJsshH4N%2BTQUMwlzRQfeVv8MXdq%2BgSTTzJrWNwT1yNzye3rSHjvOumbNl6sgBISw7QqRzhB6hZTuf8AcI%2B7&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20250511T111826Z&X-Amz-SignedHeaders=host&X-Amz-Credential=ASIAXRL7BHBKRAKCQVVB%2F20250511%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Expires=3600&X-Amz-Signature=20bb1b90e4c8dbaa4115c954387617ebe2f55269bdd517692f1380193ed3f769 |archive-url=https://web.archive.org/web/20250511111827/https://s3.amazonaws.com/crawl.prod.proquest.com/fpcache/71f445805bfb61341cbc438c8ae23bd3.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBMaCXVzLWVhc3QtMSJIMEYCIQDETX7YpaG5THA%2FNbKR0d92wr6h%2Bgg9preNcKjAsEqo%2BQIhAIlPGGWOeUc23LqhBzRYbxvSXB9aqSe2vVonl4nacAhhKp0CCLz%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMNTE4MzQ2ODQ4MzQxIgy9ji58Qtbi%2BavuKeYq8QEDL1U5KZDQ0bXFyVapeqJgE%2FX6x8DcJfFU8DAXYZPSQEwrIdfPbZWcYsH340deru%2FUHnNaGGpuHFoVzui%2FMbqBz7MANcowj%2FL1%2BQZzQ5hXh5KM3BW8E6NRzrQyuPRmBy7kQUkx8%2BjTN%2BXSMgF%2FCAs6Dn9fScgBGz3ddkwRZXDkjasqMP65RCPKhagK68cyMbf3oX%2BKS8a4Kltc2rk3CnWEhOKrZU4mIxq07DikLAXQbl8YRZJIkeOhN5TgBaLWJqyn1td2VWCMymAaFsqtPWHwXnEfsolRlfDooe6QXfE2YwX5PxBVJU7GPXRgrAqPjwtJMOCHgsEGOpwBYif%2BaDMBdz3IEghuvCvorAS0mkHzdcOz%2Fi7AzuN9nch%2FIm8llhMsN41aAWHuSG25pnhhftauFsg7rbGsrW2nl2kq2upi9zP7y%2Fnqk93jcP0kr0jM8zU12bYoSTsToQJsshH4N%2BTQUMwlzRQfeVv8MXdq%2BgSTTzJrWNwT1yNzye3rSHjvOumbNl6sgBISw7QqRzhB6hZTuf8AcI%2B7&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20250511T111826Z&X-Amz-SignedHeaders=host&X-Amz-Credential=ASIAXRL7BHBKRAKCQVVB%2F20250511%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Expires=3600&X-Amz-Signature=20bb1b90e4c8dbaa4115c954387617ebe2f55269bdd517692f1380193ed3f769 |url-status=dead |archive-date=2025-05-11 }}</ref> Such drugs are sometimes called "[[trip killer]]s" because they can prevent or abort psychedelics' hallucinogenic effects.<ref name="Jayasinha2024">{{Cite thesis | vauthors = Jayasinha BG |degree = Masters of Arts |title=Towards Safer Trips: Exploring Harm Reduction Strategies for Recreational Psychedelic Use in Aotearoa New Zealand |date=8 February 2024 |access-date=3 October 2024 |publisher=University of Otago |url=https://ourarchive.otago.ac.nz/esploro/outputs/graduate/Towards-Safer-Trips-Exploring-Harm-Reduction/9926550679501891 }}</ref><ref name="YatesMelon2024" /><ref name="Suran2024">{{Cite journal |vauthors=Suran M |date=February 2024 |title=Study Finds Hundreds of Reddit Posts on "Trip-Killers" for Psychedelic Drugs |journal=JAMA |volume=331 |issue=8 |pages=632–634 |doi=10.1001/jama.2023.28257 |pmid=38294772}}</ref> Serotonin 5-HT<sub>2A</sub> receptor antagonists that have been specifically shown in clinical studies to diminish or abolish psilocybin's effects include ketanserin, risperidone, and [[chlorpromazine]].<ref name="HalmanKongSarris2024" /><ref name="SarparastThomasMalcolm2022" />

The serotonin [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[partial agonist]] [[buspirone]] has been found to markedly reduce psilocybin's hallucinogenic effects in humans.<ref name="HalmanKongSarris2024" /><ref name="SarparastThomasMalcolm2022" /><ref name="BrandtKavanaghTwamley2018" /><ref name="PokornyPrellerKraehenmann2016" /> Conversely, the serotonin 5-HT<sub>1A</sub> receptor antagonist [[pindolol]] has been found to potentiate the hallucinogenic effects of the related psychedelic [[dimethyltryptamine]] (DMT) by 2- to 3-fold in humans.<ref name="PokornyPrellerKraehenmann2016" /><ref name="Strassman1996" /> [[Selective serotonin reuptake inhibitor]]s (SSRIs) may modify psilocybin's effects.<ref name="HalmanKongSarris2024" /><ref name="SarparastThomasMalcolm2022" /><ref name="BeckerHolzeGrandinetti2022" /> One clinical trial found that psilocybin's hallucinogenic and "good drug" effects were not modified by the SSRI [[escitalopram]], but that its "bad drug effects" such as [[anxiety]], as well as [[ego dissolution]], were reduced, among other changes.<ref name="SarparastThomasMalcolm2022" /><ref name="HalmanKongSarris2024" /><ref name="BeckerHolzeGrandinetti2022">{{cite journal | vauthors = Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME | title = Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects | journal = Clin Pharmacol Ther | volume = 111 | issue = 4 | pages = 886–895 | date = April 2022 | pmid = 34743319 | pmc = 9299061 | doi = 10.1002/cpt.2487 | url = }}</ref>

[[Benzodiazepine]]s such as [[diazepam]], [[alprazolam]], [[clonazepam]], and [[lorazepam]], as well as [[alcohol (drug)|alcohol]], which act as [[GABAA receptor positive allosteric modulator|GABA<sub>A</sub> receptor positive allosteric modulator]]s, have been limitedly studied in combination with psilocybin and other psychedelics and are not known to directly interact with them.<ref name="SarparastThomasMalcolm2022" /><ref name="HalmanKongSarris2024" /> But these [[GABAergic]] drugs produce effects such as [[anxiolytic|anxiolysis]], [[sedation]], and [[amnesia]], and may therefore diminish or otherwise oppose psychedelics' effects.<ref name="HalmanKongSarris2024" /><ref name="Jayasinha2024" /><ref name="YatesMelon2024" /><ref name="Suran2024" /><ref name="Olsen2018">{{cite journal | vauthors = Olsen RW | title = GABA<sub>A</sub> receptor: Positive and negative allosteric modulators | journal = Neuropharmacology | volume = 136 | issue = Pt A | pages = 10–22 | date = July 2018 | pmid = 29407219 | pmc = 6027637 | doi = 10.1016/j.neuropharm.2018.01.036 }}</ref> Because of this, recreational users often use benzodiazepines and alcohol as "trip killers" to manage difficult hallucinogenic experiences with psychedelics, such as experiences with prominent anxiety.<ref name="Jayasinha2024" /><ref name="YatesMelon2024" /><ref name="Suran2024" /> This strategy's [[drug safety|safety]] is not entirely clear and might have risks,<ref name="Jayasinha2024" /><ref name="SarparastThomasMalcolm2022" /><ref name="YatesMelon2024" /><ref name="Suran2024" /> but benzodiazepines have been used to manage psychedelics' adverse psychological effects in clinical studies and in [[emergency department|Emergency Rooms]].<ref name="SarparastThomasMalcolm2022" /><ref name="KaminskiReinert2024">{{cite journal | vauthors = Kaminski D, Reinert JP | title = The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review | journal = The Annals of Pharmacotherapy | volume = 58 | issue = 8 | pages = 811–826 | date = August 2024 | pmid = 37902038 | doi = 10.1177/10600280231205645 }}</ref><ref name="LeikinKrantzZell-Kanter1989">{{cite journal | vauthors = Leikin JB, Krantz AJ, Zell-Kanter M, Barkin RL, Hryhorczuk DO | title = Clinical features and management of intoxication due to hallucinogenic drugs | journal = Medical Toxicology and Adverse Drug Experience | volume = 4 | issue = 5 | pages = 324–350 | year = 1989 | pmid = 2682130 | doi = 10.1007/bf03259916 | publisher = Springer Science and Business Media LLC }}</ref><ref name="HalpernSuzukiHuertas2010">{{Cite book | vauthors = Halpern JH, Suzuki J, Huertas PE, Passie T |title=Addiction Medicine |publisher=Springer New York |year=2010 |isbn=978-1-4419-0337-2 |publication-place=New York, NY |pages=1083–1098 |chapter=Hallucinogens |doi=10.1007/978-1-4419-0338-9_54}}</ref><ref name="GartnerWanSimmons2024">{{cite journal | vauthors = Gartner HT, Wan HZ, Simmons RE, Sollee DR, Sheikh S | title = Psychedelic mushroom-containing chocolate exposures: Case series | journal = The American Journal of Emergency Medicine | volume = 85 | issue =  | pages = 208–213 | date = November 2024 | pmid = 39288500 | doi = 10.1016/j.ajem.2024.09.038 }}</ref> A clinical trial of psilocybin and [[midazolam]] coadministration found that midazolam clouded psilocybin's effects and [[memory impairment|impaired memory]] of the experience.<ref name="LimaSoaresTeixeira2024">{{cite journal | vauthors = Lima G, Soares C, Teixeira M, Castelo-Branco M | title = Psychedelic research, assisted therapy and the role of the anaesthetist: A review and insights for experimental and clinical practices | journal = British Journal of Clinical Pharmacology | volume = 90 | issue = 12 | pages = 3119–3134 | date = December 2024 | pmid = 39380091 | doi = 10.1111/bcp.16264 }}</ref><ref name="NicholasBanksLennertz2024">{{cite journal | vauthors = Nicholas CR, Banks MI, Lennertz RC, Wenthur CJ, Krause BM, Riedner BA, Smith RF, Hutson PR, Sauder CJ, Dunne JD, Roseman L, Raison CL | title = Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience | journal = Translational Psychiatry | volume = 14 | issue = 1 | article-number = 372 | date = September 2024 | pmid = 39266503 | pmc = 11393325 | doi = 10.1038/s41398-024-03059-8 }}</ref> Benzodiazepines might interfere with the therapeutic effects of psychedelics like psilocybin, such as sustained [[antidepressant]] effects.<ref name="BarnettVestDelatte2025">{{cite journal | vauthors = Barnett BS, Vest MF, Delatte MS, King Iv F, Mauney EE, Coulson AJ, Nayak SM, Hendricks PS, Greer GR, Murnane KS | title = Practical considerations in the establishment of psychedelic research programs | journal = Psychopharmacology | volume = 242 | issue = 1 | pages = 27–43 | date = January 2025 | pmid = 39627438 | pmc = 11742797 | doi = 10.1007/s00213-024-06722-6 | quote = Furthermore, benzodiazepines might attenuate the antidepressant effects of psychedelics (Hibicke et al. 2024). }}</ref><ref name="HibickeBillacNichols2024">{{cite journal | vauthors = Hibicke M, Billac G, Nichols CD | title = Preadministration of Lorazepam Reduces Efficacy and Longevity of Antidepressant-Like Effect from a Psychedelic | journal = Psychedelic Medicine | volume = 2 | issue = 1 | pages = 10–14 | date = March 2024 | pmid = 40051761 | doi = 10.1089/psymed.2023.0037 | pmc = 11658646 }}</ref>

[[Psilocin]], the [[active metabolite|active form]] of psilocybin, is a [[substrate (biochemistry)|substrate]] of the [[monoamine oxidase]] (MAO) [[enzyme]] [[MAO-A]].<ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="HolzeBeckerKolaczynska2023" /><ref name="TylšPáleníčekHoráček2014" /> The exact extent to which psilocin (and by extension psilocybin) is [[drug metabolism|metabolized]] by MAO-A is not fully clear, but has ranged from 4% to 33% in different studies based on [[metabolite]] [[excretion]].<ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="HolzeBeckerKolaczynska2023" /><ref name="TylšPáleníčekHoráček2014" /> Circulating levels of psilocin's [[deamination|deaminated]] [[metabolite]] are far higher than those of free unmetabolized psilocin with psilocybin administration.<ref name="DoddNormanEyre2023" /><ref name="HaslerBourquinBrenneisen1997" /> Combination of MAO-substrate psychedelics with [[monoamine oxidase inhibitor]]s (MAOIs) can result in [[overdose]] and [[toxicity]].<ref name="HalmanKongSarris2024" /> Examples of MAOIs that may potentiate psychedelics behaving as MAO-A substrates, such as psilocin, include [[phenelzine]], [[tranylcypromine]], [[isocarboxazid]], and [[moclobemide]], as well as [[harmala alkaloid]]s like [[harmine]] and [[harmaline]] and chronic [[tobacco]] [[smoking]].<ref name="HalmanKongSarris2024" /><ref name="SvedWeeksGrace2022">{{cite journal | vauthors = Sved AF, Weeks JJ, Grace AA, Smith TT, Donny EC | title = Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation | journal = Front Neurosci | volume = 16 | issue = | article-number = 886496 | date = 2022 | pmid = 36051642 | pmc = 9424897 | doi = 10.3389/fnins.2022.886496 | doi-access = free | url = }}</ref> An early clinical study of psilocybin in combination with short-term tranylcypromine pretreatment found that tranylcypromine marginally potentiated psilocybin's [[human body|peripheral]] effects, including [[pressor]] effects and [[mydriasis]], but overall did not significantly modify its psychoactive and hallucinogenic effects, although some of its emotional effects were said to be reduced and some of its perceptual effects were said to be amplified.<ref name="FradetKellyDonnelly2025" /><ref name="BarnettKoonsVandenEynde2024">{{cite journal | vauthors = Barnett BS, Koons CJ, Van den Eynde V, Gillman PK, Bodkin JA | title = Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine | journal = J Psychoactive Drugs | volume = 57| issue = 3| pages = 297–303 | date = June 2024 | pmid = 38903003 | doi = 10.1080/02791072.2024.2368617 | url = | doi-access = free }}</ref><ref name="VojtĕchovskýHortSafratová1968">{{cite journal | vauthors = Vojtĕchovský M, Hort V, Safratová V | title = Ovlvinĕní experimntálních psychóz po psilocybinu inhibitory MAO | trans-title = Influence of MAO inhibitors on psilocybine induced psychosis | language = Czech | journal = Act Nerv Super (Praha) | volume = 10 | issue = 3 | pages = 278–279 | date = October 1968 | pmid = 5702524 | doi = | url = }}</ref>

Psilocin may be metabolized to a minor extent by the [[cytochrome P450]] (CYP450) [[enzyme]]s [[CYP2D6]] and/or [[CYP3A4]] and appears unlikely to be metabolized by other CYP450 enzymes.<ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="FradetKellyDonnelly2025" /> The role of CYP450 enzymes in psilocin's metabolism seems to be small, and so considerable [[drug interaction]]s with CYP450 [[enzyme inhibitor|inhibitor]]s and/or [[enzyme inducer|inducer]]s may not be expected.<ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="FradetKellyDonnelly2025" /> Psilocin's major [[metabolic pathway]] is [[glucuronidation]] by [[UDP-glucuronosyltransferase]] enzymes including [[UGT1A10]] and [[UGT1A9]].<ref name="SarparastThomasMalcolm2022" /> [[Diclofenac]] and [[probenecid]] are inhibitors of these enzymes that theoretically might inhibit the metabolism of and thereby potentiate psilocybin's effects,<ref name="SarparastThomasMalcolm2022" /> but no clinical research or evidence on this possible interaction exists.<ref name="SarparastThomasMalcolm2022" /> Few other drugs are known to influence UGT1A10 or UGT1A9 function.<ref name="SarparastThomasMalcolm2022" />

==Pharmacology==
===Pharmacodynamics===
{{See also|Psychedelic drug#Pharmacology}}
{{Psilocin activities|float=right}}

Psilocybin is a [[serotonergic psychedelic]] that acts as a [[prodrug]] of [[psilocin]], the [[active metabolite|active form]] of the drug.<ref name="HolzeSinghLiechti2024" /><ref name="DoddNormanEyre2023">{{cite journal | vauthors = Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, Berk M | title = Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy | journal = CNS Spectr | volume = 28 | issue = 4 | pages = 416–426 | date = August 2023 | pmid = 35811423 | doi = 10.1017/S1092852922000888 | url = https://www.cambridge.org/core/services/aop-cambridge-core/content/view/AA1FB4F49C14BA3F398238D6E5A3947A/S1092852922000888a.pdf/div-class-title-psilocybin-in-neuropsychiatry-a-review-of-its-pharmacology-safety-and-efficacy-div.pdf}}</ref> Psilocin is a close [[structural analog|analogue]] of the [[monoamine neurotransmitter]] [[serotonin]] and, like serotonin, acts as a [[binding selectivity|non-selective]] [[agonist]] of the [[serotonin receptor]]s, including behaving as a [[partial agonist]] of the serotonin [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]].<ref name="HolzeSinghLiechti2024" /><ref name="DoddNormanEyre2023" /><ref name="TylšPáleníčekHoráček2014" /> It shows high [[affinity (pharmacology)|affinity]] for most of the serotonin receptors, with the notable exception of the serotonin [[5-HT3 receptor|5-HT<sub>3</sub> receptor]].<ref name="HolzeSinghLiechti2024" /><ref name="DoddNormanEyre2023" /><ref name="TylšPáleníčekHoráček2014" /> Psilocin's affinity for the serotonin 5-HT<sub>2A</sub> receptor is 15-fold higher in humans than in rats due to species differences.<ref name="TylšPáleníčekHoráček2014" /><ref name="GallaherChenShih1993">{{cite journal | vauthors = Gallaher TK, Chen K, Shih JC | date = 1993 | title = Higher affinity of psilocin for human than rat 5-HT2 receptor indicates binding site structure | journal = Medicinal Chemistry Research | volume = 3 | issue = | pages = 52–66 | url = https://scholar.google.com/scholar?cluster=2484757771892655822}}</ref> In addition to interacting with the serotonin receptors, psilocin is a [[partial monoamine releasing agent|partial]] [[serotonin releasing agent]] with lower [[potency (pharmacology)|potency]].<ref name="RothmanPartillaBaumann2012" /><ref name="BloughLandavazoDecker2014" /> Unlike certain other psychedelics such as [[LSD]], it appears to show little affinity for many other [[biological target|target]]s, such as [[dopamine receptor]]s.<ref name="GeigerWurstDaniels2018" /><ref name="HolzeSinghLiechti2024" /><ref name="FradetKellyDonnelly2025" /><ref name="RickliMoningHoener2016" /><ref name="BindingDB-Psilocin" /><ref name="PDSP-Psilocin" /> Psilocin is an agonist of the mouse and rat but not human [[trace amine-associated receptor 1]] (TAAR1).<ref name="GainetdinovHoenerBerry2018"/><ref name="RickliMoningHoener2016" /><ref name="ShaharBotvinnikEsh-Zuntz2022" />

Psilocybin's and psilocin's psychedelic effects are mediated specifically by agonism of the serotonin 5-HT<sub>2A</sub> receptor.<ref name="HolzeSinghLiechti2024" /><ref name="DoddNormanEyre2023" /> [[Binding selectivity|Selective]] serotonin 5-HT<sub>2A</sub> receptor [[receptor antagonist|antagonist]]s like [[volinanserin]] block the [[head-twitch response]] (HTR), a behavioral proxy of psychedelic-like effects, induced by psilocybin in rodents, and the HTR is similarly absent in serotonin 5-HT<sub>2A</sub> receptor [[knockout mice]].<ref name="DoddNormanEyre2023" /><ref name="TylšPáleníčekHoráček2014">{{cite journal | vauthors = Tylš F, Páleníček T, Horáček J | title = Psilocybin - summary of knowledge and new perspectives | journal = Eur Neuropsychopharmacol | volume = 24 | issue = 3 | pages = 342–356 | date = March 2014 | pmid = 24444771 | doi = 10.1016/j.euroneuro.2013.12.006 | url = https://www.researchgate.net/publication/259517753}}</ref><ref name="Erkizia-SantamaríaAlles-PascualHorrillo2022">{{cite journal | vauthors = Erkizia-Santamaría I, Alles-Pascual R, Horrillo I, Meana JJ, Ortega JE | title = Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response | journal = Biomed Pharmacother | volume = 154 | issue = | article-number = 113612 | date = October 2022 | pmid = 36049313 | doi = 10.1016/j.biopha.2022.113612 | url = | doi-access = free | hdl = 10810/58494 | hdl-access = free }}</ref><ref name="ShaharBotvinnikEsh-Zuntz2022">{{cite journal | vauthors = Shahar O, Botvinnik A, Esh-Zuntz N, Brownstien M, Wolf R, Lotan A, Wolf G, Lerer B, Lifschytz T | title = Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications | journal = Int J Mol Sci | volume = 23 | issue = 22 | date = November 2022 |article-number=14148 | pmid = 36430623 | pmc = 9698447 | doi = 10.3390/ijms232214148 | doi-access = free | url = }}</ref> There is a significant relationship between psilocybin's hallucinogenic effects and serotonin 5-HT<sub>2A</sub> receptor [[receptor occupancy|occupancy]] in humans.<ref name="HolzeSinghLiechti2024" /><ref name="HalberstadtGeyer2011" /><ref name="MadsenFisherBurmester2019">{{cite journal | vauthors = Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen GM | title = Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels | journal = Neuropsychopharmacology | volume = 44 | issue = 7 | pages = 1328–1334 | date = June 2019 | pmid = 30685771 | pmc = 6785028 | doi = 10.1038/s41386-019-0324-9 | url = }}</ref> Psilocybin's psychedelic effects can be blocked by serotonin 5-HT<sub>2A</sub> receptor antagonists like [[ketanserin]] and [[risperidone]] in humans.<ref name="Canal2018">{{cite journal | vauthors = Canal CE | title = Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action | journal = Handb Exp Pharmacol | series = Handbook of Experimental Pharmacology | volume = 252 | issue = | pages = 227–260 | date = 2018 | pmid = 29532180 | pmc = 6136989 | doi = 10.1007/164_2018_107 | isbn = 978-3-030-10560-0 | url = | quote = Reports from clinical trials conclude that the psychedelic effects of psilocybin and LSD are mediated by 5-HT2A receptors, because they are blocked by ketanserin (40 mg, P.O.), typically viewed as a selective 5-HT2A antagonist (Kometer et al. 2012; Kraehenmann et al. 2017; Preller et al. 2017; Quednow et al. 2012). Haloperidol, typically viewed as a selective dopamine D2 antagonist, is much less effective than ketanserin at blocking psilocybin's effects, but risperidone, an antipsychotic with combined D2/5-HT2 activity, is as effective as ketanserin (Vollenweider et al. 1998).}}</ref><ref name="HolzeSinghLiechti2024" /><ref name="DoddNormanEyre2023" /><ref name="HalberstadtGeyer2011" /><ref name="Vollenweider1998" /> Activation of serotonin 5-HT<sub>2A</sub> receptors in [[layer V]] of the [[medial prefrontal cortex]] (mPFC) and consequent [[glutamate]] release in this area has been especially implicated in the hallucinogenic effects of psilocybin and other serotonergic psychedelics.<ref name="DeGregorioEnnsNuñez2018">{{cite book | vauthors = De Gregorio D, Enns JP, Nuñez NA, Posa L, Gobbi G | chapter = D-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders | title = Psychedelic Neuroscience | series = Progress in Brain Research | volume = 242 | pages = 69–96 | date = 2018 | pmid = 30471683 | doi = 10.1016/bs.pbr.2018.07.008 | isbn = 978-0-12-814255-4 | url = | quote = Noteworthy, the activation of postsynaptic 5HT2A receptor in layer V of the medial prefrontal cortex (mPFC) is considered to be responsible for the visual hallucinations produced by LSD and other psychedelic drugs such as psilocybin (Jakab and Goldman-Rakic, 1998; Vollenweider and Kometer, 2010) (see Fig. 2). [...] Although the classic hallucinogens LSD and psilocybin do not have a direct affinity for glutamate receptors, several animal studies have highlighted that glutamate carries a significant weight of the overall downstream effects of LSD and hallucinogenic action. The activation of postsynaptic cortical 5HT2A increases extracellular glutamate release in the synaptic cleft which is reversed by selective 5-HT2A antagonists (Vollenweider et al., 1998), AMPA (α-amino-3-hydroxyl-5-methyl4-isoxazole-propionic acid) receptor antagonists (Zhang and Marek, 2008), agonists and positive allosteric modulators of mGluR2 (metabotropic glutamate receptor 2) (Benneyworth et al., 2007), and selective antagonists of the NR2B subunit of NMDA (N-methyl-D-aspartate) receptors (Lambe and Aghajanian, 2006). In particular, microdialysis in rats confirmed that systemic hallucinogen administration leads to a time-dependent increase in prefrontal cortex (PFC) glutamate levels, an effect which is blocked by administration with the selective 5HT2A antagonist M100907 (Muschamp et al., 2004). }}</ref><ref name="MarekSchoepp2021">{{cite book | vauthors = Marek GJ, Schoepp DD | chapter = Cortical influences of serotonin and glutamate on layer V pyramidal neurons | title = 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part B | series = Progress in Brain Research | volume = 261 | pages = 341–378 | date = 2021 | pmid = 33785135 | doi = 10.1016/bs.pbr.2020.11.002 | isbn = 978-0-444-64258-5 | url = }}</ref><ref name="Halberstadt2015" /><ref name="HalberstadtGeyer2018" /><ref name="WillinsMeltzer1997">{{cite journal | vauthors = Willins DL, Meltzer HY | title = Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats | journal = J Pharmacol Exp Ther | volume = 282 | issue = 2 | pages = 699–706 | date = August 1997 | pmid = 9262333 | doi = 10.1016/S0022-3565(24)36840-5| url = }}</ref> In addition, region-dependent alterations in brain glutamate levels may be related to the experience of [[ego dissolution]].<ref name="MasonKuypersMüller2020">{{cite journal | vauthors = Mason NL, Kuypers KP, Müller F, Reckweg J, Tse DH, Toennes SW, Hutten NR, Jansen JF, Stiers P, Feilding A, Ramaekers JG | title = Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin | journal = Neuropsychopharmacology | volume = 45 | issue = 12 | pages = 2003–2011 | date = November 2020 | pmid = 32446245 | pmc = 7547711 | doi = 10.1038/s41386-020-0718-8 | doi-access = free }}</ref> The [[cryo-EM]] [[protein–ligand complex|structure]]s of the serotonin 5-HT<sub>2A</sub> receptor with psilocin, as well as with various other psychedelics and serotonin 5-HT<sub>2A</sub> receptor agonists, have been solved and published by [[Bryan L. Roth]] and colleagues.<ref name="GumpperJainKim2025">{{cite journal | vauthors = Gumpper RH, Jain MK, Kim K, Sun R, Sun N, Xu Z, DiBerto JF, Krumm BE, Kapolka NJ, Kaniskan HÜ, Nichols DE, Jin J, Fay JF, Roth BL | title = The structural diversity of psychedelic drug actions revealed | journal = Nature Communications | volume = 16 | issue = 1 | article-number = 2734 | date = March 2025 | pmid = 40108183 | doi = 10.1038/s41467-025-57956-7 | pmc = 11923220 | bibcode = 2025NatCo..16.2734G }}</ref><ref name="GumpperDiBertoJain2022">{{cite conference | vauthors = Gumpper RH, DiBerto J, Jain M, Kim K, Fay J, Roth BL | title = Structures of Hallucinogenic and Non-Hallucinogenic Analogues of the 5-HT2A Receptor Reveals Molecular Insights into Signaling Bias | conference = University of North Carolina at Chapel Hill Department of Pharmacology Research Retreat September 16th, 2022 – William and Ida Friday Center | date = September 2022 | url = https://www.med.unc.edu/pharm/wp-content/uploads/sites/930/2022/07/COMPLETE-PHARM-RETREAT-PROGRAM-2022-UPDATE.pdf#page=37}}</ref>

Although serotonin 5-HT<sub>2A</sub> receptor agonism mediates the [[hallucinogen]]ic effects of psilocybin and psilocin, activation of other serotonin receptors also appears to contribute to these compounds' [[psychoactive drug|psychoactive]] and behavioral effects.<ref name="HalberstadtGeyer2011">{{cite journal | vauthors = Halberstadt AL, Geyer MA | title = Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens | journal = Neuropharmacology | volume = 61 | issue = 3 | pages = 364–381 | date = September 2011 | pmid = 21256140 | pmc = 3110631 | doi = 10.1016/j.neuropharm.2011.01.017 | url = }}</ref><ref name="DoddNormanEyre2023" /><ref name="TylšPáleníčekHoráček2014" /><ref name="CameronBenetatosLewis2023">{{cite journal | vauthors = Cameron LP, Benetatos J, Lewis V, Bonniwell EM, Jaster AM, Moliner R, Castrén E, McCorvy JD, Palner M, Aguilar-Valles A | title = Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action | journal = J Neurosci | volume = 43 | issue = 45 | pages = 7472–7482 | date = November 2023 | pmid = 37940583 | pmc = 10634557 | doi = 10.1523/JNEUROSCI.1384-23.2023 | url = }}</ref><ref name="CordnerPrandovszkyPedicini2022">{{cite journal | vauthors = Cordner Z, Prandovszky E, Pedicini M, Liu H, Macias L, Pletnikov M, Tamashiro K, Yolken R | title = ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P314. Psilocybin Alters Behavior and the Intestinal Microbiota in a Wild Type Mouse Model by Mechanisms That Are Not Fully Dependent on 5HT2A and 5HT2C Receptors | journal = Neuropsychopharmacology | volume = 47 | issue = Suppl 1 | pages = 220–370 (245–246) | date = December 2022 | pmid = 36456694 | pmc = 9714399 | doi = 10.1038/s41386-022-01485-0 | url = | quote = Psilocybin induced a robust head twitch response, increased exploratory behavior in the elevated plus maze, increased social behavior in the social interaction test, and decreased immobility in the forced swim test. Co-administration of ketanserin fully blocked the head twitch response without significantly altering psilocybin’s effects on other behavioral outcomes. In a separate cohort, treatment with psilocybin produced broad alteration of the intestinal microbiome, with particularly marked changes in the large intestine that were only partially blocked by pre-treatment with ketanserin. Finally, transplantation of intestinal contents from psilocybin-treated mice to naive untreated mice resulted in behavioral changes consistent with the effects of psilocybin treatment. [...] Our findings demonstrate that a single dose of psilocybin leads to behavioral changes in mice that are relevant for studies of resilience and affective disorders. Our results further indicate that the behavioral changes may not be fully dependent on psilocybin’s agonism of 5HT2A and 5HT2C receptors. Further, psilocybin appears to broadly alter the intestinal microbiome and transplantation of intestinal contents reproduces behavioral change associated with psilocybin treatment, suggesting a previously unknown microbiome-gut-brain mechanism of action.}}</ref><ref name="SinghShaharWolf2022">{{cite journal | vauthors = Singh S, Botvinnik A, Shahar O, Wolf G, Lotan A, Lerer B, Lifschytz T | title = ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P426. Translational Implications of Marble Burying in ICR Mice for the Anti-Obsessional Effects of Psilocybin | journal = Neuropsychopharmacology | volume = 47 | issue = Suppl 1 | pages = 220–370 (309–309) | date = December 2022 | pmid = 36456694 | pmc = 9714399 | doi = 10.1038/s41386-022-01485-0 | url = }}</ref> Serotonin [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] activation seems to inhibit the hallucinogenic effects of psilocybin and other psychedelics.<ref name="HalmanKongSarris2024">{{Cite journal |vauthors=Halman A, Kong G, Sarris J, Perkins D |date=January 2024 |title=Drug-drug interactions involving classic psychedelics: A systematic review |journal=J Psychopharmacol |volume=38 |issue=1 |pages=3–18 |doi=10.1177/02698811231211219 |pmc=10851641 |pmid=37982394}}</ref><ref name="BrandtKavanaghTwamley2018">{{cite journal | vauthors = Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL | title = Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775) | journal = Drug Test Anal | volume = 10 | issue = 2 | pages = 310–322 | date = February 2018 | pmid = 28585392 | pmc = 6230476 | doi = 10.1002/dta.2222 | url = | quote = Additionally, pretreatment with the 5‐HT1A agonist buspirone (20 mg p.o.) markedly attenuates the visual effects of psilocybin in human volunteers.59 Although buspirone failed to completely block the hallucinogenic effects of psilocybin, the limited inhibition is not necessarily surprising because buspirone is a low efficacy 5‐HT1A partial agonist.60 The level of 5‐HT1A activation produced by buspirone may not be sufficient to completely counteract the stimulation of 5‐HT2A receptors by psilocin (the active metabolite of psilocybin). Another consideration is that psilocin acts as a 5‐HT1A agonist.30 If 5‐HT1A activation by psilocin buffers its hallucinogenic effects similar to DMT58 then competition between psilocin and a weaker partial agonist such as buspirone would limit attenuation of the hallucinogenic response.}}</ref><ref name="PokornyPrellerKraehenmann2016">{{cite journal | vauthors = Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX | title = Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience | journal = Eur Neuropsychopharmacol | volume = 26 | issue = 4 | pages = 756–766 | date = April 2016 | pmid = 26875114 | doi = 10.1016/j.euroneuro.2016.01.005 | url = }}</ref><ref name="Strassman1996">{{cite journal | vauthors = Strassman RJ | title = Human psychopharmacology of N,N-dimethyltryptamine | journal = Behav Brain Res | volume = 73 | issue = 1–2 | pages = 121–124 | date = 1996 | pmid = 8788488 | doi = 10.1016/0166-4328(96)00081-2 | url = }}</ref> Some of psilocybin's non-hallucinogenic behavioral effects in animals can be reversed by antagonists of the serotonin 5-HT<sub>1A</sub>, [[5-HT2B receptor|5-HT<sub>2B</sub>]], and [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]]s.<ref name="DoddNormanEyre2023" /><ref name="TylšPáleníčekHoráček2014" /> Psilocybin produces profoundly [[hypolocomotion|decreased locomotor]] and [[exploration|investigatory behavior]] in rodents, and this appears to be dependent on serotonin 5-HT<sub>1A</sub> receptor activation but not on activation of the serotonin 5-HT<sub>2A</sub> or 5-HT<sub>2C</sub> receptors.<ref name="Halberstadt2015" /><ref name="HalberstadtGeyer2018">{{cite book | vauthors = Halberstadt AL, Geyer MA | title = Behavioral Neurobiology of Psychedelic Drugs | chapter = Effect of Hallucinogens on Unconditioned Behavior | series = Current Topics in Behavioral Neurosciences | volume = 36 | pages = 159–199 | date = 2018 | pmid = 28224459 | pmc = 5787039 | doi = 10.1007/7854_2016_466 | isbn = 978-3-662-55878-2 | chapter-url = http://www.ouramazingworld.org/uploads/4/3/8/6/43860587/halberstadt2016.pdf | quote = Compared with phenylalkylamines, tryptamine hallucinogens produce a disparate profile of effects in the mouse BPM. Administration of psilocin or 5-MeO-DMT produces a profound suppression of locomotor activity, investigatory holepokes and rearings, and center duration in C57BL/6J mice (Halberstadt et al. 2011). Most of these effects are blocked by pretreatment with the 5-HT1A antagonist WAY-100635, whereas the 5-HT2C antagonist SB242084 is ineffective. | archive-date = August 29, 2017 | access-date = February 7, 2025 | archive-url = https://web.archive.org/web/20170829193524/http://www.ouramazingworld.org/uploads/4/3/8/6/43860587/halberstadt2016.pdf | url-status = bot: unknown }}</ref><ref name="HalberstadtKoedoodPowell2011">{{cite journal | vauthors = Halberstadt AL, Koedood L, Powell SB, Geyer MA | title = Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice | journal = J Psychopharmacol | volume = 25 | issue = 11 | pages = 1548–1561 | date = November 2011 | pmid = 21148021 | pmc = 3531560 | doi = 10.1177/0269881110388326 | url = }}</ref> In addition, the serotonin [[5-HT1B receptor|5-HT<sub>1B</sub> receptor]] has been found to be required for psilocybin's persisting [[antidepressant]]- and [[anxiolytic]]-like effects as well as acute hypolocomotion in animals.<ref name="FleuryNautiyal2024">{{cite journal | vauthors = Fleury S, Nautiyal K | title = ACNP 63rd Annual Meeting: Poster Abstracts P609-P914: P691. The Non-Hallucinogenic Serotonin 1B Receptor is Necessary for the Persisting Behavioral Effects of Psilocybin in Mice | journal = Neuropsychopharmacology | volume = 49 | issue = Suppl 1 | pages = 418–594 (466) | date = December 2024 | pmid = 39643635 | doi = 10.1038/s41386-024-02013-y | url = | doi-access = free }}</ref> In humans, ketanserin blocked psilocybin's hallucinogenic effects but not all of its cognitive and behavioral effects.<ref name="HalberstadtGeyer2011" /> Serotonin 5-HT<sub>2C</sub> receptor activation and downstream inhibition of the [[mesolimbic pathway|mesolimbic dopamine pathway]] may be involved in the limited [[addictive potential]] of serotonergic psychedelics like psilocybin.<ref name="CanalMurnane2017">{{cite journal | vauthors = Canal CE, Murnane KS | title = The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens | journal = J Psychopharmacol | volume = 31 | issue = 1 | pages = 127–143 | date = January 2017 | pmid = 27903793 | pmc = 5445387 | doi = 10.1177/0269881116677104 | url = }}</ref>

In addition to its psychedelic effects, psilocin has been found to produce [[psychoplastogen]]ic effects in animals, including [[dendritogenesis]], [[spinogenesis]], and [[synaptogenesis]].<ref name="HatzipantelisOlson2024">{{cite journal | vauthors = Hatzipantelis CJ, Olson DE | title = The Effects of Psychedelics on Neuronal Physiology | journal = Annu Rev Physiol | volume = 86 | issue = | pages = 27–47 | date = February 2024 | pmid = 37931171 | doi = 10.1146/annurev-physiol-042022-020923 | pmc = 10922499 | url = }}</ref><ref name="DoddNormanEyre2023" /><ref name="LyGrebCameron2018">{{cite journal | vauthors = Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE | title = Psychedelics Promote Structural and Functional Neural Plasticity | journal = Cell Rep | volume = 23 | issue = 11 | pages = 3170–3182 | date = June 2018 | pmid = 29898390 | pmc = 6082376 | doi = 10.1016/j.celrep.2018.05.022 | url = }}</ref> It has been found to promote [[neuroplasticity]] in the brain in a rapid, robust, and sustained manner with a single dose.<ref name="HatzipantelisOlson2024" /><ref name="DoddNormanEyre2023" /> These effects appear to be mediated by [[intracellular]] serotonin 5-HT<sub>2A</sub> receptor activation.<ref name="HatzipantelisOlson2024" /><ref name="DoddNormanEyre2023" /><ref name="VargasDunlapDong2023">{{cite journal | vauthors = Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, Cameron LP, Patel SD, Hennessey JJ, Saeger HN, McCorvy JD, Gray JA, Tian L, Olson DE | title = Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors | journal = Science | volume = 379 | issue = 6633 | pages = 700–706 | date = February 2023 | pmid = 36795823 | pmc = 10108900 | doi = 10.1126/science.adf0435 | bibcode = 2023Sci...379..700V | url = }}</ref><ref name="LyGrebCameron2018" /> The psychoplastogenic effects of psilocybin and other serotonergic psychedelics may be involved in their potential therapeutic benefits in the treatment of [[psychiatric disorder]]s such as [[depression (mood)|depression]].<ref name="VargasMeyerAvanes2021">{{cite journal | vauthors = Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE | title = Psychedelics and Other Psychoplastogens for Treating Mental Illness | journal = Frontiers in Psychiatry | volume = 12 | article-number = 727117 | date = 2021 | pmid = 34671279 | pmc = 8520991 | doi = 10.3389/fpsyt.2021.727117 | doi-access = free }}</ref><ref name="Olson2021" /><ref name="DeVos2021" /> They may also be involved in the effects of [[microdosing]].<ref name="CalderHasler2023">{{cite journal | vauthors = Calder AE, Hasler G | title = Towards an understanding of psychedelic-induced neuroplasticity | journal = Neuropsychopharmacology | volume = 48 | issue = 1 | pages = 104–112 | date = January 2023 | pmid = 36123427 | pmc = 9700802 | doi = 10.1038/s41386-022-01389-z | url = }}</ref> Psilocin was also reported to act as a highly [[potency (pharmacology)|potent]] [[positive allosteric modulator]] of the [[tropomyosin receptor kinase B]] (TrkB), one of the [[receptor (biochemistry)|receptor]]s of [[brain-derived neurotrophic factor]] (BDNF),<ref name="HatzipantelisOlson2024" /><ref name="FradetKellyDonnelly2025">{{cite journal | vauthors = Fradet M, Kelly CM, Donnelly AJ, Suppes T | title = Psilocybin and hallucinogenic mushrooms | journal = CNS Spectr | volume = 29| issue = 6| pages = 611–632 | date = January 2025 | pmid = 39789676 | doi = 10.1017/S1092852924002487 | url = | quote = Upon their activation by psilocin, 5-HT2A receptors initiate complex cascades of downstream signaling. The activation of both canonical Gq/11 and β-arrestin-2 seems necessary to produce psychedelic effects,133 and so is the coactivation of Gi/o and Src tyrosine kinase.134 These specific pathways are thought to differentiate 5-HT2A receptor agonists with psychedelic properties from other agonists of the same receptor such as ergoline and lisuride that do not have hallucinogenic effects. [...] Although strong evidence supports that 5-HT2A activity mediates most of psilocin’s psychedelic properties, this substituted tryptamine also binds to many other receptors135–137. In fact, psilocin’s binding affinity is even higher for some other serotonin receptors such as 5-HT2C, 5-HT1A, and 5-HT2B137. It is currently difficult to determine the clinical significance of psilocin’s interaction with these receptors. Although they do not seem to contribute to the hallucinogenic properties of psilocin, these other serotonin receptors could potentially play a role in mediating its therapeutic effect.136, 138–140 [...] Psilocin has a very low affinity for the serotonin transporter (SERT), and it does not interact directly with the norepinephrine transporter (NET) or the dopamine transporter (DAT).137 Although it has the potential to bind with D1 and D3 receptors, it has no direct activity on the widespread D2 receptors.137 It does not interact with adrenergic, opioid, muscarinic, histamine, or cannabinoid receptors.137 | doi-access = free }}</ref><ref name="MolinerGirychBrunello2023">{{cite journal | vauthors = Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, Antenucci L, Kot EF, Goncharuk SA, Kaurinkoski K, Kuutti M, Fred SM, Elsilä LV, Sakson S, Cannarozzo C, Diniz CR, Seiffert N, Rubiolo A, Haapaniemi H, Meshi E, Nagaeva E, Öhman T, Róg T, Kankuri E, Vilar M, Varjosalo M, Korpi ER, Permi P, Mineev KS, Saarma M, Vattulainen I, Casarotto PC, Castrén E | title = Psychedelics promote plasticity by directly binding to BDNF receptor TrkB | journal = Nat Neurosci | volume = 26 | issue = 6 | pages = 1032–1041 | date = June 2023 | pmid = 37280397 | pmc = 10244169 | doi = 10.1038/s41593-023-01316-5 | url = }}</ref> but subsequent studies failed to reproduce these findings and instead found no interaction of psilocin with TrkB.<ref name="JainGumpperSlocum2025">{{cite journal | vauthors = Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, Suomivuori CM, Huang XP, Shub L, DiBerto JF, Kim K, DeLeon C, Krumm BE, Fay JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL | title = The polypharmacology of psychedelics reveals multiple targets for potential therapeutics | journal = Neuron | volume = 113| issue = 19| pages = 3129–3142.e9| date = July 2025 | pmid = 40683247 | doi = 10.1016/j.neuron.2025.06.012 | url = https://www.cell.com/cms/10.1016/j.neuron.2025.06.012/attachment/7d8365fe-51f3-4a28-bf40-9999bec837f6/mmc11.pdf | quote = Recent studies have suggested that psychedelics such as LSD directly interact with TrkB with high affinity, promoting BDNF-mediated neuroplasticity and antidepressant-like effects via allosteric potentiation of BDNF signaling in active synapses.8 To investigate this, we screened LSD across 450 human kinases, including TrkB, but found no significant interactions between LSD and any tested human kinases. Further experiments in transfected cells revealed no effect of LSD or psilocin on BDNF-mediated activation of a TrkB reporter. We note that similar negative preliminary results, which have not yet been published in a peer-reviewed journal, were recently reported by Boltaev et al.63}}</ref> Relatedly, psilocybin has been found not to enhance but rather to inhibit [[hippocampus|hippocampal]] [[neurogenesis]] in rodents.<ref name="HatzipantelisOlson2024" />

Psilocybin produces profound [[anti-inflammatory]] effects mediated by serotonin 5-HT<sub>2A</sub> receptor activation in [[preclinical research|preclinical studies]].<ref name="FlanaganNichols2022">{{cite book | vauthors = Flanagan TW, Nichols CD | title = Disruptive Psychopharmacology | chapter = Psychedelics and Anti-inflammatory Activity in Animal Models | series = Current Topics in Behavioral Neurosciences | volume = 56 | pages = 229–245 | date = 2022 | pmid = 35546383 | doi = 10.1007/7854_2022_367 | isbn = 978-3-031-12183-8 | chapter-url = | quote = In our rodent acute asthma model, psilocin, the active metabolite of psilocybin, displays a similar anti-AHR efficacy and potency to that of (R)-DOI. Surprisingly, other tryptamines with very similar structures like N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) show no efficacy to reduce OVA-induced AHR. }}</ref><ref name="WulffNicholsThompson2023">{{cite journal | vauthors = Wulff AB, Nichols CD, Thompson SM | title = Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders | journal = Neuropharmacology | volume = 231 | issue = | article-number = 109504 | date = June 2023 | pmid = 36921889 | doi = 10.1016/j.neuropharm.2023.109504 | url = | quote = Interestingly, the anti-inflammatory effects of psychedelics acting at 5-HT2A receptors do not correlate with activation of either Gαq or β-arrestin recruitment (Flanagan et al., 2020), indicating psychedelics can recruit different effector pathways from those underlying behaviors for biological effects. [...] Psilocybin and certain other psychedelics have potent anti-inflammatory effects in preclinical models of human disease that could contribute to their efficacy. For example, delivery of psilocin directly to the lungs of rats via nebulization potently suppressed inflammation and restored normal breathing in a model of allergic asthma (Flanagan et al., 2020). The amount of psilocybin necessary for full effect was far below the threshold to produce behavioral effects, suggesting that sub-behavioral levels of psilocybin or other psychedelic may represent a new therapeutic strategy to treat inflammatory disorders. Interestingly, as mentioned above, neither the Gαq or β-arrestin signaling pathways seem to be involved in these effects (Flanagan et al., 2020). | doi-access = free }}</ref><ref name="Kinderlehrer2025">{{cite journal | vauthors = Kinderlehrer DA | title = Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity | journal = Neuropsychiatr Dis Treat | volume = 21 | issue = | pages = 141–155 | date = 2025 | pmid = 39897712 | pmc = 11787777 | doi = 10.2147/NDT.S500337 | doi-access = free | url = }}</ref> These effects have a potency similar to that of [[(R)-DOI|(''R'')-DOI]], and its anti-inflammatory effects occur at far lower doses than those that produce hallucinogen-like effects in animals.<ref name="Nichols2022">{{cite journal | vauthors = Nichols CD | title = Psychedelics as potent anti-inflammatory therapeutics | journal = Neuropharmacology | volume = 219 | issue = | article-number = 109232 | date = November 2022 | pmid = 36007854 | doi = 10.1016/j.neuropharm.2022.109232 | url = | quote = Remarkably, the IC50 dose for (R)-DOI in this prophylactic paradigm is ∼0.005 mg/kg, administered via nebulization or by intraperitoneal injection (Flanagan et al., 2021). This is > 50x less than the behavioral threshold dose. We have also shown that the drug psilocin, the active form of the prodrug psilocybin, has virtually the same potency as (R)-DOI (Flanagan et al., 2021), indicating that the effects are not limited to (R)-DOI or are chemotype dependent.| doi-access = free }}</ref><ref name="FlanaganNichols2022" /><ref name="WulffNicholsThompson2023" /><ref name="FlanaganBillacLandry2021">{{cite journal | vauthors = Flanagan TW, Billac GB, Landry AN, Sebastian MN, Cormier SA, Nichols CD | title = Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore | journal = ACS Pharmacol Transl Sci | volume = 4 | issue = 2 | pages = 488–502 | date = April 2021 | pmid = 33860179 | pmc = 8033619 | doi = 10.1021/acsptsci.0c00063 | url = }}</ref> Psilocybin's anti-inflammatory effects might be involved in its potential antidepressant benefits and might also have other therapeutic applications, such as treatment of [[asthma]] and [[neuroinflammation]].<ref name="FlanaganNichols2022" /><ref name="WulffNicholsThompson2023" /><ref name="FlanaganNichols2018">{{cite journal | vauthors = Flanagan TW, Nichols CD | title = Psychedelics as anti-inflammatory agents | journal = Int Rev Psychiatry | volume = 30 | issue = 4 | pages = 363–375 | date = August 2018 | pmid = 30102081 | doi = 10.1080/09540261.2018.1481827 | url = http://usdbiology.com/cliff/Courses/Advanced%20Seminars%20in%20Neuroendocrinology/Therapeutic%20Effects%20of%20Psychedelics%2019/Flanagan%20Nichols%2018%20IntRevPsychiatry%20Psychedelics%20as%20anti-inflammatory%20agents.pdf | quote = We have previously speculated that the anti-inflammatory effects of psychedelics mediated through serotonin 5-HT2A receptor activation are a key component of not only the anti-depressant effects of psilocybin, but also contribute to its long-lasting effects after only a single treatment (Kyzar, Nichols, Gainetdinov, Nichols, & Kalueff, 2017).}}</ref> They may also be involved in microdosing effects.<ref name="KuypersErritzoeKnudsen2019">{{cite journal | vauthors = Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D | title = Microdosing psychedelics: More questions than answers? An overview and suggestions for future research | journal = J Psychopharmacol | volume = 33 | issue = 9 | pages = 1039–1057 | date = September 2019 | pmid = 31303095 | pmc = 6732823 | doi = 10.1177/0269881119857204 | url = }}</ref><ref name="Kinderlehrer2025" /> But psychedelics have been found to have anti-inflammatory effects only in the setting of preexisting [[inflammation]] and may be [[pro-inflammatory]] outside that context.<ref name="LowNgLim2024">{{cite journal | vauthors = Low ZX, Ng WS, Lim ES, Goh BH, Kumari Y | title = The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies | journal = Prog Neuropsychopharmacol Biol Psychiatry | volume = 136| issue = | article-number = 111139 | date = September 2024 | pmid = 39251080 | doi = 10.1016/j.pnpbp.2024.111139 | url = | doi-access = free }}</ref> Psilocybin has been found to have a large, long-lasting impact on the [[gut microbiome|intestinal microbiome]] and to influence the [[gut–brain axis]] in animals.<ref name="KellyClarkeHarkin2023">{{cite journal | vauthors = Kelly JR, Clarke G, Harkin A, Corr SC, Galvin S, Pradeep V, Cryan JF, O'Keane V, Dinan TG | title = Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis | journal = Int J Clin Health Psychol | volume = 23 | issue = 2 | article-number = 100349 | date = 2023 | pmid = 36605409 | pmc = 9791138 | doi = 10.1016/j.ijchp.2022.100349 | url = }}</ref><ref name="CalderMockFriedli2023">{{cite journal | vauthors = Calder A, Mock S, Friedli N, Pasi P, Hasler G | title = Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms | journal = Eur Neuropsychopharmacol | volume = 75 | issue = | pages = 1–14 | date = October 2023 | pmid = 37352816 | doi = 10.1016/j.euroneuro.2023.05.008 | url = | quote = Interestingly, both EDs and mood disorders are often comorbid with gastrointestinal symptoms and reduced diversity of the gut microbiome. (Lam et al., 2017) A dysregulated microbiome may constitute a development or maintenance factor for AN in particular. (Butler et al., 2021) It has been suggested that psychedelics exert some of their long-term effects via the microbiome. (Kuypers, 2019) Psilocybin has been shown to diversify the intestinal microbiome in mice, and this diversification appeared to be responsible for lasting antidepressant-like behavioral effects. (Cordner et al., 2022) Normalization of the gut microbiome may thus assist with recovery from both EDs and comorbid mood disorders, and presents an intriguing avenue for future research. (Kleiman et al., 2015)| doi-access = free }}</ref><ref name="ReedFoldi2024">{{cite journal | vauthors = Reed F, Foldi CJ | title = Do the therapeutic effects of psilocybin involve actions in the gut? | journal = Trends Pharmacol Sci | volume = 45 | issue = 2 | pages = 107–117 | date = February 2024 | pmid = 38216431 | doi = 10.1016/j.tips.2023.12.007 | url = }}</ref><ref name="CordnerPrandovszkyPedicini2022" /><ref name="XuKissJones2024">{{cite journal | vauthors = Xu M, Kiss AJ, Jones JA, McMurray MS, Shi H | title = Effect of oral tryptamines on the gut microbiome of rats-a preliminary study | journal = PeerJ | volume = 12 | issue = | article-number = e17517 | date = 2024 | pmid = 38846751 | pmc = 11155674 | doi = 10.7717/peerj.17517 | doi-access = free | url = }}</ref><ref name="LowYongAlrasheed2025">{{cite journal | vauthors = Low ZX, Yong SJ, Alrasheed HA, Al-Subaie MF, Al Kaabi NA, Alfaresi M, Albayat H, Alotaibi J, Al Bshabshe A, Alwashmi AS, Sabour AA, Alshiekheid MA, Almansour ZH, Alharthi H, Al Ali HA, Almoumen AA, Alqasimi NA, AlSaihati H, Rodriguez-Morales AJ, Rabaan AA | title = Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review | journal = Prog Neuropsychopharmacol Biol Psychiatry | volume = 137| issue = | article-number = 111279 | date = February 2025 | pmid = 39909170 | doi = 10.1016/j.pnpbp.2025.111279 | url = }}</ref> These effects are partially but not fully dependent on its activation of the serotonin 5-HT<sub>2A</sub> and/or 5-HT<sub>2C</sub> receptors.<ref name="CordnerPrandovszkyPedicini2022" /> Some of psilocybin's  behavioral and potential therapeutic effects may be mediated by changes to the gut microbiome.<ref name="CordnerPrandovszkyPedicini2022" /><ref name="ReedFoldi2024" /><ref name="LowYongAlrasheed2025" /> Transplantation of intestinal contents of psilocybin-treated rodents to untreated rodents resulted in behavioral changes consistent with those of psilocybin administration.<ref name="CordnerPrandovszkyPedicini2022" />

Psilocybin and other psychedelics produce [[sympathomimetic]] effects, such as increased [[heart rate]] and [[blood pressure]], by activating the serotonin 5-HT<sub>2A</sub> receptor.<ref name="Wsół2023"/><ref name="NeumannDheinKirchhefer2024">{{cite journal | vauthors = Neumann J, Dhein S, Kirchhefer U, Hofmann B, Gergs U | title = Effects of hallucinogenic drugs on the human heart | journal = Front Pharmacol | volume = 15 | issue = | article-number = 1334218 | date = 2024 | pmid = 38370480 | pmc = 10869618 | doi = 10.3389/fphar.2024.1334218 | doi-access = free | url = }}</ref><ref name="LeyHolzeArikci2023">{{cite journal | vauthors = Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME | title = Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants | journal = Neuropsychopharmacology | volume = 48 | issue = 11 | pages = 1659–1667 | date = October 2023 | pmid = 37231080 | pmc = 10517157 | doi = 10.1038/s41386-023-01607-2 | url = }}</ref> Long-term repeated use of psilocybin may result in risk of [[cardiac valvulopathy]] and other [[health complication|complication]]s by activating serotonin 5-HT<sub>2B</sub> receptors.<ref name="GeigerWurstDaniels2018" /><ref name="TagenMantuanivanHeerden2023">{{cite journal | vauthors = Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R | title = The risk of chronic psychedelic and MDMA microdosing for valvular heart disease | journal = J Psychopharmacol | volume = 37 | issue = 9 | pages = 876–890 | date = September 2023 | pmid = 37572027 | doi = 10.1177/02698811231190865 | url = }}</ref><ref name="RouaudCalderHasler2024">{{cite journal | vauthors = Rouaud A, Calder AE, Hasler G | title = Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins | journal = J Psychopharmacol | volume = 38 | issue = 3 | pages = 217–224 | date = March 2024 | pmid = 38214279 | pmc = 10944580 | doi = 10.1177/02698811231225609 | url = }}</ref><ref name="Wsół2023" /><ref name="NeumannDheinKirchhefer2024" />

There is little or no acute [[drug tolerance|tolerance]] with psilocybin, and hence its [[duration of action|duration]] is dictated by [[pharmacokinetics]] rather than by [[pharmacodynamics]].<ref name="HolzeSinghLiechti2024" /><ref name="HolzeBeckerKolaczynska2023" /> Conversely, tolerance and [[tachyphylaxis]] rapidly develop to psilocybin's psychedelic effects with repeated administration in humans.<ref name="GeigerWurstDaniels2018" /><ref name="Nichols2004">{{cite journal | vauthors = Nichols DE | title = Hallucinogens | journal = Pharmacol Ther | volume = 101 | issue = 2 | pages = 131–181 | date = February 2004 | pmid = 14761703 | doi = 10.1016/j.pharmthera.2003.11.002 | url = }}</ref><ref name="Halberstadt2015">{{cite journal | vauthors = Halberstadt AL | title = Recent advances in the neuropsychopharmacology of serotonergic hallucinogens | journal = Behav Brain Res | volume = 277 | issue = | pages = 99–120 | date = January 2015 | pmid = 25036425 | pmc = 4642895 | doi = 10.1016/j.bbr.2014.07.016 | url = }}</ref><ref name="HalberstadtGeyer2011" /> In addition, there is [[cross-tolerance]] with the hallucinogenic effects of other psychedelics such as LSD.<ref name="GeigerWurstDaniels2018" /><ref name="Nichols2004" /><ref name="Halberstadt2015" /><ref name="HalberstadtGeyer2011" /> Psilocybin produces [[downregulation]] of the serotonin 5-HT<sub>2A</sub> receptor in the brain in animals, an effect thought to be responsible for the development of tolerance to its psychedelic effects.<ref name="GeigerWurstDaniels2018" /><ref name="Nichols2004" /><ref name="Halberstadt2015" /><ref name="HalberstadtGeyer2011" /> Serotonin 5-HT<sub>2A</sub> receptors appear to slowly return over the course of days to weeks after psilocybin administration.<ref name="GeigerWurstDaniels2018" />

===Pharmacokinetics===

====Absorption====
There has been little research on psilocybin's [[bioavailability]].<ref name="OttovanderHeijdenSchoones2025" /> Its [[oral administration|oral]] bioavailability, as its [[active metabolite|active form]] [[psilocin]], was about 55.0% (± ~20%) relative to [[intravenous administration]] in one small older study (n=3).<ref name="OttovanderHeijdenSchoones2025" /><ref name="DoddNormanEyre2023" /><ref name="MacCallumLoPistawka2022" /><ref name="HaslerBourquinBrenneisen1997" /> After oral administration, psilocybin is detectable in the blood circulation within 20 to 40{{nbsp}}minutes, and psilocin is detectable after 30{{nbsp}}minutes.<ref name="MacCallumLoPistawka2022" /><ref name="TylšPáleníčekHoráček2014" /> The mean [[Tmax (pharmacology)|time to peak]] levels for psilocin is 1.05 to 3.71{{nbsp}}hours in different studies, with most around 2{{nbsp}}hours and the upper limit of 3.71{{nbsp}}hours being an [[outlier]].<ref name="OttovanderHeijdenSchoones2025" /><ref name="Manzano-NunezGomezToledo-Mendoza2025">{{cite journal | vauthors = Manzano-Nunez R, Gomez DA, Toledo-Mendoza C, Perez-Otero M, Matilla IL, Prats C, Perez-Lopez E, Pardo H, Díaz-Pellicer P, De La Torre-Fornell R, Aldea AM | title = Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics | journal = Clin Neuropharmacol | volume = 48 | issue = 1 | pages = 13–19 | date = 2025 | pmid = 39787428 | doi = 10.1097/WNF.0000000000000617 | url = }}</ref><ref name="TylšPáleníčekHoráček2014" />

Psilocybin, in terms of psilocin, shows clear linear or [[dose dependence|dose-dependent]] [[pharmacokinetics]].<ref name="OttovanderHeijdenSchoones2025" /><ref name="HolzeSinghLiechti2024" /><ref name="DoddNormanEyre2023" /><ref name="MacCallumLoPistawka2022" /><ref name="HolzeBeckerKolaczynska2023" /><ref name="BrownNicholasCozzi2017">{{cite journal | vauthors = Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR | title = Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults | journal = Clin Pharmacokinet | volume = 56 | issue = 12 | pages = 1543–1554 | date = December 2017 | pmid = 28353056 | doi = 10.1007/s40262-017-0540-6 | url = }}</ref> Maximal concentrations of psilocin were 11{{nbsp}}ng/mL, 17{{nbsp}}ng/mL, and 21{{nbsp}}ng/mL with oral psilocybin doses of 15, 25, and 30{{nbsp}}mg psilocybin, respectively.<ref name="HolzeBeckerKolaczynska2023" /> The maximal levels of psilocin have been found to range from 8.2{{nbsp}}ng/mL to 37.6{{nbsp}}ng/mL across a dose range of 14 to 42{{nbsp}}mg.<ref name="Manzano-NunezGomezToledo-Mendoza2025" /> The dose-normalized peak concentration of psilocin is about 0.8{{nbsp}}ng/mL/mg.<ref name="OttovanderHeijdenSchoones2025" /> The [[interindividual variability]] in the pharmacokinetics of psilocybin is relatively small.<ref name="HolzeBeckerKolaczynska2023" /> There is a very strong positive correlation between dose and psilocin peak levels (R<sup>2</sup> = 0.95).<ref name="Manzano-NunezGomezToledo-Mendoza2025" /> The effects of food on the pharmacokinetics of psilocybin have not been reported and are unknown, but no clear sign of food effects has been observed in preliminary analyses.<ref name="OttovanderHeijdenSchoones2025" /> It has also been said that food might delay [[absorption (pharmacokinetics)|absorption]], reduce peak levels, and reduce bioavailability.<ref name="FradetKellyDonnelly2025" />

====Distribution====
Psilocin, the active form of psilocybin, is extensively [[distribution (pharmacology)|distributed]] to all [[tissue (biology)|tissue]]s through the [[bloodstream]].<ref name="MacCallumLoPistawka2022" /> Its [[volume of distribution]] is 505 to 1,267{{nbsp}}L.<ref name="OttovanderHeijdenSchoones2025" /> Psilocybin itself is [[hydrophilic]] due to its [[phosphate]] [[functional group|group]] and cannot easily cross the [[blood–brain barrier]].<ref name="FradetKellyDonnelly2025" /><ref name="MacCallumLoPistawka2022" /> Conversely, psilocin is [[lipophilic]] and readily crosses the blood–brain barrier to exert effects in the [[central nervous system]].<ref name="MacCallumLoPistawka2022" /> The [[plasma protein binding]] of psilocybin is 66% and hence it is moderately plasma protein-bound.<ref name="ČamparaKovačić2024" />

[[File:Psilocin intramolecular hydrogen bond and pseudo-ring system.png|class=skin-invert-image|thumb|right|300px|Theoretical [[intramolecular force|intramolecular]] [[hydrogen bond]] and [[Ring (chemistry)#Rings and ring systems|pseudo-ring system]] occurring with [[psilocin]] (4-HO-DMT) but not with [[bufotenin]] (5-HO-DMT).<ref name="GumpperNichols2024" /><ref name="McBride2000" />]]

Psilocin (4-HO-DMT) is a close [[positional isomer]] of [[bufotenin]] (5-HO-DMT), which shows [[peripherally selective drug|peripheral selectivity]], and might be expected to have similarly restricted lipophilicity and blood–brain barrier permeability.<ref name="GumpperNichols2024">{{cite journal | vauthors = Gumpper RH, Nichols DE | title = Chemistry/structural biology of psychedelic drugs and their receptor(s) | journal = Br J Pharmacol | volume = | issue = | date = October 2024 | article-number = bph.17361 | pmid = 39354889 | doi = 10.1111/bph.17361 | url = | quote = In contrast to DMT, psilocybin is orally active. [...] A structurally related molecule, [5-HO-DMT], known as bufotenine, is inactive after oral administration. How does the simple transposition of the hydroxy from the 4 to the 5 position alter the physicochemical properties of the DMT core? We asked that question more than four decades ago. In a study by Migliaccio et al. (1981), the 360 MHz proton NMR, the amine pKa values and the octanol–water Log P values were determined experimentally and compared for both psilocin and bufotenine (Figure 3a). The side chain protons in the NMR for bufotenine were shown to be rapidly rotating with no preference for gauche or trans conformations, whereas the side chain for psilocin was less mobile and was determined to favour a gauche (80%) versus trans (20%) conformation. Because psilocin is a weaker base but is also more lipid soluble, it was proposed that psilocin formed an intramolecular hydrogen bond, as illustrated in Figure 3a. In the energy-minimized structure of this conformation, the length of the hydrogen bond is 1.88 Å. The weaker pKa of psilocin relative to bufotenine means that psilocin is less highly ionized at pH 7.4—that is, 8.5% free base versus 0.53% for bufotenine at pH 7.4. Ionized amines must be unionized and desolvated to cross the blood–brain barrier; the intramolecular H bond in psilocin compensates for that as reflected by the higher lipophilicity of psilocin relative to bufotenine. Finally, the mechanism of deamination by MAO involves either a single electron transfer or a nucleophilic mechanism (Gaweska & Fitzpatrick, 2011; Zapata-Torres et al., 2015), either of which is more enzymically difficult when the amine electrons are hydrogen-bonded by the 4-hydroxy group (Figure 3a). Very recently, Lenz et al. (2022) have confirmed and extended the finding of the potential intramolecular hydrogen bond partially being responsible for slow MAO deamination as well as psilocin's enhanced ability to cross the blood–brain barrier. [...] This would explain why bufotenine is still an agonist at the 5-HT2A receptor but due to its poor physiochemical properties is not psychoactive in humans. }}</ref><ref name="McBride2000">{{cite journal | vauthors = McBride MC | title = Bufotenine: toward an understanding of possible psychoactive mechanisms | journal = J Psychoactive Drugs | volume = 32 | issue = 3 | pages = 321–331 | date = 2000 | pmid = 11061684 | doi = 10.1080/02791072.2000.10400456 | url = https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=802678b9f472ee113a9df8011e68672c3681623d}}</ref> But psilocin appears to form a [[tricyclic compound|tricyclic]] [[Ring (chemistry)#Rings and ring systems|pseudo-ring system]] wherein its [[hydroxyl group]] and [[amine]] interact through [[hydrogen bond]]ing.<ref name="GumpperNichols2024" /><ref name="McBride2000" /><ref name="PlazasFaraone2023">{{cite journal | vauthors = Plazas E, Faraone N | title = Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents | journal = Biomedicines | volume = 11 | issue = 2 | date = February 2023 | page = 461 | pmid = 36830997 | pmc = 9953455 | doi = 10.3390/biomedicines11020461 | doi-access = free | url = }}</ref><ref name="LenzDörnerTrottmann2022">{{cite journal | vauthors = Lenz C, Dörner S, Trottmann F, Hertweck C, Sherwood A, Hoffmeister D | title = Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines | journal = ChemBioChem | volume = 23 | issue = 13 | article-number = e202200183 | date = July 2022 | pmid = 35483009 | pmc = 9401598 | doi = 10.1002/cbic.202200183 | url = }}</ref> This in turn makes psilocin much less [[Chemical polarity|polar]], more lipophilic, and more able to cross the blood–brain barrier and exert central actions than it would be otherwise.<ref name="GumpperNichols2024" /><ref name="McBride2000" /><ref name="PlazasFaraone2023" /><ref name="LenzDörnerTrottmann2022" /> It may also protect psilocin from metabolism by [[monoamine oxidase]] (MAO).<ref name="GumpperNichols2024" /> In contrast, bufotenin is not able to achieve this pseudo-ring system.<ref name="GumpperNichols2024" /><ref name="McBride2000" /><ref name="PlazasFaraone2023" /><ref name="LenzDörnerTrottmann2022" /> Accordingly, bufotenin is less lipophilic than psilocin in terms of [[partition coefficient]].<ref name="GumpperNichols2024" /><ref name="McBride2000" /> But bufotenin does still show significant central permeability and, like psilocybin, can produce robust hallucinogenic effects in humans.<ref name="McBride2000" /><ref name="PlazasFaraone2023" /><ref name="ShenJiangWinter2010">{{cite journal | vauthors = Shen HW, Jiang XL, Winter JC, Yu AM | title = Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions | journal = Curr Drug Metab | volume = 11 | issue = 8 | pages = 659–666 | date = October 2010 | pmid = 20942780 | pmc = 3028383 | doi = 10.2174/138920010794233495 | url = }}</ref><ref name="Ott2001a">{{cite journal | author = [[Jonathan Ott]] | title = Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine | journal = Journal of Psychoactive Drugs | volume = 33 | issue = 3 | pages = 273–281 | year = 2001 | pmid = 11718320 | doi = 10.1080/02791072.2001.10400574 | s2cid = 5877023 }}</ref>

====Metabolism====
[[File:Metabolism of psilocybin in humans and mice.png|class=skin-invert-image|thumb|right|500px|[[Drug metabolism|Metabolism]] of psilocybin and [[psilocin]] in humans and mice.<ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="FradetKellyDonnelly2025" />]]

Psilocybin is [[dephosphorylation|dephosphorylated]] into its [[active metabolite|active form]] [[psilocin]] in the body and hence is a [[prodrug]].<ref name="MacCallumLoPistawka2022" /><ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /> Psilocybin is [[metabolism|metabolized]] in the [[intestine]]s, [[liver]], [[kidney]]s, [[blood]], and other [[tissue (biology)|tissue]]s and [[bodily fluid]]s.<ref name="OttovanderHeijdenSchoones2025" /><ref name="Dinis-Oliveira2017" /><ref name="ThomannKolaczynskaStoeckmann2024">{{cite journal | vauthors = Thomann J, Kolaczynska KE, Stoeckmann OV, Rudin D, Vizeli P, Hoener MC, Pryce CR, Vollenweider FX, Liechti ME, Duthaler U | title = In vitro and in vivo metabolism of psilocybin's active metabolite psilocin | journal = Front Pharmacol | volume = 15 | issue = | article-number = 1391689 | date = 2024 | pmid = 38741590 | pmc = 11089204 | doi = 10.3389/fphar.2024.1391689 | doi-access = free | url = }}</ref> There is significant [[first-pass metabolism]] of psilocybin and psilocin with [[oral administration]].<ref name="OttovanderHeijdenSchoones2025" /><ref name="ThomannKolaczynskaStoeckmann2024" /> No psilocybin has been detected in the blood in humans after oral administration, suggesting virtually complete dephosphorylation into psilocin with the first pass.<ref name="OttovanderHeijdenSchoones2025" /><ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /><ref name="ThomannKolaczynskaStoeckmann2024" /> It is also said to be converted 90% to 97% into psilocin.<ref name="StraussGhoshMurray2022">{{cite journal | vauthors = Strauss D, Ghosh S, Murray Z, Gryzenhout M | title = Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields | journal = 3 Biotech | volume = 12 | issue = 12 | article-number = 339 | date = December 2022 | pmid = 36340802 | pmc = 9633885 | doi = 10.1007/s13205-022-03355-4 | url = }}</ref> The [[competitive inhibitor|competitive]] [[phosphatase inhibitor]] β-glycerolphosphate, which inhibits psilocybin dephosphorylation, greatly attenuates the behavioral effects of psilocybin in rodents.<ref name="TylšPáleníčekHoráček2014" /><ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="Horita1963">{{cite journal | vauthors = Horita A | title = Some biochemical studies on psilocybin and psilocin | journal = Journal of Neuropsychiatry | volume = 4 | date = 1963 | pages = 270–273 | pmid = 13954906 | url = https://apps.dtic.mil/sti/tr/pdf/AD0291057.pdf#page=3}}</ref> Psilocybin undergoes dephosphorylation into psilocin via the [[acid]]ic environment of the [[stomach]] or the actions of [[alkaline phosphatase]] (ALP) and non-specific [[esterase]]s in tissues and fluids.<ref name="PepeHesamidelaCerda2023"/><ref name="Dinis-Oliveira2017">{{cite journal | vauthors = Dinis-Oliveira RJ | title = Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance | journal = Drug Metab Rev | volume = 49 | issue = 1 | pages = 84–91 | date = February 2017 | pmid = 28074670 | doi = 10.1080/03602532.2016.1278228 | url = }}</ref><ref name="TylšPáleníčekHoráček2014" />

Psilocin is [[demethylation|demethylated]] and [[oxidative deamination|oxidatively deaminated]] by [[monoamine oxidase]] (MAO), specifically [[monoamine oxidase A]] (MAO-A), into 4-hydroxyindole-3-acetaldehyde (4-HIAL or 4-HIA).<ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /><ref name="ChenWangYong2025">{{cite journal | vauthors = Chen J, Wang Z, Yong CY, Goh EM, Moy HY, Chan EC | title = Elucidating the Phase I metabolism of psilocin in vitro | journal = Arch Toxicol | volume = 99| issue = 3| pages = 1085–1094| date = January 2025 | pmid = 39751877 | doi = 10.1007/s00204-024-03952-7 | bibcode = 2025ArTox..99.1085C | url = }}</ref> 4-HIAL is then further oxidated into 4-hydroxyindole-3-acetic acid (4-HIAA) by [[aldehyde dehydrogenase]] (ALDH) or into 4-hydroxytryptophol (4-HTOL or 4-HTP) by [[alcohol dehydrogenase]] (ALD).<ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /> Deamination of psilocin by MAO-A appears to be responsible for about 4% or 33% of its metabolism in different studies.<ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="HolzeBeckerKolaczynska2023" /><ref name="TylšPáleníčekHoráček2014" /> In contrast to psilocin, its metabolites 4-HIAA and 4-HTP showed no affinity for or activation of multiple serotonin receptors and are considered inactive.<ref name="DoddNormanEyre2023" /><ref name="FradetKellyDonnelly2025" /><ref name="ThomannKolaczynskaStoeckmann2024" /> Based on ''in vitro'' studies, it has been estimated that MAO-A is responsible for about 81% of psilocin's [[Phase I metabolism|phase I]] hepatic metabolism.<ref name="ChenWangYong2025" /> Psilocin and its metabolites are also [[glucuronidation|glucuronidated]] by [[UDP-glucuronyltransferase]]s (UGTs).<ref name="OttovanderHeijdenSchoones2025" /><ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /><ref name="ThomannKolaczynskaStoeckmann2024" /> [[UGT1A10]] and [[UGT1A9]] appear to be the most involved.<ref name="OttovanderHeijdenSchoones2025" /><ref name="DoddNormanEyre2023" /><ref name="TylšPáleníčekHoráček2014" /> Psilocybin's glucuronidated metabolites include psilocin-''O''-glucuronide and 4-HIAA-''O''-glucuronide.<ref name="DoddNormanEyre2023" /><ref name="LoweToyangSteele2021" /><ref name="ThomannKolaczynskaStoeckmann2024" /> Approximately 80% of psilocin in [[blood plasma]] is in [[conjugation (biochemistry)|conjugated]] form, and conjugated psilocin levels are about fourfold higher than levels of free psilocin.<ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="TylšPáleníčekHoráček2014" /> Plasma 4-HIAA levels are also much higher than those of free psilocin.<ref name="DoddNormanEyre2023" />

[[Norpsilocin]] (4-HO-NMT), formed from psilocin via demethylation mediated by the [[cytochrome P450]] [[enzyme]] [[CYP2D6]], is known to occur in mice ''[[in vivo]]'' and with human recombinant CYP2D6 ''[[in vitro]]'' but was not detected in humans ''in vivo''.<ref name="ThomannKolaczynskaStoeckmann2024" /> An oxidized psilocin metabolite of unknown [[chemical structure]] is also formed by hydroxyindole oxidase activity of CYP2D6.<ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="TylšPáleníčekHoráček2014" /> Oxidized psilocin is possibly a [[quinone]]-type structure like psilocin iminoquinone (4-hydroxy-5-oxo-''N'',''N''-DMT) or psilocin hydroquinone (4,5-dihydroxy-''N'',''N''-DMT).<ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="TylšPáleníčekHoráček2014" /> Additional metabolites formed by CYP2D6 may also be present.<ref name="ThomannKolaczynskaStoeckmann2024" /> Besides CYP2D6, [[CYP3A4]] showed minor activity in metabolizing psilocin, though the produced metabolite is unknown.<ref name="ThomannKolaczynskaStoeckmann2024" /> Other [[cytochrome P450]] [[enzyme]]s besides CYP2D6 and CYP3A4 appear unlikely to be involved in psilocin metabolism.<ref name="ThomannKolaczynskaStoeckmann2024" /> CYP2D6 [[pharmacogenomics|metabolizer phenotype]]s do not modify psilocin exposure in humans, suggesting that CYP2D6 is not critically involved in psilocin metabolism and is unlikely to result in interindividual differences in psilocin kinetics or effects.<ref name="FradetKellyDonnelly2025" /><ref name="ThomannKolaczynskaStoeckmann2024" /> Psilocybin and psilocin might inhibit [[CYP3A4]] and [[CYP2A6]] to some extent, respectively.<ref name="Manzano-NunezGomezToledo-Mendoza2025" />

====Elimination====
Psilocybin is [[elimination (pharmacology)|eliminated]] 80% to 85% in [[urine]] and 15 to 20% in [[bile]].<ref name="FradetKellyDonnelly2025" /> It is [[excretion|excreted]] mainly in urine as psilocin-''O''-glucuronide.<ref name="FradetKellyDonnelly2025" /><ref name="Dinis-Oliveira2017" /> The drug was eliminated approximately 20% and 80% as psilocin ''O''-glucuronide in different studies.<ref name="OttovanderHeijdenSchoones2025" /><ref name="Dinis-Oliveira2017" /><ref name="TylšPáleníčekHoráček2014" /><ref name="HolzeBeckerKolaczynska2023" /> The amount [[excretion|excreted]] as unchanged psilocin in urine is 1.5 to 3.4%.<ref name="OttovanderHeijdenSchoones2025" /><ref name="Dinis-Oliveira2017" /><ref name="DoddNormanEyre2023" /><ref name="HolzeBeckerKolaczynska2023" /> Studies conflict on the deaminated metabolites of psilocin, with one study finding that only 4% of psilocin is metabolized into 4-HIAA, 4-HIAL, and 4-HTOL<ref name="TylšPáleníčekHoráček2014" /> and another that psilocybin is excreted 33% in urine as 4-HIAA.<ref name="ThomannKolaczynskaStoeckmann2024" /><ref name="HolzeBeckerKolaczynska2023">{{cite journal | vauthors = Holze F, Becker AM, Kolaczynska KE, Duthaler U, Liechti ME | title = Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants | journal = Clin Pharmacol Ther | volume = 113 | issue = 4 | pages = 822–831 | date = April 2023 | pmid = 36507738 | doi = 10.1002/cpt.2821 | url = https://www.researchgate.net/publication/366214647| doi-access = free }}</ref> Findings also conflict on whether psilocybin can be detected in urine, with either no psilocybin excreted or 3% to 10% excreted as unchanged psilocybin.<ref name="StraussGhoshMurray2022" /><ref name="Passie2002" /><ref name="OttovanderHeijdenSchoones2025" /><ref name="LoweToyangSteele2021" /><ref name="TylšPáleníčekHoráček2014" /> A majority of psilocybin and its metabolites is excreted within three hours with oral administration and elimination is almost complete within 24{{nbsp}}hours.<ref name="TylšPáleníčekHoráček2014" /><ref name="LoweToyangSteele2021" /><ref name="HolzeBeckerKolaczynska2023" />

The [[elimination half-life]] of psilocybin, as psilocin, is 2.1 to 4.7{{nbsp}}hours on average (range 1.2–18.6{{nbsp}}hours) [[oral administration|orally]] and 1.2{{nbsp}}hours (range 1.8–4.5{{nbsp}}hours) [[intravenous administration|intravenously]].<ref name="OttovanderHeijdenSchoones2025">{{cite journal | vauthors = Otto ME, van der Heijden KV, Schoones JW, van Esdonk MJ, Borghans LG, Jacobs GE, van Hasselt CJ | title = Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis | journal = Clin Pharmacokinet | volume = 64 | issue = 1 | pages = 53–66 | date = January 2025 | pmid = 39812743 | pmc = 11762572 | doi = 10.1007/s40262-024-01454-4 | url = }}</ref><ref name="Manzano-NunezGomezToledo-Mendoza2025" /><ref name="DoddNormanEyre2023" /><ref name="TylšPáleníčekHoráček2014" /> Psilocin's elimination half-life in mice is 0.9{{nbsp}}hours, much faster than in humans.<ref name="ThomannKolaczynskaStoeckmann2024" /> Psilocin ''O''-glucuronide's half-life is about 4{{nbsp}}hours in humans and approximately 1{{nbsp}}hour in mice.<ref name="ThomannKolaczynskaStoeckmann2024" />

No dose adjustment of psilocin is thought to be required as psilocin is inactivated mainly via metabolism as opposed to renal elimination.<ref name="OttovanderHeijdenSchoones2025" /><ref name="FradetKellyDonnelly2025" /><ref name="HolzeBeckerKolaczynska2023" /> Accordingly, [[glomerular filtration rate]] (GFR) did not affect the pharmacokinetics of psilocybin.<ref name="OttovanderHeijdenSchoones2025" /><ref name="FradetKellyDonnelly2025" /><ref name="HolzeBeckerKolaczynska2023" />

====Miscellaneous====
The [[pharmacokinetics]] of administered psilocybin and psilocin in rodents, for instance in terms of psilocin tissue distribution kinetics, are described as very similar or identical, suggesting very rapid or near-immediate cleavage of psilocybin into psilocin.<ref name="BrimblecombePinder1975">{{cite book | vauthors = Brimblecombe RW, Pinder RM | chapter = Indolealkylamines and Related Compounds | pages = 98–144 | title = Hallucinogenic Agents | date = 1975 | publisher = Wright-Scientechnica | location = Bristol | isbn = 978-0-85608-011-1 | oclc = 2176880 | ol = OL4850660M | url = https://bitnest.netfirms.com/external/Books/978-0-85608-011-1 | quote = The similarity of the pharmacological profiles of the two compounds coupled with demonstration of the in vivo dephosphorylation of psilocybin make it likely that the central effects of psilocybin are exerted only after its conversion into psilocin (Horita and Weber, 1962; Horita, 1963). Thus, administration of psilocybin to intact mice results in the accumulation of high concentrations of psilocin in the kidney and liver within 10-20 minutes and in the brain within 25-30 minutes, a distribution pattern identical to that observed following administration of psilocin itself (Kalberer, Kreis, and Rutschmann, 1962; Hopf and Eckert, 1969). | archive-date = May 27, 2025 | access-date = June 15, 2025 | archive-url = https://web.archive.org/web/20250527204106/https://bitnest.netfirms.com/external/Books/978-0-85608-011-1 | url-status = dead }}</ref>

Psilocybin's [[psychoactive drug|psychoactive]] effects and [[duration of action|duration]] are strongly correlated with psilocin levels.<ref name="HolzeSinghLiechti2024" /><ref name="HolzeBeckerKolaczynska2023" /><ref name="DoddNormanEyre2023" />

Single doses of psilocybin of 3 to 30{{nbsp}}mg have been found to dose-dependently occupy the serotonin 5-HT<sub>2A</sub> receptor in humans as assessed by [[medical imaging|imaging]] studies.<ref name="DoddNormanEyre2023" /> The {{Abbrlink|EC<sub>50</sub>|half-maximal effective concentration}} for occupancy of the serotonin 5-HT<sub>2A</sub> receptor by psilocin in terms of circulating levels has been found to be 1.97{{nbsp}}ng/mL.<ref name="DoddNormanEyre2023" />

[[Body weight]] and [[body mass index]] do not appear to affect psilocybin's pharmacokinetics.<ref name="HolzeSinghLiechti2024" /><ref name="FradetKellyDonnelly2025" /><ref name="HolzeBeckerKolaczynska2023" /> This suggests that body weight-adjusted dosing of psilocybin is unnecessary and may actually be counterproductive, and that fixed-dosing should be preferred.<ref name="FradetKellyDonnelly2025" /><ref name="HolzeBeckerKolaczynska2023" /> Similarly, age does not affect psilocybin's pharmacokinetics.<ref name="OttovanderHeijdenSchoones2025" /> The influence of [[sex]] on psilocybin's pharmacokinetics has not been tested.<ref name="OttovanderHeijdenSchoones2025" />

==Chemistry==
===Physical properties===
[[File:Serotonin.svg|class=skin-invert-image|thumb|200px|The neurotransmitter [[serotonin]] is structurally similar to psilocybin.]]

Psilocybin is a naturally occurring [[substituted tryptamine]] that features an [[indole]] ring linked to an [[ethylamine|aminoethyl]] [[substituent]]. It is structurally related to [[serotonin]], a [[monoamine neurotransmitter]] that is a derivative of the [[amino acid]] [[tryptophan]]. Psilocybin is a member of the general class of tryptophan-based compounds that originally functioned as [[antioxidant]]s in earlier life forms before assuming more complex functions in multicellular organisms, including humans.<ref name=Azmitia2010/> Other related indole-containing psychedelic compounds include [[dimethyltryptamine]], found in many plant species and in trace amounts in some mammals, and [[bufotenin]], found in the skin of certain amphibians, especially the [[Colorado River toad]].<ref name = Wurst2002 />{{rp|10–13}}

Psilocybin is a white, crystalline solid that is soluble in water, [[methanol]] and [[ethanol]] but insoluble in nonpolar organic [[solvent]]s such as [[chloroform]] and [[petroleum ether]].<ref name = Wurst2002 />{{rp|15}} It has a [[melting point]] between {{convert|220|and|228|C|F}},<ref name=Merck13th/> and an [[ammonia]]-like taste.<ref name=HSDB/> Its [[pKa]] values are estimated to be 1.3 and 6.5 for the two successive [[phosphate]] [[hydroxy group]]s and 10.4 for the [[dimethylamine]] nitrogen, so it typically exists as a [[zwitterion]]ic structure.<ref name=HSDB/> There are two known crystalline polymorphs of psilocybin, as well as reported [[Water of crystallization|hydrated phases]].<ref>{{cite journal | vauthors = Sherwood AM, Kargbo RB, Kaylo KW, Cozzi NV, Meisenheimer P, Kaduk JA | title = Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples | journal = Acta Crystallographica, Section C | volume = 78 | issue = Pt 1 | pages = 36–55 | date = January 2022 | pmid = 34982048 | pmc = 8725723 | doi = 10.1107/S2053229621013164 | bibcode = 2022AcCrC..78...36S }}</ref> Psilocybin rapidly oxidizes upon exposure to light—an important consideration when using it as an analytical [[standard solution|standard]].<ref name=Anastos2006/>

===Structural analogues===
{{See also|Substituted tryptamine|List of psychedelic drugs}}

[[Structural analogue]]s of psilocybin (4-PO-DMT; ''O''-phosphorylpsilocin) and [[psilocin]] (4-HO-DMT) include [[dimethyltryptamine]] (DMT), [[5-hydroxytryptamine]] (5-HT), [[bufotenin]] (5-HO-DMT), [[6-hydroxy-DMT]], [[4-AcO-DMT]] (psilacetin; ''O''-acetylpsilocin), [[4-PrO-DMT]] (''O''-propionylpsilocin), [[psilomethoxin]] (4-HO-5-MeO-DMT; 5-methoxypsilocin), [[ethocybin]] (4-PO-DET), [[baeocystin]] (4-PO-NMT), [[aeruginascin]] (4-PO-TMT), and [[norbaeocystin]] (4-PO-T), among others.

===Laboratory synthesis===
[[Albert Hofmann]] et al. were the first to synthesize psilocybin, in 1958. Since then, various chemists have improved the methods for laboratory synthesis and purification of psilocybin. In particular, Shirota et al. reported a novel method in 2003 for the synthesis of psilocybin at the gram scale from 4-hydroxyindole that does not require [[chromatographic]] purification. Fricke et al. described an enzymatic pathway for the synthesis of psilocybin and psilocin, publishing their results in 2017. Sherwood et al. significantly improved upon Shirota's method (producing at the kilogram scale while employing less expensive reagents), publishing their results in 2020.<ref name=Serreau2023/>

===Analytical methods===
Several relatively simple [[chemical test]]s—commercially available as [[reagent testing]] kits—can be used to assess the presence of psilocybin in [[extract]]s prepared from mushrooms. The drug produces a yellow color in the [[Marquis test]] and a green color in the [[Mandelin reagent]].<ref name=Levine2003/> Neither of these tests is specific for psilocybin; for example, the Marquis test will react with many classes of controlled drugs, such as those containing [[Primary amine|primary amino]] groups and unsubstituted [[benzene ring]]s, including [[amphetamine]] and [[methamphetamine]].<ref name=Cole2003/> [[Ehrlich's reagent]] and [[DMACA reagent]] are used as chemical sprays to detect the drug after [[thin layer chromatography]].<ref name=Bresinsky1989/> Many modern techniques of [[analytical chemistry]] have been used to quantify psilocybin levels in mushroom samples. Although the earliest methods commonly used [[gas chromatography]], the high temperature required to [[Volatility (chemistry)|vaporize]] the psilocybin sample before analysis causes it to spontaneously lose its phosphoryl group and become psilocin, making it difficult to chemically discriminate between the two drugs. In [[forensic toxicology]], techniques involving [[Gas chromatography-mass spectrometry|gas chromatography coupled to mass spectrometry]] (GC–MS) are the most widely used due to their high sensitivity and ability to separate compounds in complex biological mixtures.<ref name=Kamata2010/> These techniques include [[ion mobility spectrometry]],<ref name=Keller1999/> [[capillary zone electrophoresis]],<ref name=Pedersen1997/> [[ultraviolet spectroscopy]],<ref name=Lee1985/> and [[infrared spectroscopy]].<ref name=Wurst1992/> [[High-performance liquid chromatography]] (HPLC) is used with ultraviolet,<ref name=Anastos2006/> [[Fluorescence spectroscopy|fluorescence]],<ref name=Saito2004/> [[electrochemical]],<ref name=Lindenblatt1998/> and [[Electrospray ionization|electrospray]] mass spectrometric detection methods.<ref name=RodriguezCruz2005/>

Various chromatographic methods have been developed to detect psilocin in [[body fluids]]: the rapid emergency drug identification system (REMEDi HS), a [[drug screening]] method based on HPLC;<ref name=Sticht2000/> HPLC with electrochemical detection;<ref name=Lindenblatt1998/><ref name=Kysilka1990/> GC–MS;<ref name=Grieshaber2001/><ref name=Sticht2000/> and [[Liquid chromatography–mass spectrometry|liquid chromatography coupled to mass spectrometry]].<ref name=Kamata2003/> Although the determination of psilocin levels in urine can be performed without sample cleanup (i.e., removing potential contaminants that make it difficult to accurately assess concentration), the analysis in [[blood plasma|plasma]] or [[blood serum|serum]] requires preliminary [[Liquid-liquid extraction|extraction]] followed by [[derivatization]] of the extracts in the case of GC–MS. A specific [[immunoassay]] has also been developed to detect psilocin in whole blood samples.<ref name=Albers2004/> A 2009 publication reported using HPLC to quickly separate forensically important illicit drugs including psilocybin and psilocin, which were identifiable within about 30 seconds of analysis time.<ref name=Lurie2009/> But these analytical techniques to determine psilocybin concentrations in body fluids are not routinely available and not typically used in [[Clinical chemistry|clinical]] settings.<ref name=Attema2007/>

==Natural occurrence==
{{Main|Psilocybin-containing mushroom}}
{| class="wikitable" style="max-width:16em; float:right; margin:0.5em;"
|+ Maximum reported psilocybin concentrations (%&nbsp;dry weight) in 12 ''Psilocybe'' species<ref name="Stamets_1996" />{{rp|39}}
! scope="col" | Species
! scope="col" | % psilocybin
|-
|''[[Psilocybe azurescens|P. azurescens]]''
| style="text-align: center;" | 1.78
|-
| ''[[Psilocybe serbica|P. serbica]]''
| style="text-align: center;" | 1.34
|-
| ''[[Psilocybe semilanceata|P. semilanceata]]''
| style="text-align: center;" | 0.98
|-
| ''[[Psilocybe baeocystis|P. baeocystis]]''
| style="text-align: center;" | 0.85
|-
| ''[[Psilocybe cyanescens|P. cyanescens]]''
| style="text-align: center;" | 0.85
|-
| ''[[P. tampanensis]]''
| style="text-align: center;" | 0.68
|-
| ''[[P. cubensis]]''
| style="text-align: center;" | 0.63
|-
| ''[[Psilocybe weilii|P. weilii]]''
| style="text-align: center;" | 0.61
|-
| ''[[Psilocybe hoogshagenii|P. hoogshagenii]]''
| style="text-align: center;" | 0.60
|-
| ''[[Psilocybe stuntzii|P. stuntzii]]''
| style="text-align: center;" | 0.36
|-
| ''[[Psilocybe cyanofibrillosa|P. cyanofibrillosa]]''
| style="text-align: center;" | 0.21
|-
| ''[[Psilocybe liniformans|P. liniformans]]''
| style="text-align: center;" | 0.16
|}

Psilocybin is present in varying concentrations in over 200 species of [[Basidiomycota]] mushrooms. In a 2000 review on the worldwide distribution of hallucinogenic mushrooms, [[Gastón Guzmán]] and colleagues considered these to be distributed amongst the following [[genera]]: ''[[Psilocybe]]'' (116&nbsp;species), ''[[Gymnopilus]]'' (14), ''[[Panaeolus]]'' (13), ''[[Copelandia]]'' (12), ''[[Hypholoma]]'' (6), ''[[Pluteus]]'' (6), ''[[Inocybe]]'' (6), ''[[Conocybe]]'' (4), ''[[Panaeolina]]'' (4), ''[[Gerronema]]'' (2), and ''[[Galerina]]'' (1&nbsp;species).<ref name=Guzman2000/> Guzmán increased his estimate of the number of psilocybin-containing ''Psilocybe'' to 144 species in a 2005 review. The majority of these are found in Mexico (53 species), with the remainder distributed in the United States and Canada (22), Europe (16), Asia (15), Africa (4), and Australia and associated islands (19).<ref name=Guzman2005/> The diversity of psilocybin mushrooms is reported to have been increased by horizontal transfer of the psilocybin [[Metabolic gene cluster|gene cluster]] between unrelated mushroom species.<ref>{{Cite news |date=24 August 2017 |title=How Mushrooms Became Magic |language=en-US |work=The Atlantic |url=https://www.theatlantic.com/science/archive/2017/08/how-mushrooms-became-magic/537789/ |url-status=live |access-date=March 15, 2018 |archive-url=https://web.archive.org/web/20180316084829/https://www.theatlantic.com/science/archive/2017/08/how-mushrooms-became-magic/537789/ |archive-date=March 16, 2018 |vauthors=Yong E}}</ref><ref name=Reynolds2018/> In general, psilocybin-containing species are dark-spored, [[lamella (mycology)|gilled]] mushrooms that grow in meadows and woods of the [[subtropic]]s and [[tropics]], usually in soils rich in [[humus]] and plant debris.<ref name = Wurst2002 />{{rp|5}} Psilocybin mushrooms occur on all continents, but the majority of species are found in [[Tropical and subtropical moist broadleaf forests|subtropical humid forests]].<ref name=Guzman2000/> ''Psilocybe'' species commonly found in the tropics include ''[[Psilocybe cubensis|P.&nbsp;cubensis]]'' and ''[[Psilocybe subcubensis|P.&nbsp;subcubensis]]''. ''[[Psilocybe semilanceata|P.&nbsp;semilanceata]]''—considered by Guzmán to be the world's most widely distributed psilocybin mushroom<ref name=Guzman1983/>—is found in Europe, North America, Asia, South America, Australia and New Zealand, but is entirely absent from Mexico.<ref name=Guzman2005/> Although the presence or absence of psilocybin is not of much use as a [[chemotaxonomy|chemotaxonomical]] marker at the [[family (biology)|familial]] level or higher, it is used to classify [[taxa]] of lower taxonomic groups.<ref name=Saupe1981/>

[[File:Pschoactive Psilocybe distribution.svg|class=skin-invert-image|thumb|center|upright=2.5|Global distribution of over 100 psychoactive species of genus ''Psilocybe'' mushrooms.<ref name="Guzmán 1998">{{Cite journal |vauthors=Guzmán G, Allen JW, Gartz J |year=1998 |title=A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion |url=http://www.magic-mushrooms.net/World_Wide_Distribution_of_Magic_Mushrooms.pdf |url-status=dead |journal=Annali del Museo Civico di Rovereto |volume=14 |page=207 |archive-url=https://web.archive.org/web/20100626050845/http://www.magic-mushrooms.net/World_Wide_Distribution_of_Magic_Mushrooms.pdf |archive-date=June 26, 2010 |access-date=September 17, 2017}}</ref>]]

{{Multiple image| align = right| direction = vertical| width = 165| image1 = Psilocybe mexicana 313748.jpg| alt1 = The mushroom ''Psilocybe mexicana''| caption1 = Psilocybin was first isolated from ''[[Psilocybe mexicana]]''.| image2 = Psilocybe semilanceata 6514.jpg| alt2 = The mushroom ''Psilocybe semilanceata''| caption2 = ''[[Psilocybe semilanceata|P.&nbsp;semilanceata]]'' is common in Europe, Canada, and the United States.}}

Both the [[pileus (mycology)|caps]] and the [[stipe (mycology)|stems]] contain psychoactive compounds, although the caps consistently contain more. The [[spore]]s of these mushrooms do not contain psilocybin or psilocin.<ref name=Keller1999/><ref name=Wurst1984/><ref name=Kysilka1989/> The total [[potency (pharmacology)|potency]] varies greatly between species and even between specimens of a species collected or grown from the same strain.<ref name=Bigwood1982/> Because most psilocybin biosynthesis occurs early in the formation of [[basidiocarp|fruit bodies]] or [[sclerotia]], younger, smaller mushrooms tend to have a higher concentration of the drug than larger, mature mushrooms.<ref name=Gartz1992/> In general, the psilocybin content of mushrooms is quite variable (ranging from almost nothing to 2.5% of the [[dry matter|dry weight]])<ref>{{cite journal | vauthors = Laussmann T, Meier-Giebing S | title = Forensic analysis of hallucinogenic mushrooms and khat (Catha edulis Forsk) using cation-exchange liquid chromatography | journal = Forensic Science International | volume = 195 | issue = 1–3 | pages = 160–164 | date = February 2010 | pmid = 20047807 | doi = 10.1016/j.forsciint.2009.12.013 }}</ref><ref name=Stafford1992/>{{rp|248}} and depends on species, strain, growth and drying conditions, and mushroom size.<ref name="Stamets_1996" />{{rp|36–41, 52}} Cultivated mushrooms have less variability in psilocybin content than wild mushrooms.<ref name="urlEMCDDA" /> The drug is more stable in dried than fresh mushrooms; dried mushrooms retain their potency for months or even years,<ref name="Stamets_1996" />{{rp|51–5}} while mushrooms stored fresh for four weeks contain only traces of the original psilocybin.<ref name=Amsterdam2011/>

The psilocybin contents of dried [[herbarium]] specimens of ''Psilocybe semilanceata'' in one study were shown to decrease with the increasing age of the sample: collections dated 11, 33, or 118 years old contained 0.84%, 0.67%, and 0.014% (all dry weight), respectively.<ref name=Ohenoja1987/> Mature [[mycelia]] contain some psilocybin, while young mycelia (recently [[germinated]] from spores) lack appreciable amounts.<ref name=Gross2000/> Many species of mushrooms containing psilocybin also contain lesser amounts of the analog compounds [[baeocystin]] and [[norbaeocystin]],<ref name="Stamets_1996" />{{rp|38}} chemicals thought to be biogenic [[precursor (chemistry)|precursors]].<ref name="Ballesteros_2006" />{{rp|170}} Although most species of psilocybin-containing mushrooms bruise blue when handled or damaged due to the [[Redox|oxidization]] of phenolic compounds, this reaction is not a definitive method of identification or determining a mushroom's potency.<ref name=Bigwood1982/><ref name="Stamets_1996" />{{rp|56–58}}

===Biosynthesis===
[[Isotopic labeling]] experiments from the 1960s suggested that the [[biosynthesis]] of psilocybin was a four-step process:<ref name="Agurell1968" />

# [[Decarboxylation]] of [[tryptophan]] to [[tryptamine]]
# ''N'',''N''-Dimethylation of tryptamine at the N<sup>9</sup> position to [[dimethyltryptamine]]
# 4-[[Hydroxylation]] of dimethyltryptamine to [[psilocin]]
# ''O''-[[Phosphorylation]] of psilocin to psilocybin

This process can be seen in the following diagram:<ref name=Fricke2017/>

[[File:Biosynthesis of psilocybin.svg|class=skin-invert-image|thumb|upright=2.5|center|Biosynthetic route previously thought to lead to psilocybin. It has recently been shown that 4-hydroxylation and O-phosphorylation immediately follow decarboxylation, and neither dimethyltryptamine nor psilocin are intermediates, although spontaneously generated psilocin can be converted back to psilocybin.<ref name=Fricke2017/>]]{{clear left}}

More recent research has demonstrated that—at least in ''P. cubensis''—''O''-phosphorylation is in fact the third step, and that neither dimethyltryptamine nor psilocin are intermediates.<ref name=Fricke2017/> The sequence of the intermediate steps has been shown to involve four enzymes (PsiD, PsiH, PsiK, and PsiM) in ''P. cubensis'' and ''P. cyanescens'', although it is possible that the biosynthetic pathway differs between species.<ref name = Wurst2002 />{{rp|12–13}}<ref name=Fricke2017/> These enzymes are encoded in [[Metabolic gene cluster|gene clusters]] in ''Psilocybe, Panaeolus,'' and ''Gymnopilus''.<ref name=Reynolds2018/>

''[[Escherichia coli]]'' has been genetically modified to manufacture large amounts of psilocybin.<ref>{{Cite journal |vauthors=Satyanarayana M |date=7 October 2019 |title=Modified ''E. coli'' pump out psilocybin |url=https://cen.acs.org/biological-chemistry/biotechnology/Modified-E-coli-pump-magic/97/i39 |url-status=live |journal=[[Chemical & Engineering News]] |volume=97 |issue=39 |page=11 |doi=10.1021/cen-09739-scicon9 |archive-url=https://web.archive.org/web/20191203042315/https://cen.acs.org/biological-chemistry/biotechnology/Modified-E-coli-pump-magic/97/i39 |archive-date=December 3, 2019 |access-date=December 3, 2019 |s2cid=208747979}}</ref> Psilocybin can be produced ''de novo'' in GM yeast.<ref name=Milne2020/><ref name=Wong2022/>

==History==
===Early===
[[File:Psilocybe Mushrooms statues.jpg|thumb|[[Maya architecture|Mayan]] "mushroom stones" of [[Guatemala]].]]

The use of psilocybin mushrooms in religious ceremonies dating back thousands of years is contested.<ref name=":2">{{Cite news |date=2025-05-01 |title=The ancient psychedelics myth: 'People tell tourists the stories they think are interesting for them' |url=https://www.theguardian.com/science/2025/may/01/the-ancient-psychedelics-myth-people-tell-tourists-the-stories-they-think-are-interesting-for-them |access-date=2025-09-26 |work=The Guardian |language=en-GB |issn=0261-3077}}</ref> Despite popular narratives portraying psychedelics as ancient, widespread, and primarily used by [[Shamanism|shamans]] for therapeutic healing, anthropological and historical research shows their traditional use was often limited, recent, and culturally specific, with modern Western interpretations largely shaped by idealization, tourism, and ideological agendas.<ref name=":2" /> Reliable evidence shows that psilocybin mushrooms were used ritualistically in pre-Columbian Mexico but were otherwise rare, with most claims of ancient widespread use exaggerated or misinterpreted.<ref name=":2" />

It has been argued that the [[Tassili Mushroom Figure]], discovered in [[Tassili]], [[Algeria]], is evidence of an early psilocybin-containing mushroom cult.<ref>{{cite journal | vauthors = Samorini G |date=1992 |title=The oldest representations of hallucinogenic mushrooms in the world (Sahara Desert, 9000-7000 BP) |url=https://www.academia.edu/79946409 |journal=Integration. Zeitschrift für geistbewegende Pflanzen und Kultur. |volume=2/3 |pages=69–65}}{{Dead link|date=August 2023|bot=InternetArchiveBot|fix-attempted=yes}}</ref> 6,000-year-old [[pictographs]] discovered near [[Villar del Humo]], Spain, illustrate several mushrooms that have been argued to be ''[[Psilocybe hispanica]]'', a hallucinogenic species native to the area.<ref name="Akers2011" /> Some scholars have also interpreted archaeological [[Artifact (archaeology)|artifacts]] from [[Mexico]] and the so-called [[Maya architecture|Mayan]] "mushroom stones" of [[Guatemala]] as evidence of ritual and ceremonial use of psychoactive mushrooms in the [[Maya civilization|Mayan]] and [[Aztecs|Aztec]] cultures.<ref name="Stamets_1996">{{Cite book |title=Psilocybin Mushrooms of the World: An Identification Guide |vauthors=Stamets P |publisher=[[Ten Speed Press]] |year=1996 |isbn=978-0-89815-839-7 |location=Berkeley, California |author-link=Paul Stamets}}</ref>{{rp|11}}

After Spanish [[conquistadors]] of the [[New World]] arrived in the 16th century, chroniclers reported mushroom use by the natives for ceremonial and religious purposes. According to the [[Dominican Order|Dominican]] friar [[Diego Durán]] in ''The History of the Indies of New Spain'' (published c.&nbsp;1581), mushrooms were eaten in festivities conducted on the occasion of Aztec emperor [[Moctezuma II]]'s accession to the throne in 1502. The [[Franciscan]] friar [[Bernardino de Sahagún]] wrote of witnessing mushroom use in the [[Florentine Codex]] (published 1545–1590),<ref name="Marley2010" />{{rp|164}} saying that some merchants celebrated upon returning from a successful business trip by consuming mushrooms to evoke revelatory visions.<ref name="Hofmann2009" />{{rp|118}} After the [[Spanish conquest of the Aztec Empire|defeat of the Aztecs]], the Spanish forbade traditional religious practices and rituals they considered "pagan idolatry", including ceremonial mushroom use. For the next four centuries, the Indians of [[Mesoamerica]] hid their use of [[entheogens]] from the Spanish authorities.<ref name="Marley2010" />{{rp|165}}

Dozens of species of psychedelic mushrooms are found in Europe, but there is little documented usage of them in [[Old World]] history besides the use of ''[[Amanita muscaria]]'' among Siberian peoples.<ref name="nyberg1">{{Cite journal |vauthors=Nyberg H |year=1992 |title=Religious use of hallucinogenic fungi: A comparison between Siberian and Mesoamerican Cultures |journal=Karstenia |volume=32 |issue=2 |pages=71–80 |doi=10.29203/ka.1992.294 |doi-access=free}}</ref><ref>{{Cite book |title=Soma: Divine Mushroom of Immortality |vauthors=Wasson RG |publisher=Harcourt Brace Jovanovick |year=1968 |isbn=978-0-88316-517-1 |page=161}}</ref> The few existing accounts that mention psilocybin mushrooms typically lack sufficient information to allow species identification, focusing on their effects. For example, Flemish botanist [[Carolus Clusius]] (1526–1609) described the ''bolond gomba'' ("crazy mushroom"), used in rural [[Hungary]] to prepare love potions. English botanist [[John Parkinson (botanist)|John Parkinson]] included details about a "foolish mushroom" in his 1640 [[herbal]] ''Theatricum Botanicum''.<ref name="Gartz_1997">{{Cite book |title=Magic Mushrooms Around the World |vauthors=Gartz J |publisher=LIS Publications |year=1997 |isbn=978-0-9653399-0-2 |location=Los Angeles, California}}</ref>{{rp|10–12}} The first reliably documented report of intoxication with ''Psilocybe semilanceata''—Europe's most common and widespread psychedelic mushroom—involved a British family in 1799, who prepared a meal with mushrooms they had picked in London's [[Green Park]].<ref name="Gartz_1997" />{{rp|16}}

===Modern===
[[File:Albert Hofmann Oct 1993.jpg|thumb|left|Albert Hofmann (shown here in 1993) purified psilocybin and psilocin from ''Psilocybe mexicana'' in the late 1950s.]]
[[File:Golden teacher kookoskuidussa 3.jpg|thumb|The increasing availability of information on growing techniques eventually made it possible for amateurs to grow psilocybin mushrooms (''[[Psilocybe cubensis]]'' pictured) without access to laboratory equipment.]]

American banker and amateur [[ethnomycologist]] [[R. Gordon Wasson]] and his wife, [[Valentina Pavlovna Wasson|Valentina P. Wasson]], a physician, studied the ritual use of psychoactive mushrooms by the native population in the [[Mazatec]] village [[Huautla de Jiménez]], Mexico. In 1957, Wasson described the [[Psychedelic experience|psychedelic visions]] he experienced during these rituals in "[[Seeking the Magic Mushroom]]", an article published in the American weekly ''[[Life (magazine)|Life]]'' magazine.<ref name="Wasson1957" /> Later the same year they were accompanied on a follow-up expedition by French mycologist [[Roger Heim]], who identified several of the mushrooms as ''Psilocybe'' species.<ref name="Heim1957" />

Heim cultivated the mushrooms in France and sent samples for analysis to [[Albert Hofmann]], a chemist employed by the Swiss pharmaceutical company [[Sandoz]]. Hofmann—who had synthesized [[lysergic acid diethylamide]] (LSD) in 1938—led a research group that isolated and identified the psychoactive alkaloids psilocybin and psilocin from ''[[Psilocybe mexicana]]'', publishing their results in 1958.<ref name="Hofmann2009" />{{rp|128}} The team was aided in the discovery process by Hofmann's willingness to ingest mushroom extracts to help verify the presence of the active compounds.<ref name="Hofmann2009" />{{rp|126–127}}

Next, Hofmann's team synthesized several [[structural analog]]s of these compounds to examine how these structural changes affect psychoactivity. This research led to the development of [[ethocybin]] and [[CZ-74]]. Because these compounds' physiological effects last only about three and a half hours (about half as long as psilocybin's), they proved more manageable for use in [[Psychedelic therapy#Psycholytic therapy|psycholytic therapy]].<ref name="Stafford1992" />{{rp|237}} Sandoz also marketed and sold pure psilocybin under the name Indocybin to clinicians and researchers worldwide.<ref name="Marley2010" />{{rp|166}} There were no reports of serious complications when psilocybin was used in this way.<ref name="Passie2002" />

In the early 1960s, [[Harvard University]] became a testing ground for psilocybin through the efforts of Timothy Leary and his associates [[Ralph Metzner]] and Richard Alpert (who later changed his name to [[Ram Dass]]). Leary obtained synthesized psilocybin from Hofmann through Sandoz Pharmaceuticals. Some studies, such as the [[Concord Prison Experiment]], suggested promising results using psilocybin in [[clinical psychiatry]].<ref name="Leary1963" /><ref name="Leary1965" /> But according to a 2008 review of safety guidelines in human hallucinogenic research, Leary's and Alpert's well-publicized termination from Harvard and later advocacy of hallucinogen use "further undermined an objective scientific approach to studying these compounds".<ref name="Johnson2008" /> In response to concerns about the increase in unauthorized use of psychedelic drugs by the general public, psilocybin and other hallucinogenic drugs were unfavorably covered in the press and faced increasingly restrictive laws. In the U.S., laws passed in 1966 that prohibited the production, trade, or ingestion of hallucinogenic drugs; Sandoz stopped producing LSD and psilocybin the same year.<ref name="Matsushima2009" /> In 1970, Congress passed "The Federal Comprehensive Drug Abuse Prevention and Control Act" that made LSD, peyote, psilocybin, and other hallucinogens illegal to use for any purpose, including scientific research.<ref>{{Cite news |title=The War on Drugs turns 50 today. It's time to make peace. |url=https://www.washingtonpost.com/outlook/2021/06/17/war-drugs-turns-50-today-its-time-make-peace/ |access-date=2023-08-08 |newspaper=The Washington Post}}</ref> United States politicians' agenda against LSD usage had swept psilocybin along with it into the [[Schedule I controlled substance|Schedule&nbsp;I category]] of illicit drugs. Such restrictions on the use of these drugs in human research made funding for such projects difficult to obtain, and scientists who worked with psychedelic drugs faced being "professionally marginalized".<ref name="Griffiths2010" /> Although Hofmann tested these compounds [[Self-experimentation|on himself]], he never advocated their legalization or medical use. In his 1979 book ''LSD—mein Sorgenkind'' (''LSD—My Problem Child''), he described the problematic use of these hallucinogens as inebriants.<ref name="Hofmann2009" />{{rp|79–116}}

Despite the legal restrictions on psilocybin use, the 1970s witnessed the emergence of psilocybin as the "entheogen of choice".<ref name="Ott_1993">{{Cite book |title=Pharmacotheon: Entheogenic Drugs, their Plant Sources and History |vauthors=Ott J |publisher=Natural Products Company |year=1993 |isbn=978-0-9614234-3-8 |location=Kennewick, Washington |author-link=Jonathan Ott}}</ref>{{rp|276}} This was due in large part to wide dissemination of information on the topic, which included works such as those by [[Carlos Castaneda]] and several books that taught the technique of growing psilocybin mushrooms. One of the most popular of the latter group, ''Psilocybin: Magic Mushroom Grower's Guide'', was published in 1976 under the pseudonyms O. T. Oss and O. N. Oeric by Jeremy Bigwood, [[Dennis Jon McKenna|Dennis J. McKenna]], K. Harrison McKenna, and Terence McKenna. Over 100,000 copies were sold by 1981.<ref name="Oeric1991" /> As ethnobiologist [[Jonathan Ott]] explains, "These authors adapted San Antonio's technique (for producing edible mushrooms by casing [[mycelial]] cultures on a rye grain substrate; San Antonio 1971) to the production of ''Psilocybe [Stropharia] cubensis''. The new technique involved the use of ordinary kitchen implements, and for the first time the layperson was able to produce a potent entheogen in his own home, without access to sophisticated technology, equipment or chemical supplies."<ref name="Ott_1993" />{{rp|290}} San Antonio's technique describes a method to grow the common edible mushroom ''[[Agaricus bisporus]]''.<ref>{{cite journal | vauthors = San Antonio JP | title = A laboratory method to obtain fruit from cased grain spawn of the cultivated mushoom, Agaricus bisporus | journal = Mycologia | volume = 63 | issue = 1 | pages = 16–21 | year = 1971 | pmid = 5102274 | doi = 10.2307/3757680 | url = http://www.cybertruffle.org.uk/cyberliber/59350/0063/001/0016.htm | url-status = live | access-date = September 7, 2011 | jstor = 3757680 | archive-date = September 23, 2015 | archive-url = https://web.archive.org/web/20150923224902/http://www.cybertruffle.org.uk/cyberliber/59350/0063/001/0016.htm }}</ref>

Because of lack of clarity about laws concerning psilocybin mushrooms, specifically in the form of sclerotia (also known as "truffles"), in the late 1990s and early 2000s European retailers commercialized and marketed them in [[smartshop]]s in the Netherlands, the UK, and online. Several websites{{efn|The [[EMCDDA]] lists the general-purpose websites [[Erowid]], [[Lycaeum]], [http://www.mycotopia.net Mycotopia], [http://www.shroomery.org The Shroomery], [http://www.mushroomjohn.com MushroomJohn] and [http://www.entheogenreview.com The Entheogen Review]. Regional sites focusing on hallucinogenic mushrooms listed were [http://www.mushroom.dk Copenhagen Mushroom Link] (Denmark), [http://www.champis.fr.tc Champis] (France), [http://www.daath.hu Daath] (Hungary), [http://www.gratisweb·com/delysid Delysid] (Spain), [https://enteogeneos.com.sapo.pt Enteogeneos] (Portugal), [http://drogy.jinak.cz/houbicky Kouzelné houbičky] (Czech Republic), [http://www.norshroom.org Norshroom] (Norway), [http://planetahongo.tripod.com Planetahongo] (Spain), [http://knarkkorven.magiskamolekyler.org/svampinfo/index.html Svampinfo] (Sweden), and [http://trippi.info/taikasieniforum Taikasieniforum] (Finland). It also listed [http://www.magic-mushrooms.net Magic-Mushrooms.net]. The report detailed several additional sites selling [[spore print]]s in 2006, but noted that many of these had ceased operation.}} emerged that contributed to the accessibility of information on the mushrooms' description, use, and effects, and users exchanged mushroom experiences. Since 2001, six [[EU]] countries have tightened their legislation on psilocybin mushrooms in response to concerns about their prevalence and increasing usage.<ref name="EMCDDA" /> In the 1990s, hallucinogens and their effects on human consciousness were again the subject of scientific study, particularly in Europe. Advances in [[neuropharmacology]] and [[neuropsychology]] and the availability of brain imaging techniques have provided impetus for using drugs like psilocybin to probe the "neural underpinnings of psychotic symptom formation including ego disorders and hallucinations".<ref name="Studerus2011" /> Recent studies in the U.S. have attracted attention from the popular press and brought psilocybin back into the limelight.<ref name="Keim2008" /><ref name="Miller2008" />

==Society and culture==
===Usage===
[[File:Dried Cubensis.jpg|thumb|Dried ''Psilocybe'' mushrooms showing the characteristic blue bruising on the stems.]]

A 2009 national survey of drug use by the [[US Department of Health and Human Services]] concluded that the number of first-time psilocybin mushroom users in the United States was roughly equivalent to the number of first-time users of cannabis.<ref name=Bone2011/> A June 2024 report by the [[RAND Corporation]] suggests the total number of use days for psychedelics is two orders of magnitude smaller than it is for cannabis, and unlike people who use cannabis and many other drugs, infrequent users of psychedelics account for most of the total days of use.<ref name = "Kilmer_2024">{{cite report |url=https://www.rand.org/pubs/research_reports/RRA2825-1.html |title=Considering Alternatives to Psychedelic Drug Prohibition | vauthors = Kilmer B, Priest M, Ramchand R, Rogers RC, Senator B, Palmer K | date = 27 June 2024 }}</ref> The RAND Corporation report suggests psilocybin mushrooms may be the most prevalent psychedelic drug among U.S. adults.<ref name = "Kilmer_2024" />

In European countries, the lifetime prevalence estimates of psychedelic mushroom usage among young adults (15–34 years) range from 0.3% to 14.1%.<ref name="EMDCCA2011" />

In modern Mexico, traditional ceremonial use survives among several indigenous groups, including the [[Nahuas]], the [[Matlatzinca people|Matlatzinca]], the [[Totonacs]], the [[Mazatecs]], [[Mixe people|Mixes]], [[Zapotec peoples|Zapotecs]], and the [[Chatinos|Chatino]]. Although hallucinogenic ''Psilocybe'' species are abundant in Mexico's low-lying areas, most ceremonial use takes places in mountainous areas of elevations greater than {{convert|1500|m|sp=us}}. Guzmán suggests this is a vestige of Spanish colonial influence from several hundred years earlier, when mushroom use was persecuted by the [[Catholic Church]].<ref name=Guzman2008/>

===Legal status===
{{Further|Legal status of psilocybin mushrooms|Psilocybin decriminalization in the United States}}
{{Excerpt|Legal status of psilocybin mushrooms}}

====Advocacy for tolerance====
Despite being illegal to possess without authorization in many Western countries, such as the UK, Australia, and some U.S. states, less conservative governments nurture the legal possession and supply of psilocybin and other psychedelic drugs. In [[Amsterdam]], authorities provide education on and promote the safe use of psychedelic drugs, such as psilocybin, to reduce public harm.<ref>{{Cite journal |vauthors=Hardon A, van Schipstal I, Berning M, Mishra S, Murray H, Mandler T, Kamps D, Hymans TD |date=December 2020 |title=Caring for "Hassle-Free Highs" in Amsterdam. |journal=Anthropology and Humanism |volume=45 |issue=2 |pages=212–22 |doi=10.1111/anhu.12298 |s2cid=228997721|doi-access=free |hdl=11245.1/a323041d-6737-4b4a-968e-9285d8d68ffa |hdl-access=free }}</ref> Similarly, religious groups like America's Uniao do Vegetal (UDV)<ref name="Pollan_2018">{{Cite book |title=Como mudar sua mente | vauthors = Pollan M |author1-link=Michael Pollan|date=2018 |publisher=Editora Intrinseca |isbn=9788551004173 |language=Portuguese |trans-title=How to kill your mind}}</ref> use psychedelics in traditional ceremonies.<ref>{{Cite book |title=Psychedelic mysticism: Transforming consciousness, religious experiences, and voluntary peasants in postwar America. |vauthors=Shipley M |date=November 2015 |publisher=Lexington Books |isbn=978-1-4985-0910-7}}</ref> A report from the U.S. Government Accountability Office (GAO) notes that people may petition the DEA for exemptions to use psilocybin for religious purposes.<ref>{{Cite web | vauthors = Adlin B |date=2024-07-15 |title=DEA's Process for Religious Use of Psychedelics Needs More Consistent Standards, Government Watchdog Agency Says |url=https://doubleblindmag.com/deas-process-for-religious-use-of-psychedelics-needs-more-consistent-standards-government-watchdog-agency-says/ |access-date=2024-07-17 |website=DoubleBlind Mag |language=en-US}}</ref>

From 1 July 2023, the Australian medicines regulator has permitted psychiatrists to prescribe psilocybin for the therapeutic treatment of treatment-resistant depression.<ref>{{Cite news | vauthors = Lu D |date=2023-06-30 |title=Australian psychiatrists can now prescribe MDMA and psilocybin: who can access them and how do they work? |language=en-GB |work=The Guardian |url=https://www.theguardian.com/australia-news/2023/jul/01/australian-psychiatrists-can-now-prescribe-mdma-and-psilocybin-who-can-access-them-and-how-do-they-work |access-date=2023-07-18 |issn=0261-3077}}</ref>

Advocates of legalization argue there is a lack of evidence of harm,<ref>{{Cite report |url=https://parliament.wa.gov.au/Parliament/commit.nsf/luInquiryPublicSubmissions/5F7C3C56F7ABD360482583A70009A934/$file/id.alt.063.190118.sub.Australian%20Psychedelic%20Society.pdf |title=Submission to the Western Australian Inquiry Into Alternative Approaches to Reducing Illicit Drug Use and Its Effects on the Community |date=30 January 2019 |publisher=Australian Psychedelic Society Inc. |access-date=August 23, 2021 |archive-url=https://web.archive.org/web/20210823040413/https://parliament.wa.gov.au/Parliament/commit.nsf/luInquiryPublicSubmissions/5F7C3C56F7ABD360482583A70009A934/$file/id.alt.063.190118.sub.Australian%20Psychedelic%20Society.pdf |archive-date=August 23, 2021 |url-status=live}}</ref><ref name="Johansen_2015">{{cite journal | vauthors = Johansen PØ, Krebs TS | title = Psychedelics not linked to mental health problems or suicidal behavior: a population study | journal = Journal of Psychopharmacology | volume = 29 | issue = 3 | pages = 270–279 | date = March 2015 | pmid = 25744618 | doi = 10.1177/0269881114568039 | s2cid = 2025731 }}</ref> and potential use in treating certain mental health conditions. Research is difficult to conduct because of the legal status of psychoactive substances.<ref name="Johnson_2018">{{cite journal | vauthors = Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE | title = The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | journal = Neuropharmacology | volume = 142 | pages = 143–166 | date = November 2018 | pmid = 29753748 | pmc = 6791528 | doi = 10.1016/j.neuropharm.2018.05.012 }}</ref> Advocates of legalization also promote the utility of "[[ego dissolution]]"<ref name="Pollan_2018" /> and argue bans are cultural discrimination against traditional users.<ref>{{Cite journal |vauthors=Rodd R |date=September 2018 |title=It's all you! Australian ayahuasca drinking, spiritual development, and immunitary individualism. |journal=Critique of Anthropology |volume=38 |issue=3 |pages=325–45 |doi=10.1177/0308275X18775818 |s2cid=149858755}}</ref>

In 2024, after calls for regulatory and legal change to expand terminally ill populations' access to controlled substances, two legal cases related to expanded access began moving through the federal courts under [[right-to-try law]]. The Advanced Integrative Medicine Science (AIMS) Institute in concert with the NPA filed a series of lawsuits seeking both the rescheduling of and expanded right-to-try access to psilocybin.<ref>{{Cite web | vauthors = Vossel H |date=2024-05-21 |title=Laws in Motion to Bring 'Right to Try' Psychedelics at End-of-Life |url=https://hospicenews.com/2024/05/21/laws-in-motion-to-bring-right-to-try-psychedelics-at-end-of-life/ |access-date=2025-02-13 |website=Hospice News |language=en-US}}</ref>

==Research==
===Psychiatric and other disorders===
{{See also|Psychedelic therapy|List of investigational hallucinogens and entactogens}}

Psilocybin has been a subject of clinical research since the early 1960s, when the [[Harvard Psilocybin Project]] evaluated the [[Psilocybin therapy|potential value of psilocybin]] as a treatment for certain [[personality disorder]]s.<ref name=Wark2009/> Beginning in the 2000s, psilocybin has been investigated for its possible role in the treatment of [[nicotine dependence]], [[alcohol dependence]], [[obsessive–compulsive disorder]] (OCD), [[cluster headache]], [[Psycho-oncology#Psychological|cancer-related existential distress]],<ref name=Serreau2023/><ref name=Goel2022/> [[anxiety disorder]]s, and certain [[mood disorder]]s.<ref name=Marley2010/>{{rp|179–81}}<ref name=DosSantos2016/><ref name=Ross2016/> It is also being studied in people with [[Parkinson's disease]].<ref name="BradleySakaiFernandes2023">{{cite journal | vauthors = Bradley E, Sakai K, Fernandes G, Ludwig C, Bock M, Ostrem J, Tanner C, O'Donovan A, Finley P, Busby Z, McKernan A, Zuzuarregui JR, Penn A, Wang A, Rosen R, Woolley J | date = December 2023 | title = ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P400. Psilocybin Therapy for Depression and Anxiety Associated With Parkinson's Disease: A Pilot Study | journal = Neuropsychopharmacology | volume = 48 | issue = Suppl 1 | pages = 211–354 (296–297) | doi = 10.1038/s41386-023-01756-4 | pmid = 38040810 | pmc = 10729596 }}</ref><ref name="BradleySakaiFernandes-Osterhold2024">{{cite journal | vauthors = Bradley E, Sakai K, Fernandes-Osterhold G, Szigeti B, Ludwig C, Ostrem J, Tanner C, Bock M, Llerena K, Finley P, O'Donovan A, Zuzuarregui JR, Busby Z, McKernan A, Penn A, Wang A, Rosen R, Woolley J | title = ACNP 63rd Annual Meeting: Poster Abstracts P305-P608: P594. Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: an Open-Label Pilot Study | journal = Neuropsychopharmacology | volume = 49 | issue = Suppl 1 | pages = 236–417 (407–408) | date = December 2024 | pmid = 39643634 | doi = 10.1038/s41386-024-02012-z | url = | doi-access = free }}</ref> In 2018, the United States [[Food and Drug Administration]] (FDA) granted [[breakthrough therapy]] designation for psilocybin-assisted therapy for [[treatment-resistant depression]].<ref name=Compasspathways2018/><ref name=Staines2019/> A systematic review published in 2021 found that the use of psilocybin as a pharmaceutical substance was associated with reduced intensity of depression symptoms.<ref name=Wieckiewicz2021/> The role of psilocybin as a possible [[psychoplastogen]] is also being examined.<ref name="VargasMeyerAvanes2021" /><ref name=Olson2021/><ref name=DeVos2021/> It is under development by [[Compass Pathways]], [[Cybin]], and several other companies.<ref name="RheeDavoudianSanacora2023">{{cite journal | vauthors = Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST | title = Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders | journal = Drug Discov Today | volume = 28 | issue = 12 | article-number = 103818 | date = December 2023 | pmid = 37925136 | doi = 10.1016/j.drudis.2023.103818 | url = https://drive.google.com/file/d/1mztRkW7vJu7KjpE1xKUyZoObWJ5QvEmt/view }}</ref><ref name="AdayBarnettGrossman2023">{{cite journal | vauthors = Aday JS, Barnett BS, Grossman D, Murnane KS, Nichols CD, Hendricks PS | title=Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry | journal=Psychedelic Medicine | volume=1 | issue=3 | date=1 September 2023 | issn=2831-4425 | doi=10.1089/psymed.2023.0013 | pages=150–165 | pmid=40046566 | pmc=11661494 | url=https://www.researchgate.net/publication/373171466 }}</ref>

====Depression====
[[Clinical trial]]s, including both [[open-label study|open-label trial]]s and [[blinded experiment|double-blind]] [[randomized controlled trial]]s (RCTs), have found that single doses of psilocybin produce rapid and long-lasting [[antidepressant]] effects outperforming [[placebo]] in people with [[major depressive disorder]] and [[treatment-resistant depression]].<ref name="WangKimChoi2024">{{cite journal | vauthors = Wang SM, Kim S, Choi WS, Lim HK, Woo YS, Pae CU, Bahk WM | title = Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials | journal = Clin Psychopharmacol Neurosci | volume = 22 | issue = 2 | pages = 222–231 | date = May 2024 | pmid = 38627070 | pmc = 11024689 | doi = 10.9758/cpn.23.1134 | url = }}</ref> Combined with brief [[psychotherapy|psychological support]] in a [[Phases of clinical research#Phase II|Phase II]] trial, it has been found to produce [[dose dependency|dose-dependent]] improvements in depressive symptoms, with 25{{nbsp}}mg (a moderate dose) more effective than 10{{nbsp}}mg (a low dose), and 10{{nbsp}}mg more effective than 1{{nbsp}}mg (non-psychoactive and equivalent to placebo).<ref name="WangKimChoi2024" /><ref name="GoodwinAaronsonAlvarez2022">{{cite journal | vauthors = Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MH, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E|display-authors=3 | title = Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression | journal = New England Journal of Medicine | volume = 387 | issue = 18 | pages = 1637–1648 | date = November 2022 | pmid = 36322843 | doi = 10.1056/NEJMoa2206443 | url = }}</ref> The antidepressant effects of psilocybin with psychological support have been found to last at least 6{{nbsp}}weeks following a single dose.<ref name="WangKimChoi2024" /><ref name="GoodwinAaronsonAlvarez2022" /><ref name="RaisonSanacoraWoolley2023">{{cite journal | vauthors = Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, Mletzko T, Nicholas CR, Hutson PR, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis MC, Nelson-Douthit C, Wilson S, Brown C, Linton W, Ross S, Griffiths RR|display-authors=3 | title = Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial | journal = JAMA | volume = 330 | issue = 9 | pages = 843–853 | date = September 2023 | pmid = 37651119 | pmc = 10472268 | doi = 10.1001/jama.2023.14530 }}</ref><ref name="GoodwinNowakowskaAtli2025" />

However, some trials have not found psilocybin to significantly outperform placebo in the treatment of depression.<ref name="WangKimChoi2024" /> In addition, a Phase II trial found that two 25{{nbsp}}mg doses of psilocybin 3{{nbsp}}weeks apart versus daily treatment with the [[selective serotonin reuptake inhibitor]] (SSRI) [[escitalopram]] (Lexapro) for 6{{nbsp}}weeks (plus two putatively non-psychoactive 1{{nbsp}}mg doses of psilocybin 3{{nbsp}}weeks apart) did not show a [[statistical significance|statistically significant]] difference in reduction of depressive symptoms between groups.<ref name="WangKimChoi2024" /><ref name="Carhart-HarrisGiribaldiWatts2021">{{cite journal | vauthors = Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ|display-authors=3 | title = Trial of Psilocybin versus Escitalopram for Depression | journal = New England Journal of Medicine | volume = 384 | issue = 15 | pages = 1402–1411 | date = April 2021 | pmid = 33852780 | doi = 10.1056/NEJMoa2032994 | doi-access=free }}</ref> However, reductions in depressive symptoms were numerically greater with psilocybin, some [[outcome measure|secondary measures]] favored psilocybin, and the rate of [[remission (medicine)|remission]] was statistically higher with psilocybin (57% with psilocybin vs. 28% with escitalopram).<ref name="WangKimChoi2024" /><ref name="Carhart-HarrisGiribaldiWatts2021" /> In any case, the antidepressant [[effect size]] of psilocybin over escitalopram appears to be small.<ref name="HsuTsaiKao2024">{{cite journal |display-authors=3| vauthors = Hsu TW, Tsai CK, Kao YC, Thompson T, Carvalho AF, Yang FC, Tseng PT, Hsu CW, Yu CL, Tu YK, Liang CS | title = Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis | journal = BMJ | volume = 386 | issue = |article-number=e078607 | date = August 2024 | pmid = 39168500 | pmc = 11337322 | doi = 10.1136/bmj-2023-078607 | url = }}</ref>

[[Unblinding|Functional unblinding]] by their psychoactive effects and [[subject-expectancy effect|positive psychological expectancy effect]]s (i.e., the [[placebo effect]]) are major limitations and sources of [[bias (statistics)|bias]] of clinical trials of psilocybin and other psychedelics for treatment of depression.<ref name="MuthukumaraswamyForsythLumley2021">{{cite journal | vauthors = Muthukumaraswamy SD, Forsyth A, Lumley T | title = Blinding and expectancy confounds in psychedelic randomized controlled trials | journal = Expert Rev Clin Pharmacol | volume = 14 | issue = 9 | pages = 1133–1152 | date = September 2021 | pmid = 34038314 | doi = 10.1080/17512433.2021.1933434 | url = }}</ref><ref name="LedwosRosenblatBlumberger2022">{{cite journal | vauthors = Ledwos N, Rosenblat JD, Blumberger DM, Castle DJ, McIntyre RS, Mulsant BH, Husain MI | title = A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap | journal = J Clin Psychopharmacol | volume = 42 | issue = 6 | pages = 581–588 | date = 2022 | pmid = 36193898 | doi = 10.1097/JCP.0000000000001608 | url = }}</ref><ref name="HovmandPoulsenArnfred2023">{{cite journal | vauthors = Hovmand OR, Poulsen ED, Arnfred S, Storebø OJ | title = Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review | journal = J Psychopharmacol | volume = 37 | issue = 7 | pages = 649–659 | date = July 2023 | pmid = 37403379 | pmc = 10350724 | doi = 10.1177/02698811231180276 | url = }}</ref><ref name="SzigetiHeifets2024">{{cite journal | vauthors = Szigeti B, Heifets BD | title = Expectancy Effects in Psychedelic Trials | journal = Biol Psychiatry Cogn Neurosci Neuroimaging | volume = 9 | issue = 5 | pages = 512–521 | date = May 2024 | pmid = 38387698 | doi = 10.1016/j.bpsc.2024.02.004 | url = }}</ref> Relatedly, most of the therapeutic benefit of conventional [[antidepressant]]s like the SSRIs for depression appears to be attributable to the [[placebo response]].<ref name="Kirsch2019">{{cite journal|vauthors=Kirsch I|title=Placebo Effect in the Treatment of Depression and Anxiety|journal=Front Psychiatry|volume=10|article-number=407|date=2019|pmid=31249537|pmc=6584108|doi=10.3389/fpsyt.2019.00407|doi-access=free}}</ref><ref name="HengartnerPlöderl2018">{{cite journal|vauthors=Hengartner MP, Plöderl M|title=False Beliefs in Academic Psychiatry: The Case of Antidepressant Drugs|journal=Ethical Human Psychology and Psychiatry|date=July 2018|volume=20|issue=1|pages=6–16|issn=1559-4343|eissn=1938-9000|doi=10.1891/1559-4343.20.1.6|s2cid=149608377}}</ref> It has been proposed that psychedelics like psilocybin may in fact act as [[active placebo|active]] "[[super placebo]]s" when used for therapeutic purposes.<ref name="DupuisVeissière2022">{{cite journal | vauthors = Dupuis D, Veissière S | title = Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos? | journal = Transcult Psychiatry | volume = 59 | issue = 5 | pages = 571–578 | date = October 2022 | pmid = 36263513 | doi = 10.1177/13634615221131465 | url = }}</ref><ref name="vanElkYaden2022">{{cite journal | vauthors = van Elk M, Yaden DB | title = Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review | journal = Neurosci Biobehav Rev | volume = 140 | issue = | article-number = 104793 | date = September 2022 | pmid = 35878791 | doi = 10.1016/j.neubiorev.2022.104793 | url = | quote = In addition, the strong prior expectations that many people have about psychedelics directly contribute to the psychedelic experience and as a consequence it has been suggested that psychedelics may act as a ‘super-placebo’ (Hartogsohn, 2016). Specifically, strong prior expectations (e.g., that a specific intervention will likely trigger a mystical experience) will increase the likelihood of having e.g., a mystical-type experience (Maij et al., 2019), and this placebo-effect is further boosted by the psychedelic-induced suggestibility. | hdl = 1887/3515020 | hdl-access = free }}</ref> Psilocybin has not received regulatory approval for medical use in the United States.<ref name="AdisInsight">{{cite web | title=Psilocybin - COMPASS Pathways | website=AdisInsight | date=15 May 2024 | url=https://adisinsight.springer.com/drugs/800050861 | access-date=5 September 2024}}</ref><ref name="WangKimChoi2024" /><ref name="YaoGuoLu2024">{{cite journal | vauthors = Yao Y, Guo D, Lu TS, Liu FL, Huang SH, Diao MQ, Li SX, Zhang XJ, Kosten TR, Shi J, Bao YP, Lu L, Han Y | title = Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis | journal = Psychiatry Res | volume = 335 | issue = | article-number = 115886 | date = May 2024 | pmid = 38574699 | doi = 10.1016/j.psychres.2024.115886 | url = }}</ref>

In a 2024 [[meta-analysis]] of RCTs of psychedelics and escitalopram for treatment of depression, only "high-dose" psilocybin (≥20{{nbsp}}mg) significantly outperformed escitalopram in improving depressive symptoms.<ref name="HsuTsaiKao2024"/> It showed a large effect size over placebo, but a small effect size over escitalopram.<ref name="HsuTsaiKao2024" /> A 2025 meta-analysis found a moderate effect size advantage of psilocybin relative to placebo.<ref name="BorgognaOwenPetrovitch2025" /> A 2024 [[network meta-analysis]] of RCTs of therapies for [[treatment-resistant depression]], with effectiveness measures being [[response rate (medicine)|response]] and [[remission rate]]s, likewise found that psilocybin was more effective than placebo and, considering both effectiveness and [[tolerability]] or [[drug safety|safety]], recommended it as a [[lines of therapy|first-line therapy]], along with [[ketamine]], [[esketamine]], and [[electroconvulsive therapy]] (ECT).<ref name="GuoGuoWang2024">{{cite journal | vauthors = Guo Q, Guo L, Wang Y, Shang S | title = Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs | journal = Psychiatry Res | volume = 339 | issue = | article-number = 116018 | date = September 2024 | pmid = 38924903 | doi = 10.1016/j.psychres.2024.116018 | url = }}</ref> However, the [[quality of evidence]] was generally rated as low or very low.<ref name="GuoGuoWang2024" /> Meta-analyses of psychedelics for depression and other psychiatric conditions have found that psilocybin has the greatest number of studies and the most evidence of benefit, relative to other psychedelics like [[ayahuasca]] and [[LSD]].<ref name="HsuTsaiKao2024" /><ref name="BahjiLunskyGutierrez2025">{{cite journal | vauthors = Bahji A, Lunsky I, Gutierrez G, Vazquez G | title = Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis | journal = J Psychoactive Drugs | volume = 57 | issue = 1 | pages = 1–16 | date = 2025 | pmid = 37968944 | doi = 10.1080/02791072.2023.2278586 | pmc = 12129050 | pmc-embargo-date = January 1, 2026 | url = }}</ref><ref name="YaoGuoLu2024"/><ref name="KoKopraCleare2023">{{cite journal | vauthors = Ko K, Kopra EI, Cleare AJ, Rucker JJ | title = Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis | journal = J Affect Disord | volume = 322 | issue = | pages = 194–204 | date = February 2023 | pmid = 36209780 | doi = 10.1016/j.jad.2022.09.168 | url = }}</ref>

Preliminary meta-analyses suggest that improvements in depressive symptoms with psilocybin are [[dose dependence|dose-dependent]] and that higher doses may result in greater improvements than lower doses.<ref name="LiHuChen2022">{{cite journal | vauthors = Li NX, Hu YR, Chen WN, Zhang B | title = Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis | journal = J Affect Disord | volume = 296 | issue = | pages = 26–34 | date = January 2022 | pmid = 34587546 | doi = 10.1016/j.jad.2021.09.041 | url = }}</ref><ref name="PerezLanglestMallet2023">{{cite journal | vauthors = Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, Seragnoli F, Zullino D, Kirschner M, Kaiser S, Solmi M, Sabé M | title = Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies | journal = Eur Neuropsychopharmacol | volume = 76 | issue = | pages = 61–76 | date = November 2023 | pmid = 37557019 | doi = 10.1016/j.euroneuro.2023.07.011 | url = | doi-access = free }}</ref><ref name="SwieczkowskiKwaśnyPruc2025">{{cite journal | vauthors = Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ | title = Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials | journal = Psychiatry Res | volume = 344 | issue = | article-number = 116337 | date = February 2025 | pmid = 39754904 | doi = 10.1016/j.psychres.2024.116337 | url = }}</ref> One meta-analysis found that the highest assessed dose in clinical trials, 30 to 35{{nbsp}}mg per 70{{nbsp}}kg body weight, was the most effective, with an [[effect size]] (Hedges' g) of 3.1 (relative to 1.3 overall), but based on only one study for that dosing subgroup.<ref name="LiHuChen2022" /> This meta-analysis included both RCTs and [[prospective study|prospective]] open-label studies, and calculated effect sizes by comparing to the placebo group or by using pre-treatment (baseline) values.<ref name="LiHuChen2022" /> Another meta-analysis, which included only RCTs, found that 25{{nbsp}}mg was the most effective dose, relative to lower doses like 10{{nbsp}}mg and 0.215{{nbsp}}mg/kg body weight (~15{{nbsp}}mg for a 70-kg person).<ref name="SwieczkowskiKwaśnyPruc2025" /> A third meta-analysis found that half of psilocybin's maximal antidepressant effect occurred with a dose of about 10{{nbsp}}mg per 70{{nbsp}}kg body weight, while 95% of the maximal effect occurred at a dose of about 41{{nbsp}}mg per 70{{nbsp}}kg body weight, and that higher doses might especially be better for treatment-resistant depression.<ref name="PerezLanglestMallet2023" /> The risk of [[adverse effect]]s was also greater with higher doses.<ref name="PerezLanglestMallet2023" />

A 2025 network meta-analysis of RCTs of psilocybin for depression found that it did not significantly improve depression scores relative to placebo on day 2 post-dose but did improve them day 8 and day 15 post-dose.<ref name="SwieczkowskiKwaśnyPruc2025" /> Depressive symptoms were improved only slightly more with psilocybin than with placebo.<ref name="SwieczkowskiKwaśnyPruc2025" /> Another 2024 meta-analysis found that depressive symptoms were improved on days 2, 14, and 42, with similar effect sizes.<ref name="MenonRamamurthyVenu2024">{{cite journal | vauthors = Menon V, Ramamurthy P, Venu S, Andrade C | title = Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis | journal = Acta Psychiatr Scand | volume = 151| issue = 5| pages = 557–571| date = December 2024 | pmid = 39627679 | doi = 10.1111/acps.13778 | url = }}</ref> In the previously described dose-ranging Phase II trial of psilocybin for depression, the time to median depressive event after administration of psilocybin was 92 to 189{{nbsp}}days for 25{{nbsp}}mg, 43 to 83{{nbsp}}days for 10{{nbsp}}mg, and 21 to 62{{nbsp}}days for 1{{nbsp}}mg, depending on the analysis.<ref name="GoodwinNowakowskaAtli2025">{{cite journal | vauthors = Goodwin GM, Nowakowska A, Atli M, Dunlop BW, Feifel D, Hellerstein DJ, Marwood L, Shabir Z, Mistry S, Stansfield SC, Teoh E, Tsai J, Young MB, Malievskaia E | title = Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder | journal = J Clin Psychiatry | volume = 86 | issue = 1 | pages = | date = March 2025 | pmid = 40047545 | doi = 10.4088/JCP.24m15449 | url = }}</ref> Repeated dosing of psilocybin is being explored for maximization and maintenance of depressive symptom improvement, with preliminary effectiveness observed.<ref name="Najib2024"/><ref name="LegerUnterwald2022">{{cite journal | vauthors = Leger RF, Unterwald EM | title = Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis | journal = J Psychopharmacol | volume = 36 | issue = 1 | pages = 20–30 | date = January 2022 | pmid = 34519567 | doi = 10.1177/02698811211044688 | url = }}</ref><ref name="RosenblatMeshkatDoyle2024">{{cite journal | vauthors = Rosenblat JD, Meshkat S, Doyle Z, Kaczmarek E, Brudner RM, Kratiuk K, Mansur RB, Schulz-Quach C, Sethi R, Abate A, Ali S, Bawks J, Blainey MG, Brietzke E, Cronin V, Danilewitz J, Dhawan S, Di Fonzo A, Di Fonzo M, Drzadzewski P, Dunlop W, Fiszter H, Gomes FA, Grewal S, Leon-Carlyle M, McCallum M, Mofidi N, Offman H, Riva-Cambrin J, Schmidt J, Smolkin M, Quinn JM, Zumrova A, Marlborough M, McIntyre RS | title = Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin | journal = Med | volume = 5 | issue = 3 | pages = 190–200.e5 | date = March 2024 | pmid = 38359838 | doi = 10.1016/j.medj.2024.01.005 | url = }}</ref>

In June 2025, [[Compass Pathways]], which is developing psilocybin for treatment-resistant depression, announced the results of a [[Phases of clinical research#Phase III|Phase III]] clinical trial of single-dose 25{{nbsp}}mg psilocybin (COMP360) versus placebo.<ref name="Hager2025">{{cite journal | last=Hager | first=Sandy Brian | title=The shifting fortunes of corporate psychedelia | journal=Finance and Society | date=8 September 2025 | issn=2059-5999 | doi=10.1017/fas.2025.10014 | doi-access=free | pages=1–23 | url=https://www.cambridge.org/core/services/aop-cambridge-core/content/view/A2E9484FA459A5AC584E6F70DE24D5A3/S2059599925100149a.pdf/div-class-title-the-shifting-fortunes-of-corporate-psychedelia-div.pdf | quote=The second development is the announcement of the first readout from Compass Pathways' phase 3 trial of COMP360 in late June 2025. The announcement had been described as a 'make or break moment' for the leading company in the field (Hardman, 2025). Compass Pathways (2025) declared the results 'highly statistically significant and clinically meaningful'.}}</ref><ref name="Waldron2025">{{cite web | vauthors = Waldron J | title=Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed | website=Fierce Biotech | date=23 June 2025 | url=https://www.fiercebiotech.com/biotech/compass-points-psychedelic-therapys-phase-3-win-investors-unimpressed | access-date=28 June 2025}}</ref><ref name="Sharma2025">{{cite web | vauthors = Sharma A | title=Updated: Compass claims Phase 3 win in depression for psilocybin drug, yet stock plummets | website=Endpoints News | date=23 June 2025 | url=https://endpoints.news/compass-reports-phase-3-depression-data-for-psilocybin-drug/ | access-date=28 June 2025}}</ref><ref name="Landenberger2025">{{cite web | vauthors = Landenberger L | title=Compass Pathways succeeds in phase III depression study; stock slides | website=BioWorld | date=28 June 2025 | url=https://www.bioworld.com/articles/721464-compass-pathways-succeeds-in-phase-iii-depression-study-stock-slides | access-date=28 June 2025}}</ref> Psilocybin met the primary endpoint of a significant reduction in depressive scores on the [[Montgomery-Asberg Depression Rating Scale]] (MADRS) relative to placebo.<ref name="Hager2025" /><ref name="Waldron2025" /> At the 6-week point, there was a 3.6-point reduction in depressive symptoms on the scale compared to placebo.<ref name="Waldron2025" /> The degree of improvement over placebo was small and below expectations: a minimum advantage of at least 5 points over placebo had been expected and deemed acceptable, for instance by the company's investors.<ref name="Hager2025" /><ref name="Waldron2025" /><ref name="Sharma2025" /><ref name="Landenberger2025" /> After Compass Pathways's announcement, the company's stock price fell by 36%.<ref name="Hager2025" /><ref name="Waldron2025" /><ref name="Sharma2025" /><ref name="Landenberger2025" /> Since October 2024, upon initially delaying the announcement of the results, Compass Pathways has laid off 30% of its staff and stopped all [[preclinical research|preclinical]] work unrelated to COMP360.<ref name="Waldron2025" /> A second Phase III trial by Compass Pathways involving multiple different doses of psilocybin is also underway, with results expected next year.<ref name="Waldron2025" /> Questions remain concerning the durability of psilocybin's antidepressant effects, the scalability of its treatment delivery, and regulatory uncertainity.<ref name="Hager2025" />

Most clinical trials of psilocybin for depression have had [[conflict of interest|financial conflicts of interest]] and significant risk of bias.<ref name="BorgognaOwenPetrovitch2025">{{cite journal | vauthors = Borgogna NC, Owen T, Petrovitch D, Vaughn J, Johnson DA, Pagano LA, Aita SL, Hill BD | title = Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs | journal = Psychopharmacology (Berl) | volume = 242| issue = 10| pages = 2139–2157| date = April 2025 | pmid = 40266291 | doi = 10.1007/s00213-025-06788-w | pmc = 12449434 | url = | doi-access = free }}</ref> The [[British people|British]] [[critical psychiatrist]] [[Joanna Moncrieff]] has critiqued the use and study of psychedelics like psilocybin for treatment of psychiatric disorders, highlighting concerns including excessive hype around these drugs, questionable biologically-based theories of benefit, blurred lines between medical and recreational use, flawed clinical trial findings, financial conflicts of interest, strong expectancy effects and large placebo responses, small and short-term benefits over placebo, and their potential for difficult and potentially destabilizing experiences and adverse effects, among others.<ref name="Moncrieff2025">{{cite book | last=Moncrieff | first=Joanna | chapter=Alternative Approaches: The Good, the Bad and the Worrying: Psychedelics for Depression | title=Chemically Imbalanced: The Making and Unmaking of the Serotonin Myth | publisher=Flint | date=16 January 2025 | isbn=978-1-80399-680-6 | url=https://books.google.com/books?id=e0MkEQAAQBAJ | access-date=16 October 2025 | page=}}</ref>

==See also==
{{Portal|Fungi}}
* [[List of entheogens]]
* [[Stoned ape theory]]
* [[Soma (drink)]]

==Notes==
{{Notelist}}

==References==
{{Reflist|refs=

<ref name="Agurell1968">{{cite journal | vauthors = Agurell S, Nilsson JL | title = Biosynthesis of psilocybin. II. Incorporation of labelled tryptamine derivatives | journal = Acta Chemica Scandinavica | volume = 22 | issue = 4 | pages = 1210–1218 | year = 1968 | pmid = 5750023 | doi = 10.3891/acta.chem.scand.22-1210 | doi-access = free }}</ref>

<ref name="Akers2011">{{Cite journal |vauthors=Akers BP, Ruiz JF, Piper A, Ruck CA |year=2011 |title=A prehistoric mural in Spain depicting neurotropic ''Psilocybe'' mushrooms? |journal=Economic Botany |volume=65 |issue=2 |pages=121–128 |doi=10.1007/s12231-011-9152-5 |s2cid=3955222}}</ref>

<ref name="Albers2004">{{cite journal | vauthors = Albers C, Köhler H, Lehr M, Brinkmann B, Beike J | title = Development of a psilocin immunoassay for serum and blood samples | journal = International Journal of Legal Medicine | volume = 118 | issue = 6 | pages = 326–331 | date = December 2004 | pmid = 15526212 | doi = 10.1007/s00414-004-0469-9 | s2cid = 11249439 }}</ref>

<ref name="Amsterdam2010">{{cite journal | vauthors = van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W | title = Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population | journal = European Addiction Research | volume = 16 | issue = 4 | pages = 202–207 | year = 2010 | pmid = 20606445 | doi = 10.1159/000317249 | s2cid = 207669364 }}</ref>

<ref name="Amsterdam2011">{{cite journal | vauthors = van Amsterdam J, Opperhuizen A, van den Brink W | title = Harm potential of magic mushroom use: a review | journal = Regulatory Toxicology and Pharmacology | volume = 59 | issue = 3 | pages = 423–429 | date = April 2011 | pmid = 21256914 | doi = 10.1016/j.yrtph.2011.01.006 | url = http://dl.dropbox.com/u/85192141/2011-amsterdam.pdf | url-status = dead | archive-url = https://web.archive.org/web/20150109054531/http://dl.dropbox.com/u/85192141/2011-amsterdam.pdf | archive-date = January 9, 2015 }}</ref>

<ref name="Anastos2006">{{cite journal | vauthors = Anastos N, Barnett NW, Pfeffer FM, Lewis SW | title = Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography | journal = Science & Justice | volume = 46 | issue = 2 | pages = 91–96 | year = 2006 | pmid = 17002211 | doi = 10.1016/S1355-0306(06)71579-9 }}</ref>

<ref name="Attema2007">{{cite journal | vauthors = Attema-de Jonge ME, Portier CB, Franssen EJ | title = [Automutilation after consumption of hallucinogenic mushrooms] | language = nl | journal = Nederlands Tijdschrift voor Geneeskunde | volume = 151 | issue = 52 | pages = 2869–2872 | date = December 2007 | pmid = 18257429 | trans-title = Automutilation after consumption of hallucinogenic mushrooms }}</ref>

<ref name="Azmitia2010">{{Cite book |title=Handbook of the Behavioral Neurobiology of Serotonin |vauthors=Azmitia EC |publisher=Academic Press |year=2010 |isbn=978-0-12-374634-4 |veditors=Müller CP, Jacobs BL |location=London, UK |page=7 |chapter=Evolution of serotonin: sunlight to suicide |access-date=February 27, 2016 |chapter-url=https://books.google.com/books?id=aomaKqIE1jUC&pg=PA7 |archive-url=https://web.archive.org/web/20170404000052/https://books.google.com/books?id=aomaKqIE1jUC&pg=PA7 |archive-date=April 4, 2017 |url-status=live}}</ref>

<ref name="Berge1999">{{Cite journal |vauthors=Berge JT |year=1999 |title=Breakdown or breakthrough? A history of European research into drugs and creativity |journal=Journal of Creative Behavior |volume=33 |issue=4 |pages=257–276 |doi=10.1002/j.2162-6057.1999.tb01406.x |issn=0022-0175}}</ref>

<ref name="Bigwood1982">{{cite journal | vauthors = Bigwood J, Beug MW | title = Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer | journal = Journal of Ethnopharmacology | volume = 5 | issue = 3 | pages = 287–291 | date = May 1982 | pmid = 7201054 | doi = 10.1016/0378-8741(82)90014-9 }}</ref>

<ref name="Bone2011">{{Cite book |url=https://books.google.com/books?id=Br3PU2PJhywC&pg=PA258 |title=Mycophilia: Revelations from the Weird World of Mushrooms |vauthors=Bone E |publisher=Rodale |year=2011 |isbn=978-1-60529-407-0 |location=New York, New York |pages=257–258 |access-date=February 27, 2016 |archive-url=https://web.archive.org/web/20170404054348/https://books.google.com/books?id=Br3PU2PJhywC&pg=PA258 |archive-date=April 4, 2017 |url-status=live}}</ref>

<ref name="Bresinsky1989">{{Cite book |url=https://books.google.com/books?id=EIcQGsZ2kksC&pg=PA113 |title=A Colour Atlas of Poisonous Fungi: A Handbook for Pharmacists, Doctors, and Biologists |vauthors=Bresinsky A, Besl H |publisher=Manson Publishing |year=1989 |isbn=978-0-7234-1576-3 |location=London, UK |page=113 |access-date=February 27, 2016 |archive-url=https://web.archive.org/web/20170404052509/https://books.google.com/books?id=EIcQGsZ2kksC&pg=PA113 |archive-date=April 4, 2017 |url-status=live}}</ref>

<ref name="CarhartHarris2010">{{Cite journal | vauthors = Carhart-Harris RL, Nutt DJ |author2-link=David Nutt|year=2010 |title=User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study |journal=Journal of Substance Use |volume=15 |issue=4 |pages=283–300 |doi=10.3109/14659890903271624 |s2cid=56427651}}</ref>

<ref name="Carter2005">{{cite journal | vauthors = Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX | title = Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors | journal = Journal of Cognitive Neuroscience | volume = 17 | issue = 10 | pages = 1497–1508 | date = October 2005 | pmid = 16269092 | doi = 10.1162/089892905774597191 | url = http://www.zora.uzh.ch/id/eprint/121457/1/089892905774597191.pdf | url-status = live | access-date = August 16, 2019 | s2cid = 9790150 | archive-url = https://web.archive.org/web/20190816023012/https://www.zora.uzh.ch/id/eprint/121457/1/089892905774597191.pdf | archive-date = August 16, 2019 }}</ref>

<ref name="Chen2008">{{cite journal | vauthors = Chen CY, Storr CL, Anthony JC | title = Early-onset drug use and risk for drug dependence problems | journal = Addictive Behaviors | volume = 34 | issue = 3 | pages = 319–322 | date = March 2009 | pmid = 19022584 | pmc = 2677076 | doi = 10.1016/j.addbeh.2008.10.021 }}</ref>

<ref name="Cole2003">{{Cite book |url=https://archive.org/details/analysisofcontro0000cole/page/132 |title=The Analysis of Controlled Substances |vauthors=Cole MD |publisher=John Wiley and Sons |year=2003 |isbn=978-0-471-49252-8 |location=New York, Chichester |pages=[https://archive.org/details/analysisofcontro0000cole/page/132 132–133]}}</ref>

<ref name=Compasspathways2018>{{Cite web |title=COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression |url=https://compasspathways.com/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/ |url-status=live |archive-url=https://web.archive.org/web/20181204005741/https://compasspathways.com/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/ |archive-date=December 4, 2018 |access-date=2018-12-03 |publisher=Compass Pathways}}</ref>

<ref name="Coull2011">{{cite journal | vauthors = Coull JT, Cheng RK, Meck WH | title = Neuroanatomical and neurochemical substrates of timing | journal = Neuropsychopharmacology | volume = 36 | issue = 1 | pages = 3–25 | date = January 2011 | pmid = 20668434 | pmc = 3055517 | doi = 10.1038/npp.2010.113 }}</ref>

<ref name=DeVos2021>{{cite journal | vauthors = de Vos CM, Mason NL, Kuypers KP | title = Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics | journal = Frontiers in Psychiatry | volume = 12 | article-number = 724606 | date = 2021 | pmid = 34566723 | pmc = 8461007 | doi = 10.3389/fpsyt.2021.724606 | doi-access = free }}</ref>

<ref name=DosSantos2016>{{cite journal | vauthors = Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE | title = Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years | journal = Therapeutic Advances in Psychopharmacology | volume = 6 | issue = 3 | pages = 193–213 | date = June 2016 | pmid = 27354908 | pmc = 4910400 | doi = 10.1177/2045125316638008 }}</ref>

<ref name="EMCDDA">{{Cite report |url=http://www.emcdda.europa.eu/attachements.cfm/att_31215_EN_TP_Hallucinogenic_mushrooms.pdf |title=Hallucinogenic Mushrooms: An Emerging Trend Case Study |publisher=[[European Monitoring Centre for Drugs and Drug Addiction]] (EMCDDA) |location=Lisbon, Portugal |isbn=92-9168-249-7 |access-date=September 8, 2011 |archive-url=https://web.archive.org/web/20120329044308/http://www.emcdda.europa.eu/attachements.cfm/att_31215_EN_TP_Hallucinogenic_mushroom.pdf |archive-date=March 29, 2012 |vauthors=Hillebrand J, Olszewski D, Sedefov R |year=2006 |url-status=live}}</ref>

<ref name="EMDCCA2011">{{Cite report |url=http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR2011_EN.pdf |title=Annual report 2011: the state of the drugs problem in Europe |date=November 2011 |publisher=[[Publications Office of the European Union]] |doi=10.2810/44330 |location=Luxembourg |isbn=978-92-9168-470-0 |access-date=December 4, 2011 |archive-url=https://web.archive.org/web/20111203224745/http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR2011_EN.pdf |archive-date=December 3, 2011 |vauthors=((European Monitoring Centre for Drugs and Drug Addiction)) |url-status=live}}</ref>

<ref name="Fish2006">{{Cite book |title=Drugs and Society: U.S. Public Policy |vauthors=Gable RS |publisher=Rowman & Littlefield |year=2006 |isbn=978-0-7425-4245-7 |veditors=Fish JM |location=Lanham, Maryland |pages=149–162; Table 7.1 "Safety Ratio and Dependence Potential of Psychoactive Drugs" |chapter=Acute toxicity of drugs versus regulatory status |chapter-url=http://web.cgu.edu/faculty/gabler/drug_toxicity.htm |archive-url=https://web.archive.org/web/20120107021458/http://web.cgu.edu/faculty/gabler/drug_toxicity.htm |archive-date=January 7, 2012 |url-status=live}}</ref>

<ref name=Fricke2017>{{cite journal | vauthors = Fricke J, Blei F, Hoffmeister D | title = Enzymatic Synthesis of Psilocybin | journal = Angewandte Chemie | volume = 56 | issue = 40 | pages = 12352–12355 | date = September 2017 | pmid = 28763571 | doi = 10.1002/anie.201705489 | bibcode = 2017ACIE...5612352F }}</ref>

<ref name="Gable2004">{{cite journal | vauthors = Gable RS | title = Comparison of acute lethal toxicity of commonly abused psychoactive substances | journal = Addiction | volume = 99 | issue = 6 | pages = 686–696 | date = June 2004 | pmid = 15139867 | doi = 10.1111/j.1360-0443.2004.00744.x | url = http://web.cgu.edu/faculty/gabler/toxicity%20Addiction%20offprint.pdf | url-status = live | access-date = November 16, 2011 | archive-url = https://web.archive.org/web/20060810063302/http://web.cgu.edu/faculty/gabler/toxicity%20Addiction%20offprint.pdf | archive-date = August 10, 2006 }}</ref>

<ref name="Gartz1992">{{Cite journal |vauthors=Gartz J |year=1992 |title=New aspects of the occurrence, chemistry and cultivation of European hallucinogenic mushrooms |journal=Supplemento Agli Annali dei Musei Civici di Rovereto Sezione Archeologica, Storia e Scienze Naturali |volume=8 |pages=107–124}}</ref>

<ref name="Gartz1996">{{Cite journal |vauthors=Gartz J, Samorini G, Festi F |year=1996 |title=On the presumed French case of fatality caused by ingestion of Liberty Caps |url=http://www.museocivico.rovereto.tn.it/pubblicazioni.jsp?ID_LINK=111251&area=3 |url-status=dead |journal=Eluesis |volume=6 |pages=40–41 |archive-url=https://web.archive.org/web/20120405121903/http://www.museocivico.rovereto.tn.it/pubblicazioni.jsp?ID_LINK=111251&area=3 |archive-date=April 5, 2012}}</ref>

<ref name="Gerault1996">{{Cite journal |vauthors=Gérault A, Picart D |year=1996 |title=Intoxication mortelle à la suite de la consommation volontaire et en groupe de champignons hallucinogènes |trans-title=Fatal poisoning after a group of people voluntarily consumed hallucinogenic mushrooms |journal=Bulletin de la Société Mycologique de France |language=fr |volume=112 |pages=1–14}}</ref>

<ref name="Geyer1998">{{cite journal | vauthors = Geyer MA | title = Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research | journal = Pharmacopsychiatry | volume = 31 | issue = S2 | pages = 73–79 | date = July 1998 | pmid = 9754837 | doi = 10.1055/s-2007-979350 | s2cid = 24647325 }}</ref>

<ref name="Geyer2008">{{cite journal | vauthors = Geyer MA, Vollenweider FX | title = Serotonin research: contributions to understanding psychoses | journal = Trends in Pharmacological Sciences | volume = 29 | issue = 9 | pages = 445–453 | date = September 2008 | pmid = 19086254 | doi = 10.1016/j.tips.2008.06.006 }}</ref>

<ref name=Goel2022>{{cite journal | vauthors = Goel DB, Zilate S | title = Potential Therapeutic Effects of Psilocybin: A Systematic Review | journal = Cureus | volume = 14 | issue = 10 |article-number=e30214 | date = October 2022 | pmid = 36381758 | pmc = 9650681 | doi = 10.7759/cureus.30214 | doi-access = free }}</ref>

<ref name="Grieshaber2001">{{cite journal | vauthors = Grieshaber AF, Moore KA, Levine B | title = The detection of psilocin in human urine | journal = Journal of Forensic Sciences | volume = 46 | issue = 3 | pages = 627–630 | date = May 2001 | pmid = 11373000 | doi = 10.1520/JFS15014J }}</ref>

<ref name="Griffiths2006">{{cite journal | vauthors = Griffiths RR, Richards WA, McCann U, Jesse R | title = Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance | journal = Psychopharmacology | volume = 187 | issue = 3 | pages = 268–283 | date = August 2006 | pmid = 16826400 | doi = 10.1007/s00213-006-0457-5 | url = http://www.hopkinsmedicine.org/bin/s/m/GriffithsPsilocybin.pdf | url-status = dead | s2cid = 7845214 | archive-url = https://web.archive.org/web/20111109030153/http://www.hopkinsmedicine.org/bin/s/m/GriffithsPsilocybin.pdf | archive-date = November 9, 2011 }}</ref>

<ref name="Griffiths2008">{{cite journal | vauthors = Griffiths R, Richards W, Johnson M, McCann U, Jesse R | title = Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later | journal = Journal of Psychopharmacology | volume = 22 | issue = 6 | pages = 621–632 | date = August 2008 | pmid = 18593735 | pmc = 3050654 | doi = 10.1177/0269881108094300 | url = http://www.csp.org/psilocybin/Hopkins-CSP-Psilocybin2008.pdf | url-status = dead | access-date = July 3, 2008 | df = mdy-all | archive-url = https://web.archive.org/web/20080722205309/http://www.csp.org/psilocybin/Hopkins-CSP-Psilocybin2008.pdf | archive-date = July 22, 2008 }}</ref><ref name="Griffiths2010">{{Cite journal |vauthors=Griffiths RR, Grob CS |year=2010 |title=Hallucinogens as medicine |url=http://www.csp.org/psilocybin/SciAmHallucinogens201012.pdf |url-status=dead |journal=Scientific American |volume=303 |issue=6 |pages=77–79 |bibcode=2010SciAm.303f..76G |doi=10.1038/scientificamerican1210-76 |archive-url=https://web.archive.org/web/20111003152701/http://csp.org/psilocybin/SciAmHallucinogens201012.pdf |archive-date=October 3, 2011 |access-date=July 25, 2011 |df=mdy-all}}</ref>

<ref name="Gross2000">{{cite journal | vauthors = Gross ST | title = Detecting psychoactive drugs in the developmental stages of mushrooms | journal = Journal of Forensic Sciences | volume = 45 | issue = 3 | pages = 527–537 | date = May 2000 | pmid = 10855955 | doi = 10.1520/JFS14725J | url = http://pdfs.semanticscholar.org/8dab/e1804d761d975ef16e28c2c994476d9122aa.pdf | url-status = dead | s2cid = 38006957 | archive-url = https://web.archive.org/web/20201116074539/http://pdfs.semanticscholar.org/8dab/e1804d761d975ef16e28c2c994476d9122aa.pdf | archive-date = 2020-11-16 }}</ref>

<ref name="Guzman1983">{{Cite book |title=The Genus ''Psilocybe'': A Systematic Revision of the Known Species Including the History, Distribution, and Chemistry of the Hallucinogenic Species |vauthors=Guzmán G |publisher=J.&nbsp;Cramer |year=1983 |isbn=978-3-7682-5474-8 |series=Beihefte Zur Nova Hedwigia. Heft 74 |location=Vaduz, Liechtenstein |pages=361–362}}</ref>

<ref name="Guzman2000">{{Cite journal |vauthors=Guzmán G, Allen JW, Gartz J |year=2000 |title=A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion |url=http://www.museocivico.rovereto.tn.it/UploadDocs/104_art09-Guzman%20&%20C.pdf |url-status=live |journal=Annali del Museo Civico di Rovereto: Sezione Archeologia, Storia, Scienze Naturali |volume=14 |pages=189–280 |archive-url=https://web.archive.org/web/20180205032100/http://www.museocivico.rovereto.tn.it/UploadDocs/104_art09-Guzman%20%26%20C.pdf |archive-date=February 5, 2018 |access-date=October 19, 2021}}</ref>

<ref name="Guzman2005">{{Cite journal |vauthors=Guzmán G |year=2005 |title=Species diversity of the genus ''Psilocybe'' (Basidiomycotina, Agaricales, Strophariaceae) in the world mycobiota, with special attention to hallucinogenic properties |journal=International Journal of Medicinal Mushrooms |volume=7 |issue=1–2 |pages=305–331 |doi=10.1615/intjmedmushr.v7.i12.280}}</ref>

<ref name="Guzman2008">{{Cite journal |vauthors=Guzmán G |year=2008 |title=Hallucinogenic mushrooms in Mexico: an overview |journal=Economic Botany |volume=62 |issue=3 |pages=404–412 |doi=10.1007/s12231-008-9033-8 |bibcode=2008EcBot..62..404G |s2cid=22085876}}</ref>

<ref name="Harrington1999">{{cite journal | vauthors = Harrington DL, Haaland KY | title = Neural underpinnings of temporal processing: a review of focal lesion, pharmacological, and functional imaging research | journal = Reviews in the Neurosciences | volume = 10 | issue = 2 | pages = 91–116 | year = 1999 | pmid = 10658954 | doi = 10.1515/REVNEURO.1999.10.2.91 | s2cid = 25960626 | url = https://escholarship.org/uc/item/0498n8nb }}</ref>

<ref name="Heim1957">{{Cite journal |vauthors=Heim R |year=1957 |title=Notes préliminaires sur les agarics hallucinogènes du Mexique |trans-title=Preliminary notes on the hallucination-producing agarics of Mexico |journal=Revue de Mycologie |language=fr |volume=22 |issue=1 |pages=58–79}}</ref>

<ref name=Hofmann2009>{{Cite book|vauthors=Hofmann A|author-link=Albert Hofmann|title=LSD, my problem child: reflections on sacred drugs, mysticism, and science|publisher=Multidisciplinary Association for Psychedelic Studies|location=Santa Cruz, California|year=2009|isbn=978-0979862229|url=https://archive.org/details/lsdmyproblemchil0000hofm_h2h0/mode/2up}}</ref>

<ref name="Hood1975">{{cite journal | vauthors = Arici M, Altun B, Araz M, Atmaca A, Demir T, Ecder T, Guz G, Gogas Yavuz D, Yildiz A, Yilmaz T | title = The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials | journal = Frontiers in Medicine | volume = 11 | issue = 1 |article-number=1384454 | year = 1975 | pmid = 38947237 | doi = 10.2307/1384454 | s2cid = 147200008 | jstor = 1384454 | pmc = 11214281 }}</ref>

<ref name="HSDB">{{Cite web |title=Psilocybine |url=http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+520-52-5 |url-status=dead |archive-url=https://web.archive.org/web/20180813210637/https://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+520-52-5 |archive-date=August 13, 2018 |access-date=November 21, 2011 |website=[[Hazardous Substances Data Bank]] |publisher=U.S. National Library of Medicine}}</ref>

<ref name="Hyde1978">{{cite journal | vauthors = Hyde C, Glancy G, Omerod P, Hall D, Taylor GS | title = Abuse of indigenous psilocybin mushrooms: a new fashion and some psychiatric complications | journal = The British Journal of Psychiatry | volume = 132 | issue = 6 | pages = 602–604 | date = June 1978 | pmid = 566144 | doi = 10.1192/bjp.132.6.602 | s2cid = 20020560 }}</ref>

<ref name="James1997">{{Cite book |title=The Varieties of Religious Experience |title-link=The Varieties of Religious Experience |vauthors=James W |publisher=Simon & Schuster |year=1997 |isbn=978-0-684-84297-4 |location=New York, New York}}</ref>

<ref name="JHMed: Griffiths Interview">{{Cite news |date=July 11, 2006 |title=Press release: Griffiths psilocybin |url=http://www.hopkinsmedicine.org/Press_releases/2006/GriffithspsilocybinQ |url-status=live |archive-url=https://web.archive.org/web/20110716065016/http://www.hopkinsmedicine.org/Press_releases/2006/GriffithspsilocybinQ |archive-date=July 16, 2011 |access-date=July 12, 2006 |publisher=Johns Hopkins Medicine | vauthors = Simpkins B }}</ref>

<ref name="Johnson2008">{{cite journal | vauthors = Johnson M, Richards W, Griffiths R | title = Human hallucinogen research: guidelines for safety | journal = Journal of Psychopharmacology | volume = 22 | issue = 6 | pages = 603–620 | date = August 2008 | pmid = 18593734 | pmc = 3056407 | doi = 10.1177/0269881108093587 | url = http://csp.org/psilocybin/HopkinsHallucinogenSafety2008.pdf | url-status = dead | access-date = November 20, 2017 | archive-url = https://web.archive.org/web/20171120114306/http://csp.org/psilocybin/HopkinsHallucinogenSafety2008.pdf | archive-date = November 20, 2017 }}</ref>

<ref name="Kamata2003">{{cite journal | vauthors = Kamata T, Nishikawa M, Katagi M, Tsuchihashi H | title = Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples | journal = Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences | volume = 796 | issue = 2 | pages = 421–427 | date = November 2003 | pmid = 14581081 | doi = 10.1016/j.jchromb.2003.08.030 }}</ref>

<ref name="Kamata2010">{{Cite journal |vauthors=Kamata T, Katagi M, Tsuchihashi H |year=2010 |title=Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan |journal=Forensic Toxicology |volume=28 |issue=1 |pages=1–8 |doi=10.1007/s11419-009-0087-9 |s2cid=45118221}}</ref>

<ref name="Keller1999">{{cite journal | vauthors = Keller T, Schneider A, Regenscheit P, Dirnhofer R, Rücker T, Jaspers J, Kisser W | title = Analysis of psilocybin and psilocin in Psilocybe subcubensis Guzmán by ion mobility spectrometry and gas chromatography-mass spectrometry | journal = Forensic Science International | volume = 99 | issue = 2 | pages = 93–105 | date = January 1999 | pmid = 10077856 | doi = 10.1016/S0379-0738(98)00168-6 }}</ref>

<ref name="Keim2008">{{Cite magazine |date=July 1, 2008 |title=Psilocybin study hints at rebirth of hallucinogen research |url=https://www.wired.com/wiredscience/2008/07/psilocybin-stud/ |url-status=live |magazine=[[Wired (magazine)|Wired.com]] |archive-url=https://web.archive.org/web/20110803171254/http://www.wired.com/wiredscience/2008/07/psilocybin-stud/ |archive-date=August 3, 2011 |access-date=August 8, 2011 |vauthors=Keim B}}</ref>

<ref name="Kysilka1989">{{cite journal | vauthors = Kysilka R, Wurst M | title = High-performance liquid chromatographic determination of some psychotropic indole derivatives | journal = Journal of Chromatography | volume = 464 | issue = 2 | pages = 434–437 | date = March 1989 | pmid = 2722990 | doi = 10.1016/s0021-9673(00)94264-x }}</ref>

<ref name="Kysilka1990">{{cite journal | vauthors = Kysilka R | title = Determination of psilocin in rat urine by high-performance liquid chromatography with electrochemical detection | journal = Journal of Chromatography | volume = 534 | pages = 287–290 | date = December 1990 | pmid = 2094720 | doi = 10.1016/S0378-4347(00)82176-3 }}</ref>

<ref name="Leary1963">{{cite journal | vauthors = Leary T, Litwin GH, Metzner R | title = Reactions to Psilocybjn Administered in a Supportive Environment | journal = The Journal of Nervous and Mental Disease | volume = 137 | issue = 6 | pages = 561–573 | date = December 1963 | pmid = 14087676 | doi = 10.1097/00005053-196312000-00007 | s2cid = 39777572 }}</ref>

<ref name="Leary1965">{{Cite journal |vauthors=Leary T, Metzner R, Presnell M, Weil G, Schwitzgebel R, Kinne S |year=1965 |title=A new behavior change program using psilocybin |journal=Psychotherapy: Theory, Research & Practice |volume=2 |issue=2 |pages=61–72 |doi=10.1037/h0088612}}</ref>

<ref name="Lee1985">{{cite journal | vauthors = Lee RE | title = A technique for the rapid isolation and identification of psilocin from psilocin/psilocybin-containing mushrooms | journal = Journal of Forensic Sciences | volume = 30 | issue = 3 | pages = 931–941 | date = July 1985 | pmid = 4040953 | doi = 10.1520/JFS11028J }}</ref>

<ref name="Levine2003">{{Cite book |title=Principles of Forensic Toxicology |vauthors=Jenkins AJ |publisher=American Association for Clinical Chemistry Press |year=2003 |isbn=978-1-890883-87-4 |veditors=Levine B |edition=2nd |location=Washington, D.C. |page=281 |chapter=Hallucinogens |access-date=February 27, 2016 |chapter-url=https://books.google.com/books?id=k7BInEQ-iqgC&pg=PA281 |archive-url=https://web.archive.org/web/20170403111310/https://books.google.com/books?id=k7BInEQ-iqgC&pg=PA281 |archive-date=April 3, 2017 |url-status=live}}</ref>

<ref name="Lindenblatt1998">{{cite journal | vauthors = Lindenblatt H, Krämer E, Holzmann-Erens P, Gouzoulis-Mayfrank E, Kovar KA | title = Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction | journal = Journal of Chromatography. B, Biomedical Sciences and Applications | volume = 709 | issue = 2 | pages = 255–263 | date = May 1998 | pmid = 9657222 | doi = 10.1016/S0378-4347(98)00067-X }}</ref>

<ref name=Lurie2009>{{Cite journal |vauthors=Lurie I, Li L |year=2009 |title=Use of high-temperature liquid chromatography with sub-2 μm particle C<sub>18</sub> columns for the analysis of seized drugs |url=https://zenodo.org/record/1234491 |url-status=live |journal=Journal of Liquid Chromatography & Related Technologies |volume=32 |issue=17–20 |pages=2615–2626 |doi=10.1080/10826070903245516 |archive-url=https://web.archive.org/web/20210503052027/https://zenodo.org/record/1234491 |archive-date=May 3, 2021 |access-date=August 24, 2020 |s2cid=96753191}}</ref>

<ref name="Mack1983">{{cite journal | vauthors = Mack RB | title = Phenomenally phunny phungi--psilocybin toxicity | journal = North Carolina Medical Journal | volume = 44 | issue = 10 | pages = 639–640 | date = October 1983 | pmid = 6580536 }}</ref>

<ref name=Marley2010>{{Cite book|vauthors=Marley G|title=Chanterelle Dreams, Amanita Nightmares: The Love, Lore, and Mystique of Mushrooms|publisher=Chelsea Green Publishing|location=White River Junction, Vermont|year=2010|isbn=978-1603582148}}</ref>

<ref name="Matsushima2009">{{Cite journal |vauthors=Matsushima Y, Eguchi F, Kikukawa T, Matsuda T |year=2009 |title=Historical overview of psychoactive mushrooms |journal=Inflammation and Regeneration |volume=29 |issue=1 |pages=47–58 |doi=10.2492/inflammregen.29.47 |doi-access=free}}</ref>

<ref name="McKenna1992">{{Cite book |title=Food of the Gods: The Search for the Original Tree of Knowledge. A Radical History of Plants, Drugs, and Human Evolution |vauthors=McKenna T |publisher=Bantam Books |year=1993 |isbn=978-0-553-37130-7 |location=New York, New York}}</ref>

<ref name="Merck13th">{{Cite book |url=https://archive.org/details/merckindexency00onei/page/1419 |title=The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals |publisher=Merck |year=2001 |isbn=978-0-911910-13-1 |veditors=O'Neil MJ, Smith A, Heckelman PE, Obenchain JR, Gallipeau JR, D'Arecca MA |edition=13th |location=Whitehouse Station, New Jersey |page=[https://archive.org/details/merckindexency00onei/page/1419 1419]}}</ref>

<ref name="Metzner1998">{{cite journal | vauthors = Metzner R | title = Hallucinogenic drugs and plants in psychotherapy and shamanism | journal = Journal of Psychoactive Drugs | volume = 30 | issue = 4 | pages = 333–341 | year = 1998 | pmid = 9924839 | doi = 10.1080/02791072.1998.10399709 | url = http://cdn.preterhuman.net/texts/religion.occult.new_age/occult_library/Metzner_R-Hallucinogenic_Plants.pdf | url-status = live | access-date = October 26, 2017 | citeseerx = 10.1.1.509.4769 | archive-url = https://web.archive.org/web/20170921233753/http://cdn.preterhuman.net/texts/religion.occult.new_age/occult_library/Metzner_R-Hallucinogenic_Plants.pdf | archive-date = September 21, 2017 }}</ref>

<ref name="Miller2008">{{Cite web |date=July 1, 2008 |title=A very memorable trip |url=https://www.science.org/content/article/very-memorable-trip |url-status=live |archive-url=https://web.archive.org/web/20180813175432/https://www.sciencemag.org/news/2008/07/very-memorable-trip |archive-date=August 13, 2018 |access-date=August 8, 2011 |publisher=sciencemag.org |vauthors=Miller G}}</ref>

<ref name=Milne2020>{{cite journal | vauthors = Milne N, Thomsen P, Mølgaard Knudsen N, Rubaszka P, Kristensen M, Borodina I | title = Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives | journal = Metabolic Engineering | volume = 60 | issue =  | pages = 25–36 | date = July 2020 | pmid = 32224264 | pmc = 7232020 | doi = 10.1016/j.ymben.2019.12.007 }}</ref>

<ref name="Myers1998">{{Cite journal |vauthors=Myers LS, Watkins SS, Carter TJ |year=1998 |title=Flashbacks in theory and practice |url=http://www.heffter.org/docs/hrireview/01/chapter7.pdf |url-status=live |journal=The Heffter Review of Psychedelic Research |volume=1 |pages=51–57 |archive-url=https://web.archive.org/web/20110927212935/http://www.heffter.org/docs/hrireview/01/chapter7.pdf |archive-date=September 27, 2011 |access-date=August 14, 2011}}</ref>

<ref name="Nicholas2006">{{Cite book |url=https://books.google.com/books?id=HJJmJYCl3HsC&pg=PA164 |title=Psilocybin Mushroom Handbook: Easy Indoor and Outdoor Cultivation |vauthors=Nicholas LG, Ogame K |publisher=Quick American Archives |year=2006 |isbn=978-0-932551-71-9 |location=Oakland, California |page=164 |access-date=February 27, 2016 |archive-url=https://web.archive.org/web/20170404053525/https://books.google.com/books?id=HJJmJYCl3HsC&pg=PA164 |archive-date=April 4, 2017 |url-status=live}}</ref>

<!--ref name=Nutt2007>{{Cite journal |vauthors=Nutt DJ, King LA, Saulsbury W, Blakemore C |year=2007 |title=Development of a rational scale to assess the harm of drugs of potential misuse |journal=Lancet |volume=369 |issue=9566 |pages=1047–1053 |doi=10.1016/S0140-6736(07)60464-4 |pmid=17382831}}</ref-->

<ref name="Nutt2010">{{cite journal | vauthors = Nutt DJ, King LA, Phillips LD | title = Drug harms in the UK: a multicriteria decision analysis | journal = Lancet | volume = 376 | issue = 9752 | pages = 1558–1565 | date = November 2010 | pmid = 21036393 | doi = 10.1016/S0140-6736(10)61462-6 | s2cid = 5667719 | citeseerx = 10.1.1.690.1283 }}</ref>

<ref name="Oeric1991">{{Cite book |title=Psilocybin: Magic Mushroom Grower's Guide |vauthors=Oeric OT, Os ON |publisher=Quick American Archives |year=1991 |isbn=978-0-932551-06-1 |edition=2nd |location=San Francisco, California}}</ref>

<ref name="Ohenoja1987">{{cite journal | vauthors = Ohenoja E, Jokiranta J, Mäkinen T, Kaikkonen A, Airaksinen MM | title = The occurrence of psilocybin and psilocin in Finnish fungi | journal = Journal of Natural Products | volume = 50 | issue = 4 | pages = 741–744 | year = 1987 | pmid = 3430170 | doi = 10.1021/np50052a030 | bibcode = 1987JNAtP..50..741O }}</ref>

<ref name=Olson2021>{{cite journal | vauthors = Olson DE | title = Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics | journal = Journal of Experimental Neuroscience | volume = 12 | article-number = 1179069518800508 | date = 2018-09-19 | pmid = 30262987 | pmc = 6149016 | doi = 10.1177/1179069518800508 }}</ref>

<ref name="Pagliaro2012">{{Cite book |url=https://books.google.com/books?id=Ox0U5nIZRQ8C&pg=PT257 |title=Handbook of Child and Adolescent Drug and Substance Abuse: Pharmacological, Developmental, and Clinical Considerations |vauthors=Pagliaro LA, Pagliaro AM |publisher=John Wiley & Sons |year=2012 |isbn=978-0-470-63906-1 |edition=2nd |location=Hoboken, New Jersey |page=199 |access-date=February 27, 2016 |archive-url=https://web.archive.org/web/20170403111656/https://books.google.com/books?id=Ox0U5nIZRQ8C&pg=PT257 |archive-date=April 3, 2017 |url-status=live}}</ref>

<ref name="Pahnke1966">{{Cite journal |vauthors=Pahnke WN |year=1966 |title=Drugs and mysticism |journal=International Journal of Parapsychology |volume=8 |issue=2 |pages=295–315}}</ref>

<ref name="Pahnke1969">{{cite journal | vauthors = Pahnke WN, Richards WA | title = Implications of LSD and experimental mysticism | journal = Journal of Religion and Health | volume = 5 | issue = 3 | pages = 175–208 | date = July 1966 | pmid = 24424798 | doi = 10.1007/BF01532646 | s2cid = 18464414 }}</ref>

<ref name="Passie2002">{{cite journal | vauthors = Passie T, Seifert J, Schneider U, Emrich HM | title = The pharmacology of psilocybin | journal = Addiction Biology | volume = 7 | issue = 4 | pages = 357–364 | date = October 2002 | pmid = 14578010 | doi = 10.1080/1355621021000005937 | url = https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=981b848a2785bc0c9b5a9afa1162c0c43b4d96c9 | quote = An interesting fact may be the much shorter half-life (mean 74.1 ± 19.6 minutes i.v. compared to 163 ± 64 minutes p.o.) and duration of action (subjective effects lasting only 15–30 minutes) when psilocybin is given intravenously, as performed in a recent double-blind placebo controlled trial.29 | s2cid = 12656091 }}</ref>

<ref name="Passie2008">{{cite journal | vauthors = Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A | title = The pharmacology of lysergic acid diethylamide: a review | journal = CNS Neuroscience & Therapeutics | volume = 14 | issue = 4 | pages = 295–314 | year = 2008 | pmid = 19040555 | pmc = 6494066 | doi = 10.1111/j.1755-5949.2008.00059.x }}</ref>

<ref name="Peden1982">{{cite journal | vauthors = Peden NR, Pringle SD, Crooks J | title = The problem of psilocybin mushroom abuse | journal = Human Toxicology | volume = 1 | issue = 4 | pages = 417–424 | date = October 1982 | pmid = 7173927 | doi = 10.1177/096032718200100408 | bibcode = 1982HETox...1..417P | s2cid = 7453965 }}</ref>

<ref name="Pedersen1997">{{cite journal | vauthors = Pedersen-Bjergaard S, Sannes E, Rasmussen KE, Tønnesen F | title = Determination of psilocybin in Psilocybe semilanceata by capillary zone electrophoresis | journal = Journal of Chromatography. B, Biomedical Sciences and Applications | volume = 694 | issue = 2 | pages = 375–381 | date = July 1997 | pmid = 9252052 | doi = 10.1016/S0378-4347(97)00127-8 }}</ref>

<ref name="Pubchem">{{Cite web |title=Psilocybine – Compound Summary |url=https://pubchem.ncbi.nlm.nih.gov/compound/10624 |url-status=live |archive-url=https://web.archive.org/web/20120925014943/http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10624 |archive-date=September 25, 2012 |access-date=December 4, 2011 |publisher=[[PubChem]]. [[National Library of Medicine]]}}</ref>

<ref name="Quentin1960">{{Cite thesis |title=La Psilocybine en Psychiatrie Clinique et Experimentale |degree=PhD |publisher=Paris University Medical Dissertation |language=fr |trans-title=Psilocybin in Clinical and Experimental Psychiatry |vauthors=Quentin AM |year=1960 |location=Paris, France}}</ref>

<ref name="Reinert2020">{{cite journal | vauthors = Reinert JP, Colunga K, Etuk A, Richardson V, Dunn RL | title = Management of overdoses of salvia, kratom, and psilocybin mushrooms: a literature review | journal = Expert Review of Clinical Pharmacology | volume = 13 | issue = 8 | pages = 847–856 | date = August 2020 | pmid = 32648791 | doi = 10.1080/17512433.2020.1794811 | type = Review | s2cid = 220472473 }}</ref>

<ref name=Reynolds2018>{{cite journal | vauthors = Reynolds HT, Vijayakumar V, Gluck-Thaler E, Korotkin HB, Matheny PB, Slot JC | title = Horizontal gene cluster transfer increased hallucinogenic mushroom diversity | journal = Evolution Letters | volume = 2 | issue = 2 | pages = 88–101 | date = April 2018 | pmid = 30283667 | pmc = 6121855 | doi = 10.1002/evl3.42 }}</ref>

<ref name="Richards2008">{{Cite journal |vauthors=Richards WA |year=2008 |title=The phenomenology and potential religious import of states of consciousness facilitated by psilocybin |journal=Archive for the Psychology of Religion |volume=30 |issue=1 |pages=189–199 |doi=10.1163/157361208X317196 |s2cid=144969540}}</ref>

<ref name="RodriguezCruz2005">{{Cite journal |vauthors=Rodriguez-Cruz SE |year=2005 |title=Analysis and characterization of psilocybin and psilocin using liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) with collision-induced-dissociation (CID) and source-induced dissociation (SID) |url=https://www.justice.gov/dea/programs/forensicsci/microgram/journal_v3_num34/journal_v3_num34_pg8.html |url-status=dead |journal=Microgram Journal |volume=3 |issue=3–4 |pages=175–82 |archive-url=https://web.archive.org/web/20110429075012/http://www.justice.gov/dea/programs/forensicsci/microgram/journal_v3_num34/journal_v3_num34_pg8.html |archive-date=April 29, 2011}}</ref>

<ref name=Ross2016>{{cite journal | vauthors = Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL | title = Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial | journal = Journal of Psychopharmacology | volume = 30 | issue = 12 | pages = 1165–1180 | date = December 2016 | pmid = 27909164 | pmc = 5367551 | doi = 10.1177/0269881116675512 }}</ref>

<ref name="Saito2004">{{Cite journal |vauthors=Saito K, Toyo'oka T, Fukushima T, Kato M, Shirota O, Goda Y |year=2004 |title=Determination of psilocin in magic mushrooms and rat plasma by liquid chromatography with fluorimetry and electrospray ionization mass spectrometry |journal=Analytica Chimica Acta |volume=527 |issue=2 |pages=149–156 |doi=10.1016/j.aca.2004.08.071|bibcode=2004AcAC..527..149S }}</ref>

<ref name="Saupe1981">{{Cite journal |vauthors=Saupe SG |year=1981 |title=Occurrence of psilocybin/psilocin in ''Pluteus salicinus'' (Plutaceae) |url=http://www.cybertruffle.org.uk/cyberliber/59350/0073/004/0781.htm |url-status=live |journal=Mycologia |volume=73 |issue=4 |pages=871–874 |doi=10.2307/3759505 |jstor=3759505 |archive-url=https://web.archive.org/web/20170310224135/http://www.cybertruffle.org.uk/cyberliber/59350/0073/004/0781.htm |archive-date=March 10, 2017 |access-date=August 29, 2011}}</ref>

<ref name="Schaefer2001">{{Cite book |url=https://books.google.com/books?id=CE569saGK70C&pg=PA222 |title=Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment |vauthors=Schaefer C |publisher=Elsevier |year=2001 |isbn=978-0-444-50763-1 |location=Amsterdam, the Netherlands |page=222 |access-date=February 27, 2016 |archive-url=https://web.archive.org/web/20170403152804/https://books.google.com/books?id=CE569saGK70C&pg=PA222 |archive-date=April 3, 2017 |url-status=live}}</ref>

<ref name=Serreau2023>{{cite journal | vauthors = Serreau R, Amirouche A, Benyamina A, Berteina-Raboin S | title = A Review of Synthetic Access to Therapeutic Compounds Extracted from ''Psilocybe'' | journal = Pharmaceuticals | volume = 16 | issue = 1 | pages = 40 | date = December 2022 | pmid = 36678537 | pmc = 9867295 | doi = 10.3390/ph16010040 | doi-access = free }}</ref>

<ref name="Simeon2011">{{cite journal | vauthors = Simeon D | title = Depersonalisation disorder: a contemporary overview | journal = CNS Drugs | volume = 18 | issue = 6 | pages = 343–354 | year = 2004 | pmid = 15089102 | doi = 10.2165/00023210-200418060-00002 | s2cid = 18506672 }}</ref>

<ref name="Smith2000">{{Cite book |url=https://archive.org/details/cleansingdoorsof00hust/page/101 |title=Cleansing the Doors of Perception: The Religious Significance of Entheogenic Plants and Chemicals |vauthors=Smith H |publisher=Jeremy P. Tarcher/Putnam |year=2000 |isbn=978-1-58542-034-6 |location=New York, New York |page=[https://archive.org/details/cleansingdoorsof00hust/page/101 101]}}</ref>

<ref name=Staines2019>{{Cite web | vauthors = Staines R |date=2 December 2019 |title=FDA tags psilocybin drug as clinical depression Breakthrough Therapy |url=https://pharmaphorum.com/news/fda-tags-psilocybin-drug-as-clinical-depression-breakthrough-therapy/ |url-status=live |archive-url=https://web.archive.org/web/20210907170203/https://pharmaphorum.com/news/fda-tags-psilocybin-drug-as-clinical-depression-breakthrough-therapy/ |archive-date=September 7, 2021 |access-date=7 September 2021 |publisher=Pharmaphorum}}</ref>

<ref name="Sticht2000">{{cite journal | vauthors = Sticht G, Käferstein H | title = Detection of psilocin in body fluids | journal = Forensic Science International | volume = 113 | issue = 1–3 | pages = 403–407 | date = September 2000 | pmid = 10978655 | doi = 10.1016/S0379-0738(00)00213-9 }}</ref>

<ref name="Strassman2008">{{Cite book |url=https://books.google.com/books?id=0P3_kfFtgicC&pg=PT164 |title=Inner Paths to Outer Space: Journeys to Alien Worlds through Psychedelics and Other Spiritual Technologies |vauthors=Strassman R, Wojtowicz S, Luna LE, Frecska E |publisher=Park Street Press |year=2008 |isbn=978-1-59477-224-5 |location=Rochester, Vermont |page=147 |access-date=February 27, 2016 |archive-url=https://web.archive.org/web/20170404064811/https://books.google.com/books?id=0P3_kfFtgicC&pg=PT164 |archive-date=April 4, 2017 |url-status=live}}</ref>

<ref name="Studerus2011">{{cite journal | vauthors = Studerus E, Kometer M, Hasler F, Vollenweider FX | title = Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies | journal = Journal of Psychopharmacology | volume = 25 | issue = 11 | pages = 1434–1452 | date = November 2011 | pmid = 20855349 | doi = 10.1177/0269881110382466 | s2cid = 22923427 }}</ref>

<ref name="urlEMCDDA">{{Cite web |date=September 19, 2011 |title=Drug profiles: Hallucinogenic mushrooms |url=http://www.emcdda.europa.eu/publications/drug-profiles/mushrooms |url-status=live |archive-url=https://web.archive.org/web/20111127192429/http://www.emcdda.europa.eu/publications/drug-profiles/mushrooms |archive-date=November 27, 2011 |access-date=December 4, 2011 |publisher=European Monitoring Centre for Drugs and Drug Addiction}}</ref>

<ref name="urlMedical News">{{Cite web |date=July 12, 2006 |title=Medical News: Psilocybin Viewed as Therapy or Research Tool |url=http://www.medpagetoday.com/Psychiatry/GeneralPsychiatry/tb/3721 |url-status=live |archive-url=https://web.archive.org/web/20081005205255/http://www.medpagetoday.com/Psychiatry/GeneralPsychiatry/tb/3721 |archive-date=October 5, 2008 |access-date=February 12, 2011 |website=Medpagetoday.com |vauthors=Smith M}}</ref>

<ref name="Vollenweider1998">{{cite journal | vauthors = Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D | title = Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action | journal = NeuroReport | volume = 9 | issue = 17 | pages = 3897–3902 | date = December 1998 | pmid = 9875725 | doi = 10.1097/00001756-199812010-00024 | url = http://pdfs.semanticscholar.org/b67b/b9f54c0e79bc73c8b205304a2f0d29eeb2a9.pdf | url-status = dead | s2cid = 37706068 | archive-url = https://web.archive.org/web/20190303134817/http://pdfs.semanticscholar.org/b67b/b9f54c0e79bc73c8b205304a2f0d29eeb2a9.pdf | archive-date = 2019-03-03 }}</ref>

<ref name="Vollenweider2001">{{cite journal | vauthors = Vollenweider FX, Geyer MA | title = A systems model of altered consciousness: integrating natural and drug-induced psychoses | journal = Brain Research Bulletin | volume = 56 | issue = 5 | pages = 495–507 | date = November 2001 | pmid = 11750795 | doi = 10.1016/S0361-9230(01)00646-3 | s2cid = 230298 }}</ref>

<ref name="Wackermann2008">{{cite journal | vauthors = Wackermann J, Wittmann M, Hasler F, Vollenweider FX | title = Effects of varied doses of psilocybin on time interval reproduction in human subjects | journal = Neuroscience Letters | volume = 435 | issue = 1 | pages = 51–55 | date = April 2008 | pmid = 18325673 | doi = 10.1016/j.neulet.2008.02.006 | s2cid = 22789140 }}</ref>

<ref name="Wark2009">{{cite journal | vauthors = Wark C, Galliher JF | title = Timothy Leary, Richard Alpert (Ram Dass) and the changing definition of psilocybin | journal = The International Journal on Drug Policy | volume = 21 | issue = 3 | pages = 234–239 | date = May 2010 | pmid = 19744846 | doi = 10.1016/j.drugpo.2009.08.004 }}</ref>

<ref name="Wasson1957">{{Cite magazine |date=May 13, 1957 |title=Seeking the magic mushroom |url=https://books.google.com/books?id=Jj8EAAAAMBAJ&pg=PA101 |url-status=live |magazine=Life |pages=101–120 |issn=0024-3019 |archive-url=https://web.archive.org/web/20170403231812/https://books.google.com/books?id=Jj8EAAAAMBAJ&pg=PA101 |archive-date=April 3, 2017 |access-date=February 27, 2016 |vauthors=Wasson RG}}</ref>

<ref name=Wieckiewicz2021>{{cite journal | vauthors = Więckiewicz G, Stokłosa I, Piegza M, Gorczyca P, Pudlo R | title = Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review | journal = Pharmaceuticals | volume = 14 | issue = 8 | page = 793 | date = August 2021 | pmid = 34451890 | pmc = 8399008 | doi = 10.3390/ph14080793 | doi-access = free }}</ref>

<ref name="Winkelman2007">{{Cite book |title=Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments |vauthors=Winkelman MJ |publisher=Praeger |year=2007 |isbn=978-0-275-99024-4 |veditors=Winkelman MJ, Roberts TB |volume=1 |location=Westport, Connecticut |pages=[https://archive.org/details/psychedelicmedic0000unse/page/1 1–19] |chapter=Therapeutic bases of psychedelic medicines: psychointegrative effects |chapter-url=https://archive.org/details/psychedelicmedic0000unse/page/1}}</ref>

<ref name="Wittmann2007">{{cite journal | vauthors = Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX | title = Effects of psilocybin on time perception and temporal control of behaviour in humans | journal = Journal of Psychopharmacology | volume = 21 | issue = 1 | pages = 50–64 | date = January 2007 | pmid = 16714323 | doi = 10.1177/0269881106065859 | s2cid = 3165579 }}</ref>

<ref name=Wong2022>{{cite journal | vauthors = Wong G, Lim LR, Tan YQ, Go MK, Bell DJ, Freemont PS, Yew WS | title = Reconstituting the complete biosynthesis of D-lysergic acid in yeast | journal = Nature Communications | volume = 13 | issue = 1 | article-number = 712 | date = February 2022 | pmid = 35132076 | pmc = 8821704 | doi = 10.1038/s41467-022-28386-6 | bibcode = 2022NatCo..13..712W }}</ref>

<ref name="Wurst1984">{{Cite journal |vauthors=Wurst M, Semerdžieva M, Vokoun J |year=1984 |title=Analysis of psychotropic compounds in fungi of the genus ''Psilocybe'' by reversed-phase high performance liquid chromatography |journal=Journal of Chromatography A |volume=286 |pages=229–235 |doi=10.1016/S0021-9673(01)99190-3}}</ref>

<ref name="Wurst1992">{{Cite journal |vauthors=Wurst M, Kysilka R, Koza T |year=1992 |title=Analysis and isolation of indole alkaloids of fungi by high-performance liquid chromatography |journal=Journal of Chromatography |volume=593 |issue=1–2 |pages=201–208 |doi=10.1016/0021-9673(92)80287-5}}</ref>

<ref name="Wurst2002">{{cite journal | vauthors = Wurst M, Kysilka R, Flieger M | title = Psychoactive tryptamines from basidiomycetes | journal = Folia Microbiologica | volume = 47 | issue = 1 | pages = 3–27 | year = 2002 | pmid = 11980266 | doi = 10.1007/BF02818560 | s2cid = 31056807 }}</ref>

}}

==External links==
* [https://isomerdesign.com/pihkal/explore/5058 Psilocybin - Isomer Design]
* [https://erowid.org/library/books_online/tihkal/tihkal18.shtml 4-HO-DMT (Psilocybin) - TiHKAL - Erowid]
* [https://isomerdesign.com/pihkal/read/tk/18 4-HO-DMT (Psilocybin) - TiHKAL - Isomer Design]
* [https://web.archive.org/web/20210813065107/https://www.usonainstitute.org/wp-content/uploads/2018/12/psilocybin-ib-v4-1.pdf Psilocybin Investigator's Brochure, Version 4.1 (2021) - Usona Institute]

{{Psychedelics}}
{{Antidepressants}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 =
{{Serotonin receptor modulators}}
{{Monoamine releasing agents}}
{{TAAR modulators}}
}}
{{Tryptamines}}

[[Category:5-HT1A agonists]]
[[Category:5-HT1B agonists]]
[[Category:5-HT2A agonists]]
[[Category:5-HT2B agonists]]
[[Category:5-HT2C agonists]]
[[Category:N,N-Dialkyltryptamines]]
[[Category:Dimethylamino compounds]]
[[Category:Entheogens]]
[[Category:Experimental antidepressants]]
[[Category:Experimental anxiolytics]]
[[Category:Experimental hallucinogens]]
[[Category:Partial monoamine releasing agents]]
[[Category:4-Phosphoryloxytryptamines]]
[[Category:Psilocybin| ]]
[[Category:Prodrugs]]
[[Category:Psychedelic-assisted therapy]]
[[Category:Psychedelic tryptamines]]
[[Category:Psychoplastogens]]
[[Category:Serotonin receptor agonists]]
[[Category:Serotonin releasing agents]]
[[Category:TAAR1 agonists]]
[[Category:Tryptamine alkaloids]]